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Introduction 
1.1 Reperfusion therapy for myocardial infarction 
Until 1980, coronary arteriography was considered to be contraindicated in patients 
in the early stages of myocardial infarction. The pioneering work of DeWood and 
colleagues established that emergency cardiac catheterization in patients with acute 
myocardial infarction (AMI), who were considered to be candidates for a therapeutic 
intervention, was feasible, relatively safe and that a high incidence of complete 
obstruction of the infarct-related vessel (IRY) existed in the early hours of a myocardial 
infarction [1,2]. Histopathologic, clinical and postmortem observations confirmed the 
role of thrombi as the cause of sudden occlusion. Such thrombi develop mostly at the 
site of a fissured and unstable atherosclerotic plaque [3-8]. Although Herrick in 1912 
already proposed that AMI was caused by intracoronary thrombosis [9], it was 
suggested by "antagonists" that these two were not constantly or causally related and 
even that coronary thrombosis might be a complication of AMI [10,11]. The study by 
DeWood et al. [1,2] however, ended this controversy and opened a new approach to 
the treatment of myocardial infarction. It was appreciated that spontaneous 
recanalization occurs in a considerable amount of patients within the fust 24 hours 
after myocardial infarction, but such reperfusion usually occurs too late, after the 
damage has been done. Accordingly several ways of restoring blood flow through 
occluded arteries have been proposed. Cardiosurgical coronary artery bypass grafting 
(CAB G) was the only generally accepted revascularization therapy in the seventies. 
However, although data from small studies suggested promising results of early 
reperfusion by means of CABG [12-16], this approach was never tested in large scale 
studies. 
In the late seventies Andreas Griintzig and Peter Rentrop reported revolutionary 
developments in the treatment of coronary artery disease: coronary angioplasty or 
PTCA (Percutaneous Transluminal Coronary Angioplasty) and thrombolytic therapy 
[17,18]. Coronary angioplasty was introduced in the Netherlands in 1980 by SjefEmst 
from the St. Antonius Hospital [19] and some of the flISt trials on reperfusion therapy 
were conducted in the Netherlands [20-22]. Reperfusion of the occluded IRV in 
myocardial infarction can be achieved by thrombolytic agents either given 
intracoronary or intravenously [23-27], by mechanical intervention (PTCA) [28,29] or 
by a combination of these approaches [28, 30-35]. Subsequently a series of medium 
size and large trials have been conducted to assess the clinical value and the risk of 
different reperfusion strategies. 
Initially attention was focused on the intracoronary administration of thrombolytic 
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agents but the fact that most hospitals do not have cardiac-catheterization laboratories 
stimulated evaluation of the effects of intravenous thrombolytic therapy. Several large 
studies established and defined the role of intravenous fibrinolytic therapy in patients 
with acute myocardial infarction: 
* the "Gruppo Italiano per 10 Studio della Sopravvivenza nell' Infarto 
Miocardico" trials: GISSI-l and 2 [26,36] 
* 
* 
* 
* 
the International Studies of Infarct Survival: ISIS-2 and 3 [27,37] 
the APSAC (Anisoylated Plasminogen Streptokinase Activator Complex) 
Intervention Mortality Study: AIMS [38] 
the Anglo-Scandinavian Study of Early Thrombolysis: ASSET [39] 
the Global Utilisation of Streptokinase and Tissue plasminogen activator 
for Occluded coronary arteries study: GUSTO [40,41] 
These studies included approximately 134.000 patients, randomized to receive 
different thrombolytic regimens. The estimated average reduction of early mortality 
after myocardial infarction, attributed to thrombolytic therapy, is between 20 and 30 % 
[20,26,27,42]. Besides this, the possible benefit of acetylsalicylic acid (aspirin) and 
heparin became subject of interest and initiated studies to establish the role of these 
agents for the treatment of myocardial infarction [27,40,43-45]. 
Thrombolytic therapy became the treatment of choice for patients with myocardial 
infarction but concern was raised about the potentially deleterious impact of the 
residual stenosis remaining after thrombolytic therapy. Furthermore, intravenous 
thrombolytic therapy is limited by modest reperfusion rates (Table 2 and 3), the risk of 
bleeding [46], Significant residual stenosis of the IRV in the majority of patients and a 
relatively high risk of reocclusion [40-42,47-54]. This initiated trials to assess the role of 
angioplasty immediately, early or late after thrombolytic therapy. The disappointing 
results from studies on the effects of coronary angioplasty, whether performed 
immediately, early or late after thrombolytic therapy, are summarized in Table 4 [47,55-
60]. 
Restoring myocardial perfusion by means of primary or direct percutaneous 
transluminal coronary angioplasty, without antecedent administration of a thrombolytic 
agent, as first described by Hartzler [28], has a high primary success rate but never 
became widely accepted and angioplasty was only considered as a treatment option if 
there were contraindications for thrombolysis, when failure of infarct-related artery 
recanalization after thrombolytic therapy was suspected ("salvage" or "rescue" 
PTCA) or when optimal conditions for angioplasty were present (often depending on 
the experience and enthusiasm of the cardiologist On duty) [60-62]. In fact, PTCA was 
regarded as the "step-child" in the management of acute myocardial infarction. Still, 
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some people insisted on evaluation of primary angioplasty treatment [61,64]. The 
rationale for employing immediate coronary angiography and primary coronary 
angioplasty as a primary therapy in AMI is based on the following: 
First, immediate angiography gives pivotal information for treatment stratification. 
Patients who may benefit from early cardiac surgery, for instance those with severe left 
main coronary artery stenosis, can be identified, whereas in patients with a patent or 
smallIRV no aggressive therapy will be applied thus avoiding unnecessary exposure to 
thrombolysis. Second, primary angioplasty achieves a higher success rate of 
recanalization of occluded infarct-related vessels compared with thrombolytic therapy 
(approximately 90-95% versus 75-80% respectively) and avoids the significant 
bleeding risk associated with thrombolytics. Third, primary angioplasty may not turn an 
ischemic infarction into a hemorrhagic infarction [65]. Fourth, primary angioplasty can 
be used where thrombolytic therapy is contraindicated. Fifth, primary angioplasty can 
relieve ischemia by achieving reperfusion more rapidly than thrombolytic therapy. Last, 
primary angioplasty results in a less severe residual stenotic lesion than thrombolytic 
therapy and has the potential to reduce recurrent infarction, recurrent ischemia and 
reocclusion which are seen in approximately 15-30 % of the patients after thrombolytic 
therapy [42,45,66]. 
The general considerations mentioned above will be discussed in more detaiL 
1.2 The importance of an open infarct-related vessel 
The human heart is dependent on an uninterrupted supply of substrates. These 
substrates cannot be stored in the myocardium and for this reason the heart cannot 
tolerate prolonged ischemia. Accordingly obstruction of a coronary artery is usually 
followed by cell death. The heart is the victim and not the perpetrator in the 
pathogenesis of ischemic heart disease [67]. 
Early and effective flow through the IRV results in limitation of infarct size and a 
better left ventricular function [51,68,69]. Left ventricular function in patients with 
coronary artery disease is a predictor of survival [70-74] and follow-up data of the 
Interuniversity Cardiology Institute of the Netherlands trial demonstrated a good 
prognosis after myocardial infarction in patients with a left ventricular ejection fraction 
at discharge of more than 40%, whereas short-term and long-term survival declined 
progressively as ejection fraction decreased [72]. 
Reopening of the fRY, limitation of infarct size, and time delay: 
Recovery of left ventricular function after thrombolytic therapy is determined (among 
others) by the time between onset of symptoms and achievement of full reperfusion. 
This time window for myocardial salvage is however restricted to a few hours 
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[36,68,69,75] and after acute occlusion of a coronary artery irreversible ischemic 
myocardial injury develops in a time related wave front from subendocardial to 
subepicardial layers [76]. Reperfusion on the other hand, may have deleterious effects 
on myocardial tissue, often referred to as reperfusion injury. In the animal model, 
oxygen derived free radical activity and calcium overload after prolonged episodes of 
ischemia have been hypothesized as causes for this event. Whether this reperfusion 
injury is of clinical importance in humans remains controversial [77,78]. Free radical-
scavenging drugs may playa role in cardioprotective therapy but studies in this field 
are lacking [78,79]. Reperfusion strategies should thus be aimed at the briefest time of 
ischemia. For the clinician however, this "time window" is a hazardous tool to in- or 
exclude patients for reperfusion therapy and his or her perception of time from the 
onset of infarction in the individual patient may be wrong. An advantage of 
thrombolytic therapy is, that it can be started by general practitioners and paramedical 
ambulance staff before the patients reach the hospital which may result in a reduction 
of time to start of treatment [80-82]. Coronary occlusion can be a dynamic process and 
intermittent occlusion with alternate reperfusion occurs frequently in the early hours 
after myocardial infarction [83,84]. There also is a strong variability in collateral blood 
flow to the ischemic myocardium between individual patients [85]. The presence of 
collateral vessels or residual antegrade blood flow to the infarct zone may extend the 
"time window" for myocardial salvage [85,86]. Patients with fluctuating symptoms 
andlor ST segments are likely to have residual flow to the infarct zone and effective 
reperfusion may improve their left ventricular function [84]. Another study 
demonstrated successful infarct vessel recanalization in the majority of late-entry 
patients (6-24 hours) with thrombolysis andlor angioplasty, and favorable effects on 
left ventricular remodeling [87]. "Late" reperfusion (after 6-24h) of occluded infarct-
related vessels has the ability to prevent left ventricular dilation independent of infarct 
size [88]. The Second International Study of Infarct Survival (ISIS 2) showed a 
reduction of mortality in patients treated relative late (between six and 24 hours from 
the onset of symptoms) with the combination of streptokinase and aspirin [27]. Finally 
the LATE (Late Assessment of Thrombolytic Efficacy) study and the EMERAS 
(Estudio Multicentrico Estreptoquinasa Republicas de America del Sur) Collaborative 
Group indicated beneficial effects of tPA and streptokinase respectively, until 12 h after 
symptom onset and maybe beyond this time-window, although the latter study was not 
conclusive [89,90]. 
Recanalization over time (24 hours), the so called "catch-up" phenomenon, reduces 
differences in patency after administration of different thrombolytic agents but early 
patency is important with regard to survival and left ventricular function [40,41,50,54]. 
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In addition, a lot of "circumstantial evidence" has been gathered for the theory that 
an open infarct-related vessel gives additional years to the patient after having suffered 
from a myocardial infarction eveu when reopening of the lRV is accomplished beyond 
the time window wherein direct myocardial salvage may be expected [71-74,91]. TIris 
suggests that besides limitation of infarct size other mechanisms then early myocardial 
reperfusion play an important role: 
First, enhauced infarct-healing. The frequency of myocardial rupture (including 
tamponade), formation of mural thrombus, acute mitral regurgitation, rupture of the 
iutraventricular septum and formation of left ventricular aneurysm will be reduced. 
Recovery of the left ventricular function will be better in the presence of an open lRY, 
with less dilatation and remodeling. [74,87,91,86,92,93] 
Second, electrical stability. Several studies demonstrated enhanced electrical 
stability as reflected by a reduction of the prevalence of ventricular premature 
complexes, inducible ventricular tachyarrhythmias and late potentials in patients with a 
patent IRV after thrombolysis for myocardial infarction [94-97]. All have been 
recoguized as Significant and independent adverse prognostic factors for surviVal. 
[94,96,99] 
Third, collateral circulation. In an analysis of 250 consecutive patients, treated with 
primary angioplasty the incidence of multi-vessel coronary artery disease was 57% 
[100]. An open infarct-related artery may serve as an alternative coronary conduit to 
other myocardial zones in the acute phase, as well as in the later phase of myocardial 
infarction in patients with multi-vessel coronary artery disease. In these patients 
collateral circulation may serve as an important safety-mechanism. 
1.3 Problems associated with thrombolytic therapy 
1.3.1 The problem of resistance to reperfusion therapy 
The primary goal and the cornerstone of treatment of patients with AMI is the 
achievement of early and optimal reperfusion of the lRY. The Thrombolysis in 
Myocardial Infarction (TIMI) Study Group, established by the National Heart, Lung, 
and Blood Institute iu 1983, suggested an angiographic definition of perfusion of 
coronary vessels (Table 5) based on the assumption, that grades 0 and 1 are markers of 
occlusion and grades 2 and 3 of reperfusion [101]. Recently the clinical importance of 
Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow has been recognized in 
several studies and an lRV with TIMIgrade 2 flow, although until recently considered 
to be patent, does not lead to optimal myocardial salvage [40,41,48-54]. These studies 
stressed the importance of TIMI grade 3 flow. TIMI grade 2 flow is associated with a 
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greater risk for development of recurrent ischemia, congestive heart failure, diminished 
left ventricular function and a trend towards a higher mortality, What remains unclear is 
whether TIlV!I grade 2 is a cause or a marker of adverse outcome, and diminished flow 
may in fact represent a relative no-reflow phenomenon [lO2]. 
Data for patency after intravenous thrombolytic therapy are given in Table 2(TIlV!I 2 
and 3) and Table 3 (TIl\IlI 3). The incidence of normal, TIl\IlI grade 3 flow through the 
IRVand its relation to clinical sequelae is reported from the GUSTO smdy, the TEAM 
(rrial of Eminase (anistreplase) in Acute Myocardial Infarction) 2 and 3 trials and from 
four German multicenter trials [40,41,48-51,54]. Early TIlV!I 3 patency rates were also 
reported from the TAMI (Thrombolysis and Angioplasty in Myocardial Infarction) 5 
trial [53]. The majority of studies however, do not report on TIlV!I grade 3 flow through 
the IRY. As is clear from these studies, in 20 to 30 % of the patients some kind of 
ante grade blood flow is not accomplished. The resistance of coronary artery occlusion 
to thrombolysis may either be due to obstruction of the lumen by a mechanical, 
nonthrombotic mechanism or by intrinsic resistance of thrombus to dissolution. 
Considerable evidence exists, that platelet-rich thrombi are particularly resistant to 
thrombolytic therapy and at least in some patients, who fail to get reperfusion of the 
infarct-related vessel, this phenomenon may be the underlying mechanism [lO3,104]. 
Furthermore thrombolytic therapy can result in activation of platelets by the generation 
of thrombin, a potent platelet activator, and a stimulus for the proaggregatory 
thromboxane A2 production [105]. This activation of platelets has been demonstrated 
in patients with myocardial infarction who received streptokinase as well as t-PA and 
may limit the therapeutic effectiveness of fibrinolytic agents [1 06-lO8]. All these factors 
can contribute to failure of reaching adequate reperfusion by means of thrombolysis 
alone or in combination with coronary angioplasty. The GUSTO trial suggests that 
tissue-type plasminogen activator (t-PA) given in an accelerated dosing schedule with 
intravenous heparin results in the highest early and optimal patency of the IRV (fIl\IlI 
grade 3), and in a better in-hospital survival when compared with other thrombolytic 
strategies [40,41]. 
It was demonstrated that reperfusion therapy and its clinical impact can be improved 
by using "rescue" angioplasty to open infarct-related arteries that fail to open in 
response to thrombolytic therapy, but the clinical outcome of patients who fail to have 
an open IRVafter such a combined approach is poor [53,109-111]. Data from the TAMI-
5 trial support the potential value of an aggressive catheterization strategy for patients 
with evolving myocardial infarction and individual treatment decisions can be made 
without a significantly increased risk of the catheterization procedure itself[53]. In all 
patients with signs of hemodynamic compromise (Killip class ~ 2) immediate coronary 
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arteriography should be considered. However,recently a randomized stndy, comparing 
the effects of rescue angioplasty or conventional treatment on clinical outcome in 
patients with anterior wall myocardial infarctions and failed thrombolysis, did not 
demonstrate additional benefits of rescue angioplasty [112]. 
Finally, there may be a particular resistance to thrombolytic therapy in patients 
presenting with cardiogenic shock: reduced coronary perfusion pressure and flow may 
be responsible for this phenomenon. This will be discussed in more detail in paragraph 
1.6. 
1.3.2 The problem of bleeding complications 
The major adverse event associated with thrombolytic therapy is bleeding, ranging 
from minimal oozing to serious intracrartial bleeding and death. Peripheral bleeding may 
be severe but is usually not associated with mortality or severe irreversible sequelae. 
Intracranial hemorrhage however is accompanied by a high mortality rate (35-40%) 
and often leads to persistent deficits. The estimated risk of intracrartial hemorrhage is 
approximately I % for the general population, receiving thrombolytic therapy for AMI 
[113-116]. Patients with the use of oral anticoagulants before admission, with a low 
body weight, with age> 65 years, with female gender, with hypertension and treated 
with high dose of thrombolytic for a given body weight, seem to be at higher risk. 
Initial enthusiasm for t-PA was based on presumed fibrin specificity and reduction of 
systemic bleeding complications because of reduction of the systemic fibrinolytic state, 
but the use of t-PA may be associated with a higher risk of intracranial bleeding 
compared to streptokinase therapy, although this effect seems to be dose-related 
[114,116]. In the Thrombolysis in Myocardial Infarction trial, patients who received 150 
mgof t-PAhad an incidence of 1.9 percent of intracrartialhemorrhage and this number 
was reduced to 0.5 percent after the dose was lowered to 100 mg of t-PA [58,116]. In 
the GUSTO trial accelerated tPA produced a significant excess of intracrartial 
hemorrhage but the beneficial effects on survival overwhelmed this adverse effect [40]. 
Because of the lower risk of intracrartial bleeding the use of streptokinase may be the 
preferred thrombolytic treatment in patients at risk of stroke, those with small infarcts 
and in the elderly. 
A model for individual risk assessment for intracrartial hemorrhage dnring 
thrombolytic therapy was proposed by Simoons et al., derived from data from six large 
registries: the Netherlands registry of thrombolytic therapy, the European Cooperative 
Stndy Group trials, the GISSI-2 trial, the International Study Group trials, the TIM! II 
trials, the TAMI trials and the ISAM stndy. Four factors were identified as independent 
predictors of intracrartial bleeding: age over 65 years (Odds Ratio [OR]: 2.2), body 
weight below 70 kg (OR: 2.1), hypertension on hospital admission (OR: 2.0) and 
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administration of alteplase (OR: 1.6). Patients without risk factors who receive 
streptokinase have a 0.26%. with one risk factor 0.96%, with two risk factors 1.32%, 
and with three risk factors a 2.17% probability of intracranial hemorrhage [46]. 
1.3.3 The problem of intramyocardial hemorrhage 
After thrombolytic therapy and successful reperfusion, hemorrhagic myocardial 
infarction and extension of already infarcted tissue can occur and several reports have 
described extensive intramyocardial hemorrhage in post-mortem studies and even in 
survivors [65,117-127]. Whether reperfusion in a thrombolytic state induces additional 
myocardial necrosis remains the subject of debate but a study by Waller and co-
workers gives some interesting information on the effects of thrombolytic agents on 
myocardial tissue. Their series of patients however, were small [65]. Although data from 
the large clinical trials of thrombolytic therapy have demonstrated benefit of the 
administration of thrombolytic agents late after onset of symptoms, as was already 
mentioned, this may increase the risk of cardiac rupture, usually accompanied by 
extensive hemorrhagic transformation of the infarcted tissue involved [123]. The 
puzzling observation of the excess of deaths early after thrombolytic therapy may in 
part be explained by the combination ofreperfusion injury and myocardial hemorrhage 
[46]. Primary angioplasty may not have these deleterious effects and after primary 
angioplasty an "anemic infarction" was seen in a small group of patients [65]. 
Furthermore, intramural hemorrhage in the vessel wall, due to the thrombolytic state, 
may lead to abrupt closure of the initially reopened IRV [65]. Further clinical 
information on these phenomena is needed. 
1.3.4 The problem of the residnal stenosis 
After successful thrombolytic therapy a high grade residual stenosis of the IRV may 
be of concern. Somerimes it is difficult to angiographically distinguish the underlying 
atherosclerotic plaque from residual thrombus, especially in the first few days after 
initially successful thrombolytic therapy [128-130]. If a high-grade residual stenosis 
persists after successful thrombolytic therapy, the incidence of reocclusion of the 
infarct-related vessel and reinfarction is increased, despite the use of additional therapy 
with heparin and aspirin [21,66,131,132]. Blood flow conditions act in concert with the 
involved platelets and the coagulation system. One study showed a close non-linear 
relation between the degree of residual stenosis of the IRV and the degree of left 
ventricular dilation 6 months and 12 months after first myocardial infarction [133] and 
reduction of the degree of residual stenosis of the IRV may be a very effective therapy 
for preventing topographic changes to the left ventricle (left ventricular remodeling) 
[92]. 
In a study to assess the degree of residual stenosis after streptokinase therapy for 
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AMI, 83% of the patients had a residual stenosis of 70 % or more and in most of these 
patients the culprit lesion was considered to be suitable for coronary angioplasty [129], 
In the study by O'Neill and colleagues, comparing the effects of intracoronary 
streptokinase and primary angioplasty, the greatest improvement in global and infarct 
zone function was found in patients with lower residual stenosis of the IRV [134]. The 
residual coronary artery obstruction may limit the flow in the IRV after successful 
thrombolysis and result in continuing ischemia, delayed recovery and even ongoing 
necrosis of the myocardial tissue involved [101,135,136]. Coronary angioplasty has the 
potential advantage of relieving the degree of obstruction but few angiographic data 
are available: Holmes and coworkers reported a reduction of luminal stenosis of the IRV 
from 98% to 33% in a small series of patients who underwent primary angioplasty, 
without antecedent thrombolysis, for acute myocardial infarction [137]. The residual 
luminal stenosis of the IRV in the first randomized trial of primary angioplasty versus 
thrombolytic therapy by O'Neill et al. was reported to be 43% in the patients assigned 
to angioplasty, versus 83% in the patient group, treated with thrombolysis [134]. 
Clinical evidence indicates, that the residual stenosis after thrombolytic therapy is 
perhaps the most important determinant of the frequency of reocclusion and this 
concern initiated in fact the phase 2 of the TIMI trial where the role and timing of 
coronary angioplasty after thrombolysis were evaluated. 
1.3.5 The problem of reocclusion 
Reocclusion of the infarct-related vessel may result in death, reinfarction, and 
worsening of left ventricular function. [45,53,74,109] Evidence has accumulated that 
patency of the IRVat the time of discharge is of paramount importance for long-term 
survival, even independent of its influence on left ventricular function. In the Western 
Washington study, intracoronary streptokinase reduced the one-year mortality among 
patients with myocardial infarction, but this improvement occurred only among those in 
whom thrombolysis resulted in coronary artery patency [138]. Reocclusion of the IRV 
therefore is an important risk factor in patients who had initially successful reperfusion 
therapy [109]. Reocclusion after successful thrombolysis may occur early or late and 
may lead to severe clirtical symptoms but may also occur "silently". In many studies on 
thrombolytic therapy for myocardial infarction the true incidence of reocclusion is not 
known. Angiographically documented reocclusion after successful reperfusion therapy 
occurred in 15 percent in the TAMI-I study and in 24 percent of the patients in the 
TIMI-I study [101,139]. Ohman et al. reported a 12.4 % incidence of reocclusion after 
initially successful reperfusion therapy and 42% of these reocclusions occurred 
without symptoms [109]. Patients with reocclusion of the IRV at follow-up 
angiography had worse global as well as infarct-zone left ventricular function 
Introduction 19 
compared to patients with sustained patency, regardless if the reocclusion was 
accompanied by symptoms or not. They also made the interesting observation that the 
right coronary artery seems to be more susceptible for reocclusion then other coronary 
vessels, an observation also made by others. [32,139]. 
The APRICOT (Antithrombotics in the Prevention of Reocclusion In Coronary 
Thrombolysis) study demonstrated a high incidence of reocclusion of the IRV three 
months after initially successful thrombolysis with intravenous streptokinase (25-30% 
reocclusion). This study also suggested a deleterious effect of this phenomenon on left 
ventricular function [45]. 
Immediate addition of aspirin after thrombolytic therapy has some effect to prevent 
reocclusion and reinfarction after initially successful thrombolysis as was also 
demonstrated in the second International Study of Infarct Survival (ISIS-2) and the 
APRICOT study [27,45,140]. Long term follow-up data from the Western Washington 
Study suggested an improvement of early survival after streptokinase therapy for AMI 
when compared with placebo treatment, but after 3-8 years, this initial improvement 
was not seen anymore [141]. Reocclusion of the IRVover time could be an explanation 
for this observation. 
Reocclusion at the site of the often critical residual coronary vessel stenosis within 
the following days after myocardial infarction led several cardiologists to perform 
percutaneous transluminal coronary angioplasty at varying intervals after thrombolysis 
and as early as 1982, Meyer et aI. reported very encouraging results of this aggressive 
treatment [30,31,142] and others were soon to follow [21]. If reocclusion can be 
prevented, immediateangioplasty may be beneficial in selected patients [91]. However 
residual thrombus may obscure the true severity of the underlying atherosclerotic 
plaque (especially early after thrombolytic therapy) and may itself be activated in the 
"thrombolytic state" [128,143]. This may in part be the explanation of the 
disappointing results of routine angioplasty after initially successful thrombolytic 
therapy. An important problem to be solved is the identification of non-invasive 
markers of reperfusion after thrombolytic therapy. Time delay after failure of 
thrombOlytic therapy may, as was already stated, results in further damage of 
myocardial tissue. 
1.4 Combination of thrombolytic and angiopJasty therapy 
After the initial enthusiastic reports on successful angioplasty during, after or 
without thrombolytic therapy, several studies were designed to establish the role of 
coronary angioplasty in the treatment of myocardial infarction [28,30-33,35,47,55-
60,134,144-146]. Table 4 summarizes the most important studies. The results of these 
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trials indicate, that routine angioplasty intended to correct the residual stenosis of the 
IRY, whether performed immediately or early after thrombolytic therapy, or days later is 
ineffective" may be hazardous and is unnecessarily expensive. Possible explanations 
were mentioned before, namely activation of residual thrombotic material by 
intracoronary manipulation in a "thrombolytic state" and IRV intra-plaque hematoma 
formation both leading to an increased incidence of reocclusion. A pragmatic policy of 
conventional care with intervention only for clinical indications (,"watchful waiting") 
was advocated. However,only about 60-70 % of the angioplasty assigned patients in 
the TAMIl, TIMI II A, TIMI IIB and SWIFT trials actually underwent the procedure and 
patients with an occluded IRV did not have a PTCA. These patients may have had 
considerable benefits of an open IRY. Recently O'Neill and colleagues evaluated 
possible differences in clinical outcome in patients treated with angioplasty with 
adjunctive thrombolytic therapy and primary coronary angioplasty as a stand alone 
procedure, and demonstrated clearly that intravenous streptokinase therapy should not 
be routinely given in patients with angioplasty treatment for myocardial infarction 
[146]. 
The incidence of bleeding complications is increased when cardiac catheterization 
or coronary angioplasty is performed in the setting of thrombolytic therapy [47,55,56] 
but one major advantage of immediate angiography and angioplasty above substantive 
intravenously administrated thrombolytic therapy is the ability to document successful 
reperfusion and coronary anatomy accurately. At least 25 % of all patients receiving 
thrombolytic therapy fail to have recanalization (TIMI grade 2 and 3),90-120 minutes 
after start of therapy and emergency coronary angioplasty to achieve vessel patency 
has been termed "salvage" or "rescue" angioplasty. Successful angioplasty in this 
setting has a good prognosis, comparable to that of patients with patency of the IRV 
after thrombolysis, but failure of rescue PTCA is associated with a much higher 
mortality rate. [63,110] The role of rescue PTCA was only evaluated in one randomized 
study of patients with anterior wall involvement. In this study problems with including 
patients were encountered as interventional cardiologists from many centers who were 
invited to participate (including our hospital) felt it unethical to withhold a patient 
coronary angioplasty in case an occluded IRV was found [112]. None of all the above 
mentioned studies however was designed to investigate the possible role of stand-
alone PTCA therapy. 
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1.5 Eligibility for thrombolysis and contraindications for this therapy 
Possible contraindications for thrombolytic therapy are considered to be: 
gastrointestinal bleeding, prolonged resuscitation, recent surgery or trauma, recent 
stroke, recent vascular puncture, known bleeding disorder, uncontrolled hypertension 
despite vasopressor treatment, oral anticoagulant therapy and in premenopausal 
WOmen (imminent) menstruation. Furthermore, thrombolytic agents are probably not 
being used so often in older patients because of their worse functional status before 
their infarctions, a higher frequency of co-existing illnesses, more time delay in 
presentation to the hospital, and more frequently non-diagnostic electrocardiograms 
often with less chest discomfort [147]. From the physicians point of view there is a 
reluctance because of the fear for a catastrophic intracerebral hemorrhage. 
One study strongly suggested that prolonged (out-of-hospital) cardiopulmonary 
resuscitation by itself does not have to be a contraindication to thrombolytic therapy 
[148]. Earlier reports on thrombolysis have suggested that more than 70% of patients 
with AMI were not eligible for thrombolytic therapy with these strict criteria, many of 
them having more than one reason for exclusion [62,149]. However, the mortality 
without reperfusion therapy in this patient group was very high (19%). The in-hospital 
mortality of myocardial infarction is increased threefold in patients older than 70 years 
and may even exponentially increase with increments of age, in patients older than 75 
years [147,149]. So the higher risk of intracranial hemorrhage in elderly patients seems 
to be less important than the gain to be expected from reperfusion therapy. Patients 
with bundle branch block were thought to be not eligible for thrombolytic therapy but 
recent data showed also beneficial effects in these patients, provided that they present 
with good clinical evidence for myocardial infarction [27]. 
The selection of patients with AMI, who should receive thrombolytic therapy, has 
gradually become broader as more data from trials were published and the majority of 
patients are candidates for this therapy nowadays The benefit in these subsets of 
patients will outweigh the riSk. An overview of nine large trials demonstrated that 
thrombolytic therapy reduces mortality in a much wider range than is generally 
accepted at the present time, with clear benefits in patients presenting between 12 to 18 
hours after symptom onset, irrespective of age, sex, blood pressure, heart rate, a history 
of previous myocardial infarction or diabetes [46]. Still, a considerable number of 
patients with AMI will have definite contraindications for thrombolytic therapy and are 
probably candidates for primary angioplasty [149-151]. 
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1.6 Treatment of patients presenting with cardiogenic shock 
About 5-10% of all patients, admitted to a hospital for acute myocardial infarction, 
develop cardiogenic shock [26,152], This condition represents failure of the pumping 
action of the heart to provide adequate perfusion of the organs and tissue to meet 
resting metabolic demands, The mortality rate of this condition has remained in the 
range of 70-90% in many published studies [152]' Early treatment with inotropic 
agents and mechanical counterpulsation circulatory support (Intra-aortic Balloon 
Pumping; IABP), although important therapeutical improvements, cannot eliminate the 
cause of myocardial ischemia, namely occlusion of the IRV [153]. Massive cell death 
and permanent loss of function in large areas of the heart cannot be prevented without 
effective reperfusion of the IRV. After initially hopeful results of the use of the IABP 
during the course of myocardial infarction and signs of left ventricular failure, a 
randomized study failed to document a major impact on survival when used alone 
[154]. Thrombolysis can reduce the incidence of cardiogenic shock following AMI, but 
once the shock state has developed the effectiveness of this reperfusion regimen is 
disappointing [155-157]. It appears that thrombolytic treatment is relatively ineffective 
in these patients. Recent non-randomized studies showed improvement of survival of 
patients who developed cardiogenic shock in the course of myocardial infarction and 
were treated with primary coronary angioplasty, but large selection bias cannot be 
excluded. [144,158-161] 
Prevention of reocclusion after initially successful reperfusion in patients with 
cardiogenic shock is clearly an essential factor in ultimate patient survival and by 
supporting the coronary circulation (increase of coronary blood flow) in the IRVand 
the other, often also compromised coronary arteries, the IABP can contribute to this 
goal. Further benefits of the IABP include: support of the post-ischemic "stunned" 
myocardium, reduction of the afterload of the left ventricle and enhancement of the 
colIateral circulation. AlI patients with severe hemodynamic problems during the acute 
phase of myocardial infarction (even beyond the time window of 4 hours) should be 
considered candidates for primary coronary angioplasty with additional supportive 
measures and in community hospitals, transferal to hospitals with facilities for cardiac 
catheterization and interventional cardiology should be initiated to perform primary 
coronary angioplasty as soon as possible [157]. 
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1.7 Primary or direct coronary angioplasty 
Hartzler and colleagues were the first to report on the results of primary or direct 
coronary angioplasty (without antecedent or concomitant thrombolytic therapy) as a 
treatment modality for myocardial infarction [28]. The primary success rate of the 
procedure was vety high for single vessel coronary artety disease (99%) as well as for 
multivessel-disease (90%) [100.162.163]; there were few procedural complications, the 
in-hospital mortality was low and at three-year follow-up the survival rate was 87% -
92%. In patients with previous coronary bypass surgery primary angioplasty appeared 
also to be effective and safe [164]. 
Gacioch and Topol have reported a high incidence of complications and death after 
angioplasty in patients with AMI and occlusion of the right coronary artery, attributed 
to a higher reocclusion rate, an exaggerated Bezold-Jarisch reflex, and reperfusion 
injury [165]. This could not be confirmed by another major study on complications of 
angioplasty in the setting of AMI, although minor catheterization related events were 
more common in patients presenting with an occlusion of the right coronary artery 
[100]. Combined results from nine, non-randomized, descriptive studies of primary 
coronary angioplasty with data from 2015 patients demonstrated an in-hospital 
mortality between 5 and 14%, probably reflecting the heterogeneity of the patient 
groups [166]. This stressed the need for randomized comparisons of thrombolytic 
therapy and primary angioplasty therapy for myocardial infarction. 
The first trial that assigned patients to undergo primary PICA or to receive 
thrombolytic therapy (intracoronary streptokinase) On a randomized, prospective base, 
was the study by O'Neill and colleagues (1986) [134] and demonstrated a more 
effective preservation of myocardial function and a less severe residual stenosis of the 
infarct-related coronary artery in patients treated with primary coronary angioplasty. 
Coronary reperfusion was established in 83% of the patients treated with angioplasty 
and in 85% of those treated with thrombolysis. The time from symptom onset to 
reperfusion was the same in both groups. Marco and co-workers also demonstrated the 
effectiveness, safety and beneficial effects on left ventricular function of primary 
coronary angioplasty in a non-randomized group of 43 patients with AMI [167]. 
An overview of reports on primary angioplasty is given in Table 6. Primary 
angioplasty is an effective means of complete recanalization in patients with acute 
myocardial infarction with reduction of the residual stenosis of the IRVand with the 
potential to eliminate thrombus ("squeezing the thrombus"). Bleeding complications, 
especially intracranial hemorrhage, may be significantly less than for thrombolytic 
therapy. Primary angioplasty may also be useful in patients beyond the traditional time 
window of 4-6 hours, especially when there are signs of ongoing ischemia [84,151]. 
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1.8 Limitations of primary coronary angioplasty treatment for AMI 
A limited number of hospitals have angioplasty facilities and in the United States 
only an estimated 10% of the hospitals is equipped to perform emergency angioplasty 
(Braunwald, comment: "This week in the New England Journal of Medicine", April 
1993), In the Netherlands, coronary angioplasty is performed in 13 hospitals, all of them 
with on-site cardiac surgical support which, in the opinion of the Netherlands Society 
of Cardiology, is a prerequisite for performing coronary angioplasty [168]. The 
geographical distribution of these centers in the Netherlands is such that almost every 
community hospital is within 60 kilometers of a hospital with interventional cardiology 
facilities. Patients with large myocardial infarctions and hemodynamic compromise can 
be referred to these hospitals but the risk of serious complications during transportation 
should be kept in mind. Performance of primary coronary angioplasty for AMI in 
hospitals without interventional cardiology experience would probably result in a high 
incidence of adverse events, as was shown by Brodie and co-workers [149]. The risk of 
the angioplasty procedure is low in experienced hands but definitely not zero and 
serious unexpected problems with severe clinical implications can be encountered 
[55,100,165]. Emergency coronary artery bypass surgery after primary coronary 
angioplasty is indicated in approximately 5% of the patients versus 1% - 2% of patients 
undergoing elective PTCA [169]. 
The costs of having a complete catheterization laboratory team available on a 24 
hour base and the possible time-delay in mobilizing this team to establish rapid 
reperfusion of the IRV should be kept in mind and could be a drawback to perform 
primary angioplasty on a routine base, even in hospitals with all the facilities, mentioned 
above. 
A biological obstacle of coronary angioplasty (often referred to as the "Achilles' 
heel") to be overcome remains the problem of restenosis after initially successful 
angioplasty procedures. After elective coronary angioplasty the incidence of restenosis 
is reported to be 20%-40% whereas this incidence is probably higher after angioplasty 
for unstable coronary syndromes [170-172]. The true incidence of restenosis and 
reocclusion after primary coronary angioplasty for AMI is unknown and may be higher 
than that reported for elective PTCA. It may be comparable to that in patients with 
unstable angina or recanalization of occluded coronary arteries [171]. In two studies 
the restenosis rate after primary coronary angioplasty was 31 % and 36% and the 
reocclusion rate was 9%, but repeat angiography was performed only in approximately 
70% of these patients [173,174]' DepOSition and accumulation of platelets at the site of 
angioplasty is strongly related to restenosis and reocclusion and adequate antiplatelet 
therapy may be an important tool to prevent these phenomena [175,176]. 
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Conclusion 
Treatment of patients with acute myocardial infarction is changing and improving 
rapidly. Early reopening of the IRV with avoidance of subsequent reocclusion appears 
to be the cornerstone of therapy. Thrombolytic strategies for acute myocardial 
infarction have reached their "third generation" stage and combinations of already 
well known thrombolytic agents, newer drugs, accelerated dosing schedules and front-
loading administration have recentiy been introduced and have shown to reduce 
mortality [40,177,178-181]. Potentially exciting new agents for antiplatelet therapy like 
the monoclonal antibody c7E3 Fab, an inhibitor of the glycoprotein IIb-IIIareceptors 
on the platelet surface, and potent thrombin inhibitors are under investigation. Ongoing 
clinical trials are examining modifications of these regimens [182]. The combined use of 
thrombolytic and angioplasty therapy for the treatment of AMI has been abandoned 
after disappointing study results. Advances in technique, equipment and development 
of new devices have expanded the use of coronary angioplasty, and coronary artery 
lesions only recently considered to be unsuitable for this non-surgical approach, are 
treated with a high rate of success. Howeve~ only an experienced team of operators 
with competent cardiosurgical support will achieve these excellent results [183]. The 
possibility that the results of angioplasty therapy for myocardial infarction may be 
worse because of the addition of thrombolytic therapy by the combination of 
intramyocardial hemorrhage, intra-plaque hemorrhage and activation of platelets by 
thrombolytic agents, has only recently been the subject of interest. One trial was 
designed to find out if thrombolytic therapy improved or deteriorated the outcome of 
angioplasty for AMI and these data demonstrated no beneficial effects on preservation 
of left ventricular function, no reduction of restenosis and a higher rate of 
complications in patients with adjunctive intravenous streptokinase therapy [146] 
However comparisons of primary angioplasty with other reperfusion strategies were 
lacking. This thesis tries to redefine the role of coronary angioplasty in acute 
myocardial infarction. During the completion of this work [184], results of two other 
prospective randomized studies with regard to primary angioplasty have been 
published and have given support to the conclusions drawn in this thesis [185,186]. 
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Table 1: Questions, addressed in this thesis are indicated with a question mark. 
Thrombolysis Primary Angioplasty 
Success for achieving reperfusion ++ +++ 
Infarct size reduction + +? 
PreseNation LV function + ? 
Effect on sUNival + ? 
Long term effect on residual stenosis ± ? 
Risk of reocclusion 
Early: + ? 
Late + ? 
Hemorrhagic changes 
Intramural + -? 
Intraluminal + 
Risk of bleeding (non-cerebral) + 
Risk of stroke 
Intracranial bleeding + 
Ischemic + ? 
Availability +++ + 
Convenience +++ 
Initial costs + +++ 
Long term costs ++ ? 
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Table 2: Studies of intravenous thrombolytic therapy and reported angiographic 
patency rates (TlMI grade 2 and 3). 
Time from start therapy 
60 min: 
Streptokinase: 
tPA: 
Accelerated tPA: 
90 min: 
Streptokinase: 
tPA: 
Accelerated tPA: 
120 - 180 min: 
Streptokinase: 
tPA: 
Accelerated tPA: 
1 d: 
Streptokinase: 
tPA: 
Accelerated tPA: 
3-21 d: 
Streptokinase: 
tPA: 
Accelerated tPA: 
n 
224 
487 
643 
789 
1648 
671 
280 
147 
376 
1837 
323 
543 
2327 
210 
patency 
48% (93/192) 
62% (241/425) 
74% (401/545) 
51% (411/799) 
70% (1107/1585) 
84% (533/632) 
70% (189/270) 
73% (103/142) 
86% (294/344) 
84% (1347/1606) 
86% (253/293) 
74% (324/438) 
80% (1626/2042) 
89% (158/177) 
From: Granger CB, Califf RM, Topol EJ. Thrombolytic therapy for acute myocardial 
infarction. A review. Drugs 1992;44:293-325 [42J. With kind permission from the 
authors. 
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Table 3: Studies of intravenous thrombolytic therapy and TIMI grade 3 flow. 
TIme from start therapy n patency TIMI 3 
90 min: 
Streptokinase + SC Heparin (GUSTO) 293 29% (85/293) 
Streptokinase + IV Heparin (GUSTO) 283 32% (91/283) 
Urokinase + heparin (TAMI 5) 95 40% (38/95) 
tPA + Streptokinase (GUSTO) 299 38% (114/299) 
tPA + Urokinase + heparin (TAMI 5) 97 61% (59/97) 
tPA + heparin (TAMI 5) 95 56% (53/95) 
Accelerated tPA (GUSTO) 292 54% (157/292) 
120 min: 
Streptokinase (TEAM-2) 182 53% (93/176) 
APSAC (TEAM-2) 188 60% (110/183) 
180 min: 
Streptokinase + SC Heparin (GUSTO) 106 35% (37/106) 
Streptokinase + IV Heparin (GUSTO) 97 41% (40/97) 
tPA + Streptokinase (GUSTO) 91 53% (48/91) 
Accelerated tPA (GUSTO) 93 43% (40/93) 
1 d: 
Streptokinase + SC Heparin (GUSTO) 83 51% (42183) 
Streptokinase + IV Heparin (GUSTO) 92 41% (38/92) 
APSAC (TEAM-3) 149 75% (1121149) 
tPA + Streptokinase (GUSTO) 93 60% (56/93) 
tPA (TEAM-3) 149 73% (109/149) 
Accelerated tPA (GUSTO) 104 45% (47/104) 
5-7d: 
Streptokinase + SC Heparin (GUSTO) 93 51% (47/93) 
Streptokinase + IV Heparin (GUSTO) 96 58% (56/96) 
tPA + Streptokinase (GUSTO) 89 55% (49/89) 
Accelerated tPA (GUSTO) 83 58% (48183) 
TAMI = Thrombolysis and Angioplasty in Myocardial Infarction trial; GUSTO = Global Utilisation 
of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study; 
TEAM = Trial of Eminase (anistreplase) in Acute Myocardial Infarction; tPA = tissue-type 
plasmi~ogen activator; APSAC = Anisoylated plasminogen streptokinase activator complex. 
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Table 4: Mortality in the randomized studies of routine coronary angioplasty after 
thrombolytic therapy. 
Study n Agent time thrombolysis early mortality 
(year of publication - angioplasty C A 
and reference nr.) 
Immediate angioplasty 
Erbel et al. (1986) [31] 162 SK <2h 11% 7% 
TAMI I (1987) • [47] 99 tPA <2h 4% 
TIMI IIA (1988) • [56] 195 tPA <2h 7.2% 
Simoons ECSG-5 (1988) 367 tPA <3h 3% 7% 
[55] 
----------------------.-------------------------------------------------------------------------------------------
Deferred - late angioplasty 
TIMIIiA (1988) • [56] 194 tPA 18-48h 5.7% 
TIMIIiB (1989) [58] 3262 tPA 18 - 48 h 4.7% 5.2% 
SWIFT (1991) [59] 800 APSAC 24 h -7 d 2.7% 3.3% 
vd Brand (1992) [144] 218 tPA 48h-5d 2.9% 0.9% 
Barbash et al. (1990) [60] 201 tPA 5d 4% 5% 
TAMI I (1987) • [47] 98 tPA 7 -10 d 10/0 
Ellis (1992) [187] 87 SKitPA 4 -14 d 0% 0% 
• The TAMI I and TIMI IIA trials compared immediate and deferred angioplasty. 
C = Conservative therapy, A = Angioplasty therapy (intention to treat). TAMI = 
Thrombolysis and Angioplasty in Myocardial Infarction trial; ECSG = European 
Cooperative Study Group; TIMI = Thrombolysis in Myocardial Infarction; SWIFT = 
Should We Intervene Following Thrombolysis; SK = streptokinase; tPA = tissue-type 
plasminogen activator; APSAC = Anisoylated plasminogen streptokinase activator 
complex. 
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Table 5: Definitions of perfusion in the TIMI trials 
Grade 0 (no perfusion): There is no antegrade flow beyond the point of occlusion. 
Grade 1 (penetration without perfusion): The contrast material passes beyond 
the area of obstruction but "hangs up" and fails to opacify the entire 
coronary bed distal to the obstruction for the duration of the cine-
angiographic filming sequence. 
Grade 2 (partial perfusion): The contrast material passes across the obstruction 
and opacifies the coronary bed distal to the obstruction. However, the rate 
of entry of contrast material into the vessel distal to the obstruction or its 
rate of clearance from the distal bed (or both) are perceptibly slower than 
its entry into or clearance from comparable areas not perfused by the 
previously occluded vessel - e.g., the opposite coronary artery or the 
coronary bed proximal to the obstruction. 
Grade 3 (complete perfusion): Antegrade flow into the bed distal to the obstruction 
occurs as promptly as antegrade flow into the bed proximal to the 
obstruction, and clearance of contrast material from the involved bed as 
rapid as clearance from an uninvolved bed in the same vessel or the 
opposite artery. 
Definition of the Thrombolysis in Myocardial Infarction (TIMI) study flow grades, used 
in Chapters 4 and 5. 
Reference: Chesebro JH, Knatterud G, Roberts R et al.Thrombolysis in myocardial 
infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen 
activator and intravenous streptokinase. Circulation 1987;76:142-54. 
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Table 6: Studies of primary coronary angioplasty for acute myocardial infarction. 
Study n success reocclusion # restenosis in-hospital 
(First author, year of death 
publication, reference nr.) 
Hartzler 1984 [188]t 78 90% 15% 8% 
Kimura 1984 [189] 58 88% 16% 
O'Neill 1986 [133] * 29 83% 8.3% 6.8% 
Rothbaum 1987 [177] 151 87% 9% 31% 7% 
Marco 1987 [171] 43 95% 22% 30% 9.3% 
Miller 1987 [178] 81 92% 7.9% 35% 7.8% 
Flaker 1989 [190] t 93 78% 11% 34% 14% 
DeWood 1989 [191] * 18 
O'Neill 1992 [149] * 63 93% 11% 37% 6.5% 
Zijlstra 1993 [184] * 70 98% 9% 24% 2% 
Grines 1993 [185] * 195 97% 2.6% 
Gibbons 1993 [186] * 47 93% 4% 
Ribeiro 1993 [192] * 40 90% 2.5% 6% 
Saito 1994 [193] 198 93% 7.5% 8% 
O'Keefe 1993 [194] 1000 94% 13% 8% 
O'Neill 1994 [195] 271 92% 4% 
#, indicates early or late reocclusion, depending on study design; * ,indicates if the 
study was a prospective randomized trial; t, some patients in the whole study group 
also received thrombolytic agents; t, only anterior wall infarcts were included. 
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Abstract Background. Despite the widespread use of intravehous thrombolytic 
therapy and of immediate percutaneous transluminal coronary angioplasty for the 
treatment of acute myocardial infarction, randomized comparisons of the two 
approaches to reperfusion are lacking. We report the results of a prospective, 
randomized trial comparing immediate coronary angioplasty (without previous 
thrombolytic therapy) with intravenous streptokinase treatment. 
Methods. A total of 142 patients with acute myocardial infarction were 
randomly assigned to receive one of the two treatments. The left ventricular ejection 
fraction was measured by radionuclide scanning before hospital discharge. Quantitative 
coronary angiography was performed to assess the degree of residual stenosis in the 
infarct-related arteries. 
Results. A total of 72 patients were assigned to receive streptokinase and 
70 patients to undergo immediate angioplasty. Angioplasty was technically successful 
in 64 of the 65 patients who underwent the procedure. lnfarction recurred in nine 
patients assigned to receive streptokinase, but in none of those assigned to receive 
angioplasty (P = 0.003). Fourteen patients in the streptokinase group had unstable 
angina after their infarction, but only four in the angioplasty group (P= 0.02). The mean 
(± SD) left ventricular ejection fraction as measured before discharge was 45 ± 12 
percent in the streptokinase group and 51 ± 11 percent in the angioplasty group (P = 
0.004). The infarct-related artery was patent in 68 percent of the patients in the 
streptokinase group and 91 percent of those in the angioplasty group (P = 0.001). 
Quantitative coronary angiography revealed stenosis of 36 ± 20 percent of the luminal 
diameter in the angioplasty group, as compared with 76 ± 19 percent in the 
streptokinase group (P < 0.001). 
Conclusions. Immediate angioplasty after acute myocardial infarction was 
associated with a higher rate of patency of the infarct-related artery, a less severe 
residual stenotic lesion, better left ventricular function and less recurrent myocardial 
ischemia and infarction than was intravenous streptokinase. 
N Eng1 J Moo 1993;328;680·84. 
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In 1980 De Wood et al. [1] showed that acute transmural myocardial infarction is 
usually associated with total coronary occlusion due to an intraluminal coronary 
thrombus superimposed on an atherosclerotic lesion. Over the past decade the efficacy 
of thrombolytic therapy and coronary angioplasty in restoring patency to the infarct-
related coronary artery has been studied extensively [2-9]. Although "rescue"· 
angioplasty may be advantageous in infarct-related arteries that fail to reperfuse after 
thrombolytic therapy [10]. in general there is no additional benefit of routine 
angioplasty after thrombolytic therapy [7.8]. The results of recently published 
randomized trials indicate that the combination of streptokinase. aspirin and heparin is 
the generally accepted treatment for patients with acute myocardial infarction [11-13]. 
Immediate coronary angioplasty without previous thrombolytic therapy avoids the 
potentially adverse effects of myocardial and intraplaque hemorrhage that can occur 
after thrombolysis [14]. Immediateangioplasty is therefore advocated by some authors 
as the preferred treatment of acute myocardial infarction [9,15]. This approach has the 
additional advantage of reducing the hemodynamic importance of the underlying 
atherosclerotic lesion. One report suggested, however, that the incidence of 
complications is high after immediate angioplasty [16]. Except for a small randomized 
study comparing intracoronary streptokinase treatment with immediate angioplasty [17], 
comparisons of the two approaches are lacking. For that reason we performed a 
prospective, randomized trial comparing immediate angioplasty with intravenous 
streptokinase treatment in patients with acute myocardial infarction. 
Methods 
Patients 
The research protocol was reviewed and approved by our institutional review 
board. The enrollment of patients began on August 20, 1990, and ended on February 10, 
1992. Inclusion criteria were as follows: symptoms of acute myocardial infarction that 
persisted for more than 30 minutes, accompanied by an elevation of more than 1 mm (0,1 
m V) in the ST segment in two or more contiguous electrocardiographic leads; 
presentation within 6 hours after the onset of symptoms (or between 6 and 24 hours, if 
there was evidence of continuing ischemia); an age of less than 76 years; and no 
contraindication to thrombolytic therapy, including previous stroke or other known 
intracranial disease, recent trauma or surgery, refractory hypertension, active bleeding or 
prolonged cardiopulmonary resuscitation. Previous coronary-artery bypass grafting, 
previous Q-wave or non-Q-wave infarction, and cardiogenic shock were not reasons for 
N Eng1 J Mcd 1993:328:680-84. 
50 Chapter 2 
exclusion. Before randomization we recorded each patient's age, sex, Killip class on 
admission [18], electrocardiographic site of infarction, history of infarction, heart rate, 
arterial pressure, time of onset of symptoms, and time of hospital admission. 
Randomization and Treatment Protocol 
After infonned consent was obtained, the patients were randomly assigned to one of 
the two treatment groups by means of a closed-envelope system. All the patients 
received 300 mg of aspirin intravenously, followed by 300 mg of aspirin per day orally 
and intravenous nitroglycerin in a dose designed to maintain a systolic blood pressure 
of 1I0 mm Hg. Intravenous heparin was given in a dose designed to maintain the 
activated partial-thromboplastin time between two and three times the nonnal value for 
at least two days.This partial-thromboplastin time was measured twice a day. Although 
values more than three times the nonnal value occurred at least once in 57 percent of 
the patients, values less than two times the nonnal value were observed in only 13 
percent. Drugs such as lidocaine, calcium-channel blockers, and B-adrenergic blockers 
were given only at the discretion of the attending physicians. Fourteen percent of the 
patients in the streptokinase group and 16 percent of those in the angioplasty group 
received intravenous lidocaine; 31 percent and 41 percent, respectively, received 
calcium-channel blockers; and 39 percent and 27 percent received B-adrenergic 
blockers. Patients assigned to streptokinase received 1.5 million units intravenously 
over a period of one hour. Patients assigned to undergo coronary angioplasty were 
moved to the catheterization laboratory as quickly as possible and underwent coronary 
angiography. Both coronary arteries were visualized; left ventriculography was not 
perfonned. The time from admission to the initiation of therapy was calculated as the 
time to the start of the streptokinase infusion or the fIrst balloon inflation. 
Stndy End Points 
The variables we measured were the rate of recurrent ischemia before discharge, the 
left ventricular ejection fraction. and vessel patency. Recurrent ischemia before hospital 
discharge included the following: stable angina. defIned as chest pain and a positive 
exercise test; unstable angina defIned as chest pain and changes in the ST-T segment at 
rest; and recurrent myocardial infarction, defIned as chest pain. changes in the ST-T 
segment~ and a second increase in the creatine kinase level to more than two times the 
upper limitof nonnal,or an increase of >200 U per liter over the previous value if the 
level had not dropped below the upper limit of nonnaL All electrocardiograms and 
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laboratory results were reviewed for evidence of recurrent ischemia by two cardiologists 
blinded to assigned therapy. Electrocardiographic changes that were required for a 
diagnosis of ischemia were $I-segment depression or a new elevation of the $I-segment 
of at least I mm in two or more contiguous leads during chest pain; alternatively, 
unchanged or pseudonormal $I-segments had to be present during chest pain, with the 
T waves becoming inverted after the pain was relieved. These inverted T waves had to 
have a minimal depth of 2 mm and had to develop within three hours after the 
recurrence of chest pain. A symptom-limited bicycle exercise test was performed with 
the patient in the supine position, with increments of lOW per minute. An exercise test 
indicating ischemia was defined as a test with an ST depression of more than I rom 
measured 60 msec after the J point. In patients with base-line abnormalities in the $I-T 
wave, a depression of more than I mm in the ST segment was considered to indicate 
ischemia. 
The left ventricular ejection fraction was measured with a radionuclide technique 
before hospital discharge [19-21]. The technique used in our hospital has been 
previously described [22]. Briefly, it involved the multiple-gated equilibrium method 
after the labeling of red blood cells with [99mTc] pertechnetate. A gamma camera 
(General Electric Milwaukee) with a low-energy, all-purpose, parallel-hole collimator 
was used. The global ejection fraction is calculated automatically by computer (Star 
View, General-Electric), with the PAGE program. The data on ejection fractions were 
gathered by a specialist in nuclear medicine who was blinded to the clinical data. This 
use of a software program whose results did not depend on the operator protected 
against possible bias. The reproducibility of the method is excellent, the mean (±SD) 
difference between duplicate measurements being 1.2 ± 1.1 percent [22]. 
Arterial patency, defined as a Thrombolysis in Myocardial Infarction (TIMI) grade 
2 or 3 flow in the infarct-related coronary artery [6], was assessed by coronary 
angiography. In the angioplasty group, angiography was repeated, preferably after 
three months, to assess the rate of restenosis [23]. Only the patient's name, date of birth, 
and electrocardiographic site of infarction were known during the assessment of the 
angiogram. All infarct-related vessels were analyzed quantitatively with a personal-
computer-based-system of cardiovascular analysis (Cardiovascular Measurement 
System, Medis Medical Imaging Systems, Nuenen, the Netherlands) [24]. The basic 
algorithms have been described elsewhere [25]. The system uses a high-quality 
converter that allowed a selected cine frame to be projected onto a digital camera 
through a zoom lens. The video signal of the magnified region of interest was 
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subsequently digitized. For calibration. tbe boundaries of a nontapering part of the 
catheter were determined automatically over a length of approximately 2 em. To 
determine the contours of tbe vessel tbe user had only to indicate tbe beginning and 
end of the coronary segment to be analyzed, after which a path was computed 
connecting these two points [26]. The contour procedure was then performed 
iteratively by resampling tbe image along scan lines perpendicular to tbe patb computed 
in tbe fIrst iteration. Next, a matrix of cost coeffIcients was computed that represented 
for each point in tbe resampled matrix tbe edge strength based on tbe weighted sum of 
the fIrst and second derivative functions. The initial contours were found by the 
minimal-cost contour-detection technique applied to tbe cost-coeffIcient matrix [27]. In 
tbe second iteration, the contours determined in tbe fIrst iteration functioned as models 
for tbe subsequent determination. The edge strengths were corrected for the limited 
resolution of the entire imaging chain, a procedure that is of particularly important for 
tbe accurate measurement of smalI vessels. From tbe fInal contours a new center line was 
computed. A diameter was determined in absolute terms (in millimeters) by computing 
along the vessel center line tbe shortest distances between tbe left and right contours. 
The reference diameter was defIned as previously described [27]. 
Statistical analysis 
All end points were analyzed according to the principle of intention to treat. 
Student's t-test was used to compare mean values. Comparisons of tbe rates of recurrent 
ischemia, vessel patency, and complications were made witb a conventional chi-square 
test, but Fisher's exact test was used if tbere was an expected cell value of less tban 5. 
Al! calculated P values are two-tailed. In our presentation of the data, continuous base-
line and outcome variables are given as means ±SD, whereas discrete variables are given 
as absolute values and percentages. 
Results 
The patient's base-line clinical and angiographic characteristics are shown in Table 
I. The mean time from admission to the start of tbe streptokinase infusion was 30 ± 15 
minutes. All the patients assigned to angioplasty underwent emergency angiography. 
The infarct-related vessel showed a flow of TIM! grade 0 in 87 percent of tbe patients. 
Two patients witb open vessels were treated conservatively. Three patients witb severe 
multivessel disease or stenosis of tbe left main artery underwent emergency coronary-
artery bypass grafting after tbe insertion of an intraaortic counterpulsation balloon. The 
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remaining 65 patients underwent immediate angioplasty of the infarct-related vessel, 
with success in 64 patients (98 percent). (The angioplasty was considered to be 
technically successful if there was residual stenosis of less than 50 percent on visual 
estimation and a flow of TIMI grade 2 or 3.) In one patient the infarct-related vessel 
could not be reopened: this patient underwent immediate coronary-artery bypass 
grafting. The time from admission to the first balloon inflation was 61 ± 22 minutes. 
The creatine kinase level rose to 1327 ± 1304 U per liter in the streptokinase gronp 
and 1477 ± 1215 U per liter in the angioplasty group (P = 0.49). The normal value for 
creatine kinase is less than 100 U per liter in our hospital. 
Complications and required procedures are shown in Table 2. Intercerebral bleeding 
and bleeding necessitating a blood transfusion were considered to be bleeding 
complications. There were fewer complications overall in the patients assigned to 
immediate angioplasty than is those assigned to streptokinase. In particular, death, 
bleeding, and heart failure occurred less frequently in the angioplasty group. Tbirty-
eight percent of the patients in the streptokinase group had recurrent ischemia, but only 
9 percent of those in the angioplasty group (P < 0.001) (Table 3). The frequency of 
stable angina was similar in the two groups, but the incidence of recurrent myocardial 
infarction and unstable angina was higher in the patients who received streptokinase. 
Additional revascularization procedures were more often necessary in the streptokinase 
group (Table 3). Four patients assigned to angioplasty underwent bypass surgery within 
24 hours after admission, three without having undergone angioplasty.Three patients 
had elective bypass surgery for anatomical reasons after successful angioplasty [6, 9, 
and 10 days after admission). Only one patient in the angioplasty group underwent 
emergency repeat angioplasty for threatened reocclusion. Two patients in the 
angioplasty group underwent elective angioplasty of non-infarct-related arteries (7 and 
11 days after admission). In the streptokinase group, 2 patients had emergency bypass 
surgery, 6 had elective bypass surgery (13 ± 6 days after admission), 14 had emergency 
angioplasty, and 8 had elective angioplasty for recurrent ischemia (7 ± 5 days after 
admission). 
The left ventricular ejection fraction at rest was measured in all 138 survivors; it was 
45 ± 12 percent in the streptokinase group and 51 ± 11 percent in the angioplasty group 
(P = 0.004). Exercise testing was performed before discharge in 63 of the 72 patients in 
the streptokinase group (88 percent) and 67 of the 70 in the angioplasty group (96 
percent), with exercise capacities of 87 ± 31 and 97 ± 30 W, respectively (P = 0.07). 
Angina was present during exercise in 10 of 63 who received streptokinase (16 percent) 
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and in 5 of 67 patients who underwent angioplasty (7 percent, P = 0.13). Significant ST-
segment depression occurred in 41 percent of the streptokinase group (26 of 63 
patients) and in 21 percent of the angioplasty group (14 of 67, P = 0.01). The ejection 
fraction measured during exercise was 46 ± IS percent. Coronary angiography was 
performed after 21 ± 31 days in 68 of the 72 patients given streptokinase. Repeat 
angiography was performed after 82 ± 67 days in 63 of the 65 patients in the 
angioplasty group who actually underwent the procedure. The infarct-related vessel 
was patent in 68 percent of the patients who received streptokinase (49 of72) and 91 
percent of those assigned to angioplasty 64 of 70, P = 0.001). Among the patients 
assigned to angioplasty, only 7 percent had patent infarct-related arteries at base line, 47 
percent had patent vessels 60 minutes after admission, 84 percent 90 minutes after 
admission, and 91 percent 120 minutes after admission and at fOllow-up. Quantitative 
angiographic analysis of the infarct-related vessels is shown in Table 4. Restenosis, 
defined as stenosis of more than 50 percent in the dilated vessel, was observed in 11 of 
63 patients in the angioplasty group (17 percent). Although evidence has accumulated 
that the incidence of restenosis reaches a plateau at three months (23], the clinical 
implications of restenosis will become clear only after at least six months of follow-up. 
Excluding all angiography without evidence of restenosis performed within three 
months after angioplasty, we found the rate of restenosis to be 11 of 46, or 24 percent. 
Discussion 
Our study shows that in patients with acute myocardial infarction, direct 
angioplasty results in a higher rate of patency of the infarct-related coronary arteries, 
less severe residual stenotic lesions, better left ventricular ejection fraction, and a lower 
incidence of recurrent myocardial ischemia than intravenous streptokinase. 
Over the past decade, great efforts have been made to assess the optimal approach 
to patients with acute myocardial infarction, with much attention being directed to 
large-scale trials in which mortality is the primary end point. However, the funds and 
numbers of patients needed to support multiple large trials are simply not available [28]. 
Left ventricular ejection fraction has been proposed [29], as well as rejected [28], as end 
point in trials of acute myocardial infarction. Long-term survival after reperfusion 
therapy is strongly related to the left ventricular ejection fraction [30], but one of the 
main objections to the use of the ejection fraction as an end point has been the problem 
of "missing values" and the consequent debate about imputating data because studies 
are unavailable or technically inadequate [28]. We therefore chose a radionuclide 
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technique that is easy to perform, requires only 10 to 15 minutes, and is not cumbersome 
for the patient. We were thus able to measure the ejection fraction in almOSt all patients. 
The difference between groups in the left ventticular ejection fraction (51 percent in the 
angioplasty group and 45 percent in the streptokinase group) is comparable to that 
reported by O'Neill et al [17]. 
The primary target of all reperfusion therapies is the reopening of occluded coronary 
arteries. Two characteristics of patency are important in this regard. The fIrst is the time 
needed to reestablish flow in the infarct-related artery. The patients in our angioplasty 
group had rates of early patency that cannot be obtained with currently available 
thrombolytic agents. The second is the persistence of patency of the infarct-related 
artery, which is related to long-term survival [2]. The consequences of reocclusion after 
initially successful reperfusion are certainly a major concern [31]. However, the 
frequency of this phenomenon is low. The rate of patency in the patients who received 
streptokinase, assessed after a mean of 21 days, was 68 percent. The rate of patency in 
the angioplasty group was 91 percent, two hours after admission, and it was still 91 
percent at follow-up angiography after a mean of 82 days. So, regardless of the timing 
of angiography for assessment, patients who undergo angioplasty have a higher rate of 
patency. 
The third end point of our study was recurrent myocardial ischemia. Since the 
mortality from acute myocardial infarction has steadily declined recent years and is less 
than 10 percent in many recently published ttials [8-11], morbidity in the survivors 
becomes the most relevant clinical end point. Immediate angioplasty, as compared with 
streptokinase treatment, reduces the incidence of recurrent myocardial ischemia 
drastically. A composite clinical end point has recently been proposed [28] and used 
[10]. It includes not only recurrent infarction or angina, but also death, stroke, 
reocclusion, and heart failure. Freedom from any of these adverse events can than be 
compared. Of the 72 patients in our study who were treated with streptokinase, 34 (47 
percent) had one or more of these adverse events. Of the 70 patients assigned to 
angioplasty 13 (19 percent) had one or more of these adverse events. In the phase 5 of 
the Thrombolysis and Angioplasty in Myocardial Infarction ttial [10], the group 
receiving urokinase followed by ""delayed"" coronary angiography had a rate of 
freedom from events of 55 percent, which is comparable to our streptokinase group (53 
percent), whereas those who received a combination of tissue plasminogen activator 
and urokinase fOllowed by "aggressive" catheterization had a rate of 72 percent. The 
patients in our angioplasty group had a rate of freedom from adverse events rate of 81 
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percent, significantly better than the rate in the streptokinase group (53 percent, P = 
0.001). 
The participation of a cardiac surgeon becomes important if coronary angiography 
is performed immediately after admission. A large majority of the patients randomly 
assigned to angioplasty had, on anatomical grounds, a clear-cut indication for 
angioplasty but there were exceptions. In our series, three patients had coronary 
anatomy that was highly unfavorable for angioplasty and therefore required emergency 
bypass surgery of all m'\ior coronary arteries, including the infarct-related vessel. Three 
other patients with extensive multivessel disease had direct angioplasty of the infarct-
related vessel and subsequently underwent elective bypass surgery. Eight patients in 
the streptokinase group underwent bypass surgery for recurrent ischemia. Given that 
the coronary anatomy was known soon after admission in the angioplasty group, and 
not in the streptokinase group, clinical decision making was influenced by anatomical 
considerations. Finally, the implications of tltis study with respect to cost effectiveness 
require a formal analysis, which will be performed after one year of follow-up. 
We are indebted to Vera Derks for assistance in the preparation of the manuscript; to Gijs van den 
Brandhof for assistance in the collection of the data; to the many general practitioners of the region 
for their speedy referral of patients with acute myocardial infarction; and to the staff of the 
catheterization laboratory, without whose enthusiastic assistance this work would not have been 
possible. 
Appendix 
The physicians who participated in the study were as follows: at the Ziekenhuis de Weezenlanden, 
M.R.E Bloemers, MJ. de Boer, R. Enthoven, H.A. Holtkamp, J.C.A. Hoorntje, 
w.J.S. Louridtz,A.C.M. van Nus, H.A. OudeLuttikhuis,P'A.J. Remkes, H. Suryapranata,and 
E Zijlstra. (department of cardiology); R. Bakhuizen, M.M.P. Haalebos, EG. Leicher, and H.T. 
Sie (department of cardiovascular surgery); J. Damen, B.W. Mooi, A.W. Siemons, P.J.A.v.d. 
Starre, and J.E.A.T. Wever (department of cardiovascular anesthesiology); and S. Reiffers 
(department of nuclear medicine); and at University Hospital. Leiden, J.H.C. Reiber. 
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Table 1. Base-line Clinical and Angiographic Characteristics of the Study Patients 
Streptokinase Angioplasty 
Group Group 
Characteristic (N = 72) (N = 70) 
Age (yr) 61± 9 59 ± 10 
Male - sex no. (%) 59 (82) 62 (89) 
Anterior infarction - no. (%) 30 (42) 31 (44) 
Previous infarction - no. (%) 10 (14) 13 (19) 
Time from onset to admission (min) 162 ± 145 167± 165 
Killip class on admission-no. (%) 
1 58 (81) 55 (78) 
2 9 (13) 11 (16) 
3 4 (6) 2 (3) 
4 1 (1) 2 (3) 
Diseased vessels - no. of patients (%) 
o or 1 27 (37) 25 (36) 
2 18 (25) 20 (29) 
3 22 (31) 22 (31) 
Left main artery 1 (1) 2 (3) 
Unknown 4 (6) 0 
Infarct-related artery - no. of 
patients (%) 
Left anterior descending 23 (32) 26 (37) 
Left circumflex 11 (15) 12 (17) 
Right coronary 30 (42) 30 (43) 
Left main 1 (1) 1 (1) 
Graft 3 (4) 1 (1) 
Unk~own 4 (6) 0 
• Plus-minus values are means ± SO. Not all percentages sum to 100. 
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Table 2. Complications and Procedures in the Study Patients. 
Variable 
Death 
Stroke 
Bleeding 
Mechanical ventilation 
Femoral-artery repair 
Heart Failure 
Ventricular tachycardia and 
ventricular fibrillation 
Bypass surgery * 
Any of the above 
Streptokinase 
Group 
(N = 72) 
Angioplasty 
Group 
iN = 70) 
no. (%) 
4 (6) 0 
2 (3) 0 
6 (8) 2 (3) 
1 (1) 1 (1) 
0 1 (1) 
8 (11) 4 (6) 
6 (8) 5 (7) 
2 (3) 4 (6) 
19 (26) 10 (14) 
P Value 
0.13 
0.51 
0.29 
1.00 
0.49 
0.25 
0.79 
0.44 
0.07 
61 
* Coronary-artery bypass grafting was required within 24 hours after admission to the 
hospital. 
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Table 3. Recurrent Ischemia and Additional Procedures in the Study Patients' 
Streptokinase Angioplasty 
Group Group 
(N = 72) (N = 70) P Value 
no. (%) 
Recurrent ischemia 27 (38) 6 (9) < 0.001 
Stable angina 4 (6) 2 (3) 0.68 
Unstable angina 14 (19) 4 (6) 0.02 
Recurrent MI 9 (13) 0 0.003 
Procedure 
Counterpulsation 9 (13) 8 (11) 0.84 
PTCA 22 (31) 3 (4) < 0.001 
Bypass surgery 8 (11) 7 (10) 0.83 
• MI denotes myocardial infarction, and PTCA percutaneous transluminal angioplasty. 
N Engl J Moo 1993:328:680·84. 
z 
!l' 
0-," 
~ 
[ 
:;; 
'" w 
W 
'0 00 
0-
~ 
Variable 
Projections 
analyzed (no.) 
Stenosis ('Yo) 
Minimal luminal 
diameter (mm) 
Reference 
diameter (mm)t 
Largest balloon 
(mm) 
Table 4: Quantitative Angiographic Data' 
Angioplasty Group 
Before After Follow-Up 
at 82 ± 67 Days 
(N = 70) (N = 65) (N = 63) 
2.0 ± 0.5 2.2 ± 0.6 2.2 ± 0.5 
97 ± 10 29 ± 12 36±20 
0.11 ± 0.42 2.25 ± 0.62 2.04 ± 0.86 
2.98 ± 0.39 
3.17±0.66 3.15±0.64 
(1.89-5.03) (1.45-4.99) 
P Value 
< 0.001 
< 0.001 
0.244 
• Plus-minus values are means ± SD. t By the interpolated method. 
Streptokinase Group 
at21 ±31 Days 
(N = 68) 
2.1±0.6 
76± 19 
0.70 ±0.58 
3.02 ±0.66 
(1.72 - 4.82) 
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Beauchamp C, Westman EC, Govert JA. Treatment of acute myocardial infarction. 
Letter to the editor. N Eng! J Med 1993;329:430. 
To the Editor: "Referral filter" bias can affect the generalizability of the results of any 
clinical trial (I). The three clinical trials comparing angioplasty with thrombolytic 
therapy in the March 11 issue of the J oumal did not mention the referral filter that led to 
the enrolled samples (2-4). Physicians have no way of knowing whether the study 
populations are similar to their own patients without a clinical deScription of the patients 
who were excluded. Could the authors comment on the number of patients excluded 
and the reasons for exclusion? 
I. Sacket DL. Haynes RE. Guyatt GH, Tugwell P. Clinical epidemiology: a basic science for 
clinical medicine. 2nd ed. Boston: Little, Brown, 1991. 
2. Grines CL, Browne KE Marco J. et aI. A comparison of immediate angioplasty with 
thrombolytic therapy for acute myocardial infarction. N Engl J Moo 1993;328:673-9. 
3. Zijlstra F. De Boer MJ, Hoorntje JCA, Reiffers S, Reiber JHC, Suryapranata H. A comparison 
of immediate coronary angiopJasty with intravenous streptokinase in acute myocardial 
infarction, N Engl J Med 1993;328:680-4. 
4. Gibbons RJ, Holmes DR, Reeder GS, Bayley KR, Hopfenspirger MR, Gersh BJ. Immediate 
angioplasty compared with the administration of a thrombolytic agent followed by conservative 
treatment for myocardial infarction. N Engl J Med 1993;328:685-91. 
Zijlstra F, de Boer MJ, Suryapranata H. Treatment of acute myocardial infarction. 
Letter to the editor. N Eng! J Med 1993;329:432. 
The authors reply: 
To the Editor: We agree with Beauchamp and colleagues that referral-filter bias can 
affect the generalizability of the results of a clinical trial. We registered all patients 
admitted to our hospital who fulfilled the inclusion criteria for our study, but were 
excluded for other reasons. During the study period, six eligible patients were not 
randomized. Two patients declined to participate, one died in the emergency room 
before randomization, and one who lived outside the Netherlands was not randomized 
because of anticipated problems with follow-up. In two cases the attending physicians 
did not wish to include the patient in the srudy. 
Felix Zijlstra, M.D.,Ph.D. 
Menko Jan de Boer, M.D. 
Harry Suryapranata, M.D., Ph.D. 
N Eng! J Moo 1993:328:680-84. 
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Hospital Mortality and Reinfarction. 
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Objectives: The purpose of the present study was to compare intravenous 
streptokinase with immediate coronary angioplasty without antecedent thrombolytic 
therapy with regard to left ventricular function and hospital mortality and reinfarction. 
Background: Despite the widespread use of intravenous thrombolytic therapy and 
immediate percutaneous transluminalcoronary angioplasty, these two strategies to treat 
patients with an acute myocardial infarction have only recently been compared in 
randomized trials. Coronary angioplasty has been shown to resuIt in a higher patency 
rate of the infarct-related coronary artery, with a less severe residual stenotic lesion, 
compared with streptokinase therapy, but whether this more favorable coronary 
anatomy results in clinical benefit remains to be established. 
Methods: We studied 301 patients with acute myocardial infarction randomly 
assigned to undergo immediate coronary angioplasty without antecedent thrombolytic 
therapy or to receive intravenous streptokinase therapy. Before discharge left 
ventricular ejection fraction was measured by radionuclide scanning. 
Results: The in-hospital mortaIity rate in the streptokinase group was 7% (11 of 149 
patients) compared with 2% (3 of 152) in the angioplasty group (p = 0.024). In the 
streptokinase group recurrent myocardial infarction occurred in 15 patients (10%) 
versus in 2 (1%) in the angioplasty group (p < 0.001). Either death or nonfatal 
reinfarction occurred in 23 patients (15%) in the streptokinase group and in 5 patients 
(3%) in the angioplasty group (p = 0.001). Left ventricular ejection fraction was 44 ± 
11 % (mean ± SD) in streptokinase group versus 50 ± 11 % in the angioplasty group (p < 
0.001). 
Conclusions: These findings indicate that immediate coronary angioplasty without 
antecedent thrombolytic therapy resuIts in better left ventricular function and lower 
risk of death and recurrent myocardial infarction than treatment with intravenous 
streptokinase. 
(J Am Call CardioI1994;23:1004-8) 
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During the past decade the efficacy of thrombolytic therapy and coronary 
angioplasty in restoring patency of the infarct-related coronary artery has been studied 
extensively [1-11]. Currently, the combination of streptokinase, aspirin and heparin is 
one of the generally accepted treatment strategies in patients with acute myocardial 
infarction [8-10]. Direct coronary angioplasty without antecedent thrombolytic therapy 
avoids the potentially adverse effects of myocardial and intraplaque hemorrhage that 
can be observed after thrombolytic therapy [12] and may be an appropriate alternative 
therapy [7,13-15]. In a previous report we showed that direct coronary angioplasty is 
associated with a higher patency rate, a less severe residual stenotic lesion in the 
infarct-related vessel, better preserved left ventricular function as well as less recurrent 
ischemia before hospital discharge compared with intravenous streptokinase therapy 
[13]. However, several important questions are still to be answered before direct 
angioplasty can be accepted as the therapy of choice in patients with acute myocardial 
infarction. In particular, does the superior coronary anatomy result in a mOre favorable 
clinical outcome? Although the results of the Primary Angioplasty In Myocardial 
Infarction trial [14] showed a strong trend toward survival benefit and lower rate of 
reinfarction with angioplasty versus intravenous tissue plasminogen activator~ 
additional data are needed before definitive conclusions can be drawn. We therefore 
extended our trial to investigate differences in mortality, recurrent myocardial infarction 
and left ventricular ejection fraction before hospital discharge. 
Methods 
The research protocol was reviewed and approved by the institutional review 
board. The enrollment of patients began on August 20, 1990 and ended on April 26, 
1993. Inclusion criteria were: 1) symptoms of acute myocardial infarction persisting> 
30 min, accompanied by an electrocardiogram (ECG) with> I-mm (0, 1 m V) ST segment 
elevation in two or more contiguous leads; 2) presentation within 6 h after symptom 
onset or between 6 and 24 h, if there was evidence of continuing ischemia; 3) age < 76 
years; 4) no contraindication to thrombolytic intervention. Before randomization the 
following variables were recorded: age, gender, Killipclass on admission [16], ECG site 
of infarction, history of previous infarction, time of symptom onset and time of hospital 
admission. 
Randomization and Treatment. 
After informed consent was obtained, patients were randomly assigned to one of 
the two treatment modalities by means of a closed-envelope system. All patients 
J Am Col! CardioI1994;23:1004-8. 
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received aspirin and heparin. Heparin was given intravenously and titrated to a dose 
that resulted in an activated partial thtomboplastin time of two to thtee times the normal 
value. Patients assigned to streptokinase therapy received 1.5 million U intravenously 
in I h. Patients assigned to undergo coronary angioplasty were immediately 
transported to the catheterization laboratory for coronary angiography. If the coronary 
anatomy was suitable for angioplasty. this procedure was performed immediately using 
standard techniques. 
End points. 
The study end points were the following: 1) death before hospital discharge. 2) 
Recurrent myocardial infarction before hospital discharge, defined as chest pain 
accompanied by changes in ST-T waves or new Q waves, and a second increase in 
creatine kinase of more than two times the upper limit of normal or an increase of this 
magnitude over the previous value if the level had not decreased below the upper limit 
of normal [13]. 3) Left ventricular ejection fraction was measured with a radionuclide 
technique before hospital discharge. The technique used in our hospital has been 
described elsewhere [13]. 
Statistical analysis. 
Statistical analysis was performed with an SPSS personal computer, version 4.01, 
1990. All end points were analyzed according to the principle of intention to treat. 
Differences between group means were tested by a two-tailed Student t test. A chi-
square method was used to test differences between proportions, with calculation of 
relative risks and exact 95% confidence intervals [17]. Patients randomized to undergo 
angioplasty were defined as the reference group. The Fisher exact test was used if there 
was an expected cell value < 5. Statistical Significance was defined as a p value < 0.05. 
Multivariate analysis was performed by fitting a logistic regression model, permitting 
calculation of odds ratios that could be interpreted as relative risk and their 95% 
confidence interval (eI). All baseline characteristics that could have had an effect on 
the occurrence of in-hospital death or recurrent infarction were incorporated into the 
model to estimate the proper treatment effect. In the multivariate analysis, adjustments 
were made for differences in age (continuous variable), gender, infarct location (anterior 
versus nonanterior), Killip class on admission, time from onset of symptoms to admission 
and previous myocardial infarction. In the presentation of the data, continuous 
variables are given as mean value ±SD, whereas discrete variables are given as absolute 
values and percents. 
J Am Coli Cardiol 1994;23:1004-8. 
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Results 
The 301 patients in this study include the 142 patients evaluated previously [13]. 
During the enrollment period, 301 patients were randomized to undergo either 
streptokinase therapy (149 patients) or coronary angioplasty (152 patients). All 
patients assigned to the angioplasty group underwent immediate coronary 
angiography, with one exception: One patient died of cardiogenic shock immediately 
after randomization. Five patients had an open infarct-related artery and were treated 
conservatively. Six patients with extensive coronary artery disease not suitable for 
angioplasty underwent primary coronary artery bypass grafting. Angioplasty was 
performed in 140 patients, and the procedure was successful in 136 (97%). In four 
patients angioplasty failed to reopen the infarct-related vessel. Three of them 
underwent emergency coronary artery bypass grafting, and one patient was treated 
conservatively. Of the 136 patients with successful angioplasty, 7 underwent elective 
coronary artery bypass grafting for left main coronary artery or extensive three-vessel 
coronary artery disease. All patients assigned to therapy with intravenous 
streptokinase were treated accordingly, with one exception: One patient died of 
cardiogenic shock immediately after randomization. Another 16 patients with 
hemodynamic compromise and signs of ongoing ischemia within 24 h after admission 
underwent rescue angioplasty, with procedural success in 15 patients. Emergency 
coronary artery bypass grafting was performed in one patient. Sixteen patients 
underwent emergency coronary angioplasty because of signs of recurrent ischemia, 
with emergency coronary artery bypass grafting in 1 patient, and procedural success in 
15 patients. Nine patients underwent elective angioplasty, and 13 patients underwent 
elective coronary artery bypass grafting for exercise-induced signs of myocardial 
ischemia. The remaining 94 patients were treated conservatively. Coronary 
angiography was performed in 141 of the 149 patients assigned to receive 
streptokinase (95%). Baseline characteristics are shown in table I, and additional 
clinical data are shown in Table 2. 
End points, 
Death: A total of 14 patients (5%) died, 11 (7%) in the streptokinase group and 3 
(2%) in the angioplasty group (p = 0.024). The cause of death is shown in Table 3. If 
patients in cardiogenic shock were excluded, there was still a significantly lower 
mortality in the patients randomized to undergo angioplasty (2 of 144 versus 10 of 146, 
P = 0.03). 
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Recurrent myocardial infarction. A total of 17 patients (6%) had a recurrent 
myocardial infarction, 15 (10%) in the streptokinase group and 2 (I %) in the 
angioplasty group p < 0.001). Death or a nonfatal recurrent infarction occurred in 23 
patients (15%) in the streptokinase group and in 5 patients (3%) in the angioplasty 
group (p = 0.001). The results of the univatiate analysis are shown in Table 3. 
Age was associated with mortality. Non-survivors were 66 ± 9.8 years old and 
survivors were 59 ± 5.5 years old (p = 0.01). After multivatiateanalysis, age, Killip class 
on admission, previous myocardial infarction and treatment with streptokinase were 
associated with the endpoints of death and recurrent myocardial infarction, as well as 
the combination of death and nonfatal recurrent infarction. Patients with a previous 
myocardial infarction had an increased risk of recurrent infarction (relative risk 4.5, 
95% CI 1.4 to 14.5). Killip class on admission was associated with an increased risk of 
death (relative risk 3.6 per step, 95% CI 2.0 to 6.6). After adjustments were made for 
differences in age, gender, previous myocardial infarction, time from onset of symptoms 
to admission, location of the infarction and Killip class on admission, the relative risk of 
reinfarction in the streptokinase group was 9.7 (95% CI 2.1 to 45.1) compared with the 
angioplasty group, and the relative risk of death was 8.5 (95% CI 1.7 to 41.7) in the 
streptokinase group compared with the angioplasty group. 
Left ventricular ejection fraction. Left ventricular ejection fraction was measured 
in 140 patients (94%) in the streptokinase group and in 149 patients (98%) in the 
angioplasty group. Patients in the streptokinase group had an ejection fraction of 
44±1l % and those in the angioplasty group had an ejection fraction of 50 ± 11% (p < 
0.001). A previous myocardial infarction, the location of the infarction and the time 
from symptom onset to admission were related to ejection fraction, as shown in Table 4. 
Before discharge 260 (86%) of the 30 I patients performed a symptom-limited exercise 
stress test. The results are shown in Table 5. 
Discussion 
Although thrombolytic therapy is one of the major advances in the care of patients 
with an acute myocardial infarction [1-4,6,9,1O],reperfusion of the occluded infarct-
related artery is not obtained in 20% to 32% of patients [8,11,13]. Recent trials have 
shown that immediate coronary angioplasty without antecedent thrombolytic therapy 
results in a reperfusion rate> 90% [7,13,14]. Furthermore, signs of recurrent myocardial 
ischemia that occur often in patients after thrombolytic therapy and result in 
reinfarction, as well as subsequent in-hospital interventions [5], seem to be reduced 
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after immediate angioplasty [13, 14], We therefore extended our previous trial [13] to 
investigate whether these differences in coronary patency and recurrent ischemia 
would result in differences in mortality and the incidence of recurrent myocardial 
infarction, Our data support this hypothesis, 
Myocardial salvage and left ventricular ejection fraction. 
Left ventricular ejection fraction has been proposed [18], as well as rejected [19], as 
an end point in trials of acute myocardial infarction. Long-term survival is strongly 
related to left ventricular ejection fraction [6], but one of the main objections to the use 
of ejection fraction as an end point has been the problem of "missing values", and the 
consequent debate about imputing data because studies are unavailable Or technically 
inadequate [19]. We therefore chose a radionuclide technique that is easy to perform, 
requires only 10 to 15 min and is not cumbersome for the patient [13]. We were thus 
able to measure ejection fraction in nearly all of our patients (289 [96%] of 301). Our 
results show (Table 4) that immediate angioplasty salvages more myocardium than 
thrombolytic therapy, especially in patients with an infarction of the anterior wall, and 
in patients with a short interval between symptom onset and hospital admission. 
Impact of coronary angiography immediately after hospital admission. 
All but one patient randomized to undergo angioplasty underwent immediate 
coronary angiography. Therefore, in patients randomized to undergo angioplasty 
coronary anatomy was known at an early stage as opposed to patients randomized to 
receive streptokinase. This knowledge of the coronary anatomy certainly played a role 
in the subsequent therapeutic strategy because it allowed emergency surgical 
intervention in patients with a high risk coronary anatomy. In patients randomized to 
receive streptokinase, revascularization procedures were performed only on clinical 
indication. "Rescue" angioplasty for failed thrombolysis was performed in 11 % of 
patients, and angioplasty or bypass surgery for recurrent ischemia was performed in 
26% of patients randomized to streptokinase. The difference in results between the two 
groups might therefore not only be due to differences in initial treatment but, possibly, 
to subsequent different management as welL 
Which patients with acute myocardial infarction should have primary 
angioplasty? 
If immediate angioplasty were offered to all patients with an acute myocardial 
infarction, a tremendous logistic burden would result and be impossible to organize at 
the present time [15]. However, this may not be necessary. A substantial number of 
patients fare very well with thrombolytic therapy. The most important task for the 
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coming years will therefore be to identify on admission those patients that will do well 
with thrombolytic therapy and to apply immediate angioplasty without antecedent 
thrombolytic therapy in subgroups of patients who are likely to gain the most benefit 
from this procedure [15]. This policy of "tailored" angioplasty and thrombolytic 
therapy in patients with a low risk of death or other complications should be based on 
easily obtainable clinical data that are available immediately after hospital admission. 
Study Limitations 
Given the limited number of patients in our study it is impossible to conclude 
exactly which subgroups do benefit most from angioplasty. the only easy applicable 
criterion being Killip class ~ II on admission. Also the magnitude of the effect of 
angioplasty on the risks of reinfarction and death should be viewed with caution 
because of the wide confidence intervals. 
Conclusion. 
Our results show that immediate coronary angioplasty without antecedent 
administration of a thrombolytic agent results in better left ventricular function and a 
lower in-hospital incidence of recurrent infarction and death than treatment with 
intravenous streptokinase. 
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Table 1: Baseline Characteristics of the Patients 
Streptokinase p Angioplasty 
(N = 149) Value (N = 152) 
Age (years) 61 ±9 0.06 59 ± 10 
Male sex 121 (81%) 0.59 127 (84%) 
Anterior infarction 68 (46%) 0.27 79 (52%) 
Previous infarction 21 (14%) 0.11 32 (21 %) 
Time onset-admission (min)' 176 ± 172 0.43 195 ± 227 
Killip class on admission: I. 122 (82%) 0.22 116 (76%) 
II. 15 (10%) 0.26 22 (14%) 
Ill. 9 (6%) 0.41 6 (4%) 
IV. 3 (2%) 0.14 8 (5%) 
Multivessel disease 88 (59%) 0.63 95 (63%) 
• From onset of symptoms of myocardial infarction to hospital admission (the 
moment the ambulance drives through the door). Values presented are mean 
value ± SD or number (%) 
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Table 2: Clinical Data 
Streptokinase p Angioplasty 
Group Value Group 
(N= 149) (N= 152) 
Hospital stay 14.4 ± 6.8 0.003 12.3 ± 5.3 
Stroke 3 (2%) 0.37 (1%) 
Vascular repair 0 (0%) 1.0 1 (1%) 
Mechanical ventilation 3 (2%) 0.68 2 (1%) 
Heart failure 17 (11%) 0.03 7 (5%) 
Bleeding 9 (6%) 0.97 8 (5%) 
IABP 12 (8%) 0.28 19 (13%) 
Peak CK 1,403 ± 1,276 0.33 1,268 ± 1,088 
Values presented are mean value ± SO or number (%). Bleeding = bleeding 
requiring a blood transfusion or intracranial bleeding; CK = creatine kinase; Heart 
failure = signs of heart failure requiring therapy with diuretic agents and angiotensin-
converting enzyme inhibitors < 24 hours after admission; IABP = intraaortic balloon 
pump; Vascular repair = surgical repair of the femoral artery. 
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Table 3: Comparison of Outcome Between 149 Patients Assigned to Streptokinase 
Therapy and 152 Patients Assigned to Coronary Angioplasty (Univariate analysis) 
Death 
Cardiogenic shock 
Cardiac rupture 
Sudden death 
Stroke 
Recurrent infarction 
Death or 
recurrent infarction 
Streptokinase Angioplasty p-value 
11 
5 
2 
3 
1 
15 
23 
3 
2 
o 
1 
o 
2 
5 
0.024 
0.001 
0.0003 
RR 95%CI 
3.96 1.01 - 22.5 
8.40 1.89 - 76 
5.40 1.91 - 81 
CI = Confidence Interval; pts = patients; RR = Relative Risk of outcome of 
streptokinase-treated patients compared to angioplasty-treated patients. 
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Table 4. Left Ventricular Ejection Fraction 
Streptokinase Group 
(n=149) 
Angioplasty Group 
(n=152) 
Chapter 3 
% (mean ±SO) No. % (mean ±SO) No. p value 
All pts 
Anterior infarction 
No anterior infarction 
Previous infarction 
No previous infarction 
> 120-min from onset to admission 
< 120-min from onset to admission 
< 60-min from onset to admission 
All pts 
Anterior infarction 
No anterior infarction 
Previous infarction 
No previous infarction 
> 120-min from onset to admission 
< 120-min from onset to admission 
< 60-min from onset to admission 
pts = patients 
J Am Coli Cardiol 1994;23:1004-8. 
44 ± 11 140 50 ± 11 149 
38 ± 12 61 47± 12 76 
48± 9 79 52± 9 73 
37 ± 12 18 43 ± 14 31 
45 ± 11 122 51 ± 9 118 
44± 12 63 49 ± 9 48 
46 ± 10 59 53± 8 71 
44± 13 20 57± 6 15 
Difference 
Absolute Relative 
(% ) (% ) 
6 12 
9 19 
4 8 
6 14 
6 12 
5 10 
7 13 
13 23 
< 0.001 
< 0.001 
0.006 
0.136 
< 0.001 
0.01 
< 0.001 
0.002 
8. The basic instinct tbat seduces tbe angioplaster to dilate a non-culprit lesion in 
patients witb unstable coronary syndromes often turns out to be fatal attraction. 
9. "Onderdilatatie". dat wil zeggen coronaria-angioplastiek uitgevoerd met een 
ballon die in verhouding te klein is voor de te dilateren kransslagader. is een 
belangrijke oorzaak van re-stenose. 
10. Zo er al een mortaliteitsreductie van het cho1estero1verlagend effect van het eten 
van een tot twee teentjes knoflook per dag bestaat. zal die teniet worden gedaan 
door de toename van geweldsdelicten tegen mensen die deze therapie volgen. 
11. Als over tien jaar de parlementaire enquete over de teloorgang van de 
Nederlandse gezondheidszorg gehouden wordt. zullen de huidige 
verantwoordelijke politici beweren. dat de regelgeving en wetten op zich juist 
waren, maar dat de uitvoering door medici sterk te wensen over heeft gelaten. 
12. Om het promoveren op rijpere leeftijd te bevorderen dient een "Old Investigator's 
Award" ingesteld te worden. 
13. Een homeopatbisch afslankrniddel, mits voldoende verdund, heeft het voordeel 
dat men er nauwelijks dikker van wordt. 
14. De systematische evaluatie van de tberapeutische effectiviteit van nieuwe 
medische behandelingsmetboden is niet uitsluitend een universitaire of 
wetenschappelijke taak maar moet een integraal deel van de gezondheidszorg 
zijn, waarbij de behandelaar, de ziektekostenverzekeraar, de overheid en ook de 
patient dienen mee te werken. 
15. Zonder berniddeling van Ivan Vaughan zou de historische ontmoeting tussen 
J.W. Lennon en J.P. MacCartuey op Zaterdag 6 Juli 1957 tijdens een tuinfeest bij 
de St. Peter's Church te Woollon, Liverpool, nooit hebben plaatsgevonden. 
(P.M. MacCartney, persoonlijke mededeling)' 
Rotterdam, 21 September 1994 
M.J. de Boer 
Stellingen 
L Het gunstige effect van primaire coronaria-angioplastiek wordt voomamelijk 
bepaald door vroege, effectieve en blijvende doorgankelijkbeid van het met 
het hartinfarct samenhangende val, 
(dit proefschrift) 
2. Infarct angioplastiek heef! ioveel verraderlijke aspecten dat een nuttig effect 
alleen te verwachten valt indien dit, met cardiochirurgische standby, door 
geoefende handen wordt uitgevoerd. 
(dit proefschrift) 
3. Primaire coronaria-angioplastiek kan de sterfte aan een voorwandinfarct en een 
onderwandinfarct reduceren in een mate waardoor het onderlinge verschil in 
ziekenhuissterfte, zoals gezien wordt bij conventionele behandeling, vrijwel 
verdwijnt. 
(dit proefschrift en N Engl J Med 1993;328:673-679) 
4. Prehospitale trombolyse ontneemt de patient met een hartinfarct de kans op 
behandeling met primaire coronaria-angioplastiek. 
5. Blokkade van de thrombocyten glycoproteine IIblIIIa receptor door het 
chimerisch 7E3 (c7E3) monoclonaal antilichaam Fab fragment geeft een 
aanzienlijke vermindering van complicaties voor, tijdens en na coronaria-
angioplastiek wegens onstabiele angina pectoris. 
(Circulation 1994;89:596-603) 
6. \Toege TIMI (Thrombolysis in Myocardial Infarction) graad 3 perfusie van de met 
het infarct samenhangende kransslagader kan opnieuw worden gebruikr als een 
altematief eindpunt in studies naar nieuwe behandelingsmethoden van het acute 
hartinfarcl, 
(dit proefschrift en N Engl J Med 1993;329:1615-1622) 
7. Enerzijds beschermt NO door vasodilatatie de vaatwand tegen shear-stress 
schade, echter anderzijds vormt het een emstige bedreiging voor het endotheel 
in de vorm van het toxische peroxynitriet (ONOO ': het product van NO en O2'), 
waardoor het mogelijk een rol speelt in de pathogenese van atherosclerose. 
(J Bioi Chern 1991;266:4244-4250 en Bioi Chern 1994;375:81-88) 
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Table 5: Bicycle exercise test before discharge 
Angina 
> 1 mm ST depression 
Maximal workload (Watt) 
Streptokinase 
Group 
(N = 122) 
17 (14%) 
49 (40%) 
90 ± 30 
p Angioplasty 
Value Group 
(N = 138) 
0.04 9 (7%) 
< 0.001 30 (22%) 
0.03 98 ± 30 
Values presented are mean value ± SO or number (%). 
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Background 
Early and effective flow through the infarct-related vessel is probably of paramount 
importance for limitation of infarct size and preservation of left ventricular function in 
patients with acute myocardial infarction. Primary coronary angioplasty may offer 
advantages in these respects compared with thrombolytic therapy. The purpose of the 
present study was to assess the effects on estimated enzymatic infarct size and left 
ventricular function in patients with acute myocardial infarction randomly assigned to 
undergo primary angioplasty or to receive intravenous streptokinase. 
Methods and results 
We evaluated 301 patients with signs of acute myocardial infarction and without 
contraindications for thrombolysis who presented within 6 hours after onset of 
symptoms or between 6 and 24 hours if there was evidence of ongoing ischemia. One 
hundred fifty-two patients were randomly assigned to undergo primary angioplasty, and 
149 patients were assigned to receive treatment with streptokinase, (1.5 million U IV). 
Infarct size was estimated from enzyme release. Global left ventricular ejection fraction 
and regional wall motion, if possible in combination with exercise testing, were 
evaluated by radionuclide ventriculography before discharge. Thrombolysis in 
Myocardial Infarction (TlMI)flow grade 3 through the infarct-related vessel within 120 
minutes after admission was achieved in 92 % of all patients assigned to receive primary 
angioplasty therapy. Myocardial infarct size was 23 % smaller in the angioplasty group 
compared with patients assigned to receive streptokinase (1003±784 U/L versus 
131O±1l98 U/L, P = .012). Global left ventricular ejection fraction (50±9% versus 
45±1l %, P < .001) and regional wall motion in the infarcHelated zones (42±14% versus 
34±13%, P < .001) were better in the angioplasty group, which could mainly be 
contributed to myocardial salvage in the infarct-related areas. The observed differences 
were more pronounced in patients with an anterior wall myocardial infarction, although 
patients with a nonanterior infarct location also showed a beneficial effect of primary 
coronary angioplasty on left ventricular function compared with streptokinase therapy. 
Furthermore, the observed differences appeared to be more pronounced in patients 
presenting relatively early (within 2 hours) after onset of symptoms. 
Conclusions 
In patients with acute myocardial infarction, primary angioplasty results in a smaller 
infarct size and a better preserved myocardial function compared with patients 
randomized to receive treatment with intravenous streptokinase. This is probably due to 
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early and optimal blood flow through the infarct-related vessel, as can be accomplished 
in a very high percentage of patients undergoing primary coronary angioplasry. 
Key Words * myocardial infarction * angioplasty * thrombolysis * left ventricle * 
infarcts 
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In patients with acute myocardial infarction, early treatment resulting in restoration 
of adequate blood flow through the infarct-related vessel results in limitation of infarct 
size, preservation of left ventricular function and reduction of mortality [1-8). Several 
large clinical trials have established that thrombolytic therapy reduces mortality, and 
thrombolysis is the treatment of choice in patients with acute myocardial infarction [4,6-
8). Recently we demonstrated a higher patency rate of the infarct-related coronary 
vessels, a reduction of the severity of the residual stenotic lesions, and a lower incidence 
of recurrent myocardial ischemia in patients with acute myocardial infarction who 
underwent primary (or direct) coronary angioplasty compared with those who received 
intravenous streptokinase. Furthermore, global left ventricular ejection fraction, as 
measured with a quantitative radionuclide method, was better in the patients assigned to 
undergo primary angioplasty [9,10). After completion of this initial series of 142 patients 
[9), the randomized study was extended to a total of 301 patients to achieve greater 
certainty about the benefit of primary coronary angioplasty. Previous studies of 
percutaneous transluminal coronary angioplasty (PTCA) in acute myocardial infarction 
did not yield additional benefit in patients pretreated with thrombolytic agents. [11-15]. 
This lack of benefit has been attributed to activation of coagUlation during thrombolytic 
therapy but could also be related to hemorrhage in the wall of the infarct-related artery 
or in the infarcted myocardium. [16,17). Primary coronary angioplasty without 
pretreatment with thrombolytic agents may be advantageous since these deleterious 
phenomena are avoided. [9, 17,18). 
This report describes the results of the full cohort of 301 patients with special 
emphasis on infarct size as measured from enzyme release and on global and regional 
left ventricular function. 
Methods 
Patient Selection 
The research protocol was approved by the institutional review board of the 
Weezenlanden Hospital. Enrollment began on August 20, 1990, and ended on April 26, 
1993. Inclusion criteria were: (1) symptoms compatible with acute myocardial infarction 
persisting for more than 30 minutes accompanied by an ECG with more than O.l-m V ST-
segment elevation in two or more contiguous leads; (2) all patients presenting within 6 
hours after symptom onset, as well as those presenting between 6 and 24 hours if they 
had evidence of continuing ischemia; (3) age less than 76 years and (4) no 
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contraindication to thrombolytic therapy, including prior stroke or other known 
intracranial diseases, recent trauma or surgery, refractory hypertension, active bleeding, 
or prolonged cardiopulmonary resuscitation. Prior coronary artery bypass grafting, prior 
Q-wave or non-Q-wave infarction, and cardiogenic shock were no reasons to exclude a 
patient. After informed consent was obtained, patients were randomly assigned to one 
of the two treatment modalities using a closed envelope system. 
Treatment Protocol 
All patients received 300 mg aspirin IV followed by 300 mg/d PO and N 
nitroglycerin in a dosage aimed at a systolic blood pressure of llO mmHg. Intravenous 
heparin was given in a bolus of 10 000 U and thereafter as a continuous infusion 
adjusted to maintain the activated partial thromboplastin time between two and three 
times the normal value for at least 2 days. Other drugs such as B-adrenergic blockers, 
lidocaine, or calcium antagonists were given on indication only. Patients randomized to 
streptokinase received 1.5 million U IV in I hour. Patients randomized to coronary 
angioplasty were immediately transported to the catheterization laboratory and 
underwent coronary angiography followed by immediate coronary angioplasty if 
indicated. Both coronary arteries were visualized, and left ventriculography was not 
performed. Time from admission to therapy was calculated as time from admission to the 
first balloon inflation or to start of the streptokinase infusion. 
Enzyme Measurements and Infarct Size 
Creatine kinase (CK) and lactate dehydrogenase (LDH) were determined 
enzymatically on a Hitachi 717 automatic analyzer according to the International 
Federation of Clinical Chemistry (IFCC) recommendation at 300 C [20]. Reference 
values for LDH are <320 UIL (adults) and for CK are <llO UIL (females) and <130 UIL 
(males). Infarct size was estimated by measurements of enzyme activities using LDH as 
the reference enzyme. This method is equal to estimation of infarct size from 0:-
hydroxybutyrate dehydrogenase (HBDH) and has been described in detail [2,20]. 
Cumnlative enzyme release from five to seven serial measurements up to 72 hours after 
symptom onset (LDH Qn) was calculated by the Cardiovascular Research Institute 
Maastricht (W.Th.H.) with blinding to all data other then hospital registration number 
and date of birth. 
A two-compartment model was used, which has been validated in several studies on 
the turnover of radio-labeled plasma proteins and circulating tissue enzymes [2,20-22]. 
The plasma activity of enzyme C at time t is determined by input of enzyme from the 
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heart and elimination of enzyme determined by a fractional catabolic rate constant 
(FCRLDH). In addition, there is extravasation of enzyme, determined by a fractional 
transcapillary escape rate constant (TER), and return to plasma from the extravascular 
pool E(t) determined by a fractional extravascular return rate constant (ERR). 
Cumulative release of enzyme per liter of plasma from zero time up to time t is given by: 
(1) Q(t) = cet) + E(t) + 0 J t FCRLDH'ce~) d~ 
where cet) and E(t) are the activities still present in the intravascular and extravascular 
spaces and the integral term encompasses eliminated activity. A value of FCRLDH = 
0.015 h-I was used. The extravascular pool E(t) is determined by the time-dependent 
plasma activity and TER and ERR: 
(2) E(t) = TER.exp (-ERR.t). 0 J t exp (ERR.~) C (~) d't 
Values of cet) in Equations 1 and 2 were obtained by subtraction of the normal activities 
in plasma from the actual activities measured at time t. Individual values of these normal 
activities were estimated from the first sample of each patient when this sample was 
obtained within 3 hours after first symptoms. Otherwise, a fixed mean normal value of 
175 UIL was used. Fixed values ofTER = 0.014 h·1 and ERR = 0.018 h-I were used. 
Radionuclide Ventriculography 
Left ventricular ejection fraction was measured before discharge by radionuclide 
ventriculography using the multiple gated equilibrium method following the labeling of 
red blood cells of the patient with 99mTc-pertechnetate [23]. A General Electric 300 
gamma camera with a low-energy all-purpose parallel- hole collimator was used. Global 
ejection fraction was calculated by a General Electric Star View computer using the fully 
automatic PAGE program. The use of this software program protects against operator 
bias. The reproducibility of this method is excellent, with a mean difference C±SD) 
between first and second values of duplicate measurements of 1.2±1.l % [23]. The left 
anterior oblique projection with some degree of cranial angulation to separate the right 
and the left ventricle, was used to analyze regional wall motion. The left ventricle was 
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divided into five zones corresponding to the posterolateral, inferolateral, inferoapical, 
basoseptal, and anteroseptal regions, The area involving the valve planes was excluded, 
Regional wall motion was calculated from maximal and minimal counts in all regions and 
was expressed in percentages, Infarct- and non-infarct-related segments were indicated 
by two investigators using the ECG site of infarction and coronary anatomy as 
references, without further knowledge of clinical data, A symptom-lintited bicycle 
exercise test was performed with participants in the supine positiou at increments of 10 
W/min, only in patieuts without contraindications to exercise, An exercise test 
indicating ischentia was defined as a test with an ST-segment depression of more than I 
mmmeasured 60 ntilliseconds after the J point. In patients with baseline abnormalities in 
the ST-T wave, an additional downward shift of more than I mmin the STsegment was 
considered to indicate ischentia. 
Angiography and AngiopJasty Data 
Data of the coronary angiography and angioplasty procedures were collected and 
judged by two of the investigators. Because blinding to angioplasty procedures was 
not possible, all angiograms were subsequently reviewed by an independent and highly 
experienced investigator (M.v.d.B.) who was not involved in other aspects of the ttial. 
Consensus on collateral flow, procedural success, Thrombolysis in Myocardial Infarction 
(TIMI) graded flow before and after the angioplasty procedure, and extent of coronary 
artery disease was reached in all cases. Collaterals to the infarct-related vessel were 
classified as proposed by Rentrop et al [24]. 
Statistical Analysis 
Differences between group mean values were tested by two-tailed Student's t test 
with a separate variance estimate if the F disttibution of variances was significant at the 
two-sided 5% level. For comparison of rates of discrete outcome variables, a 
conventional X 2 test was used. Fisher's exact test was used if there was an expected 
cell value of less than 5. Simple linear regression analysis was used for correlation of 
ejection fraction and enzymatic infarct size. In our presentation of the data, continuous 
baseline and outcome variables are given as mean ± I SD, whereas discrete variables are 
given as absolute values and percentages. 
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Results 
Baseline and Clinical Data 
A total of 301 patients were included in the study: 152 patients were randomly 
assigned to undergo primary coronary angioplasty and 149 patients to receive 
intravenous streptokinase therapy. Baseline characteristics of the two groups were 
similar (Table 1). One hundred fifty-one patients assigned to angioplasty underwent 
emergency coronary angiography; one patient died before angiography could be 
performed. The infarct-related vessel showed TIMI grade 0 or I flow in 124 of the 151 
patients (82%). Coronary angioplasty was performed in 140 patients. Five patients with 
an open or small infarct-related artery were treated conservatively. Six patients with 
severe multi vessel disease or left main stenosis had emergency coronary artery bypass 
grafting after insertion of an intra-aortic counterpulsation balloon. The time between 
admission to start of therapy defined as the first balloon inflation was 64 ± 26 minutes. 
In 4 patients. the infarct-related vessel could not be reopened. Three of these patients 
underwent immediate coronary artery bypass grafting; I was treated conservatively. 
Of the 149 patients assigned to streptokinase therapy. I died before infusion could 
be started. The time from admission to start of infusion was 29 ± 16 minutes. Sixteen 
patients underwent a rescue coronary angioplasty because there was clinical evidence 
of failed reperfusion or hemodynamic collapse. In 15 patients, this procedure was 
successful; I underwent emergency coronary artery bypass grafting and was discharged 
after an uneventful in-hospital stay. 
Additional procedures during the in-hospital stay were infrequent in the 
angioplasty assigned patients: 3 patients had an additional angioplasty procedure of a 
non-infarct-related vessel and 7 underwent coronary artery bypass grafting. In the 
streptokinase assigned patients, 24 underwent an angioplasty procedure and 14 
patients had coronary artery bypass grafting before discharge. 
The in-hospital mortality was 2% (3 patients) in the angioplasty-assigned patient group 
and 7% (11 patients) in the streptokinase group. (P = .024) 
Angiographic Data 
Baseline angiographic data of all patients assigned to receive primary coronary 
angioplasty are given in Table 2. Three of the angioplasty-assigned patients (2%) had 
no significant coronary artery disease, 54 (36%) had one-vessel disease and 95 (62%) 
had multi vessel disease. Not all patients had angiography of the non-infarct-related 
vessel before a coronary angioplasty was done; thus, classification of collaterals to the 
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infarct-related vessel could be assessed only in 141 patients (Table 2). Patency rates and 
TIM! flow rates before therapy are given for all patients undergoing angiography. The 
angioplasty was considered to be technically successful if there was a residual stenosis 
of less than 50 % and a flow of TIMI grade 2 or 3 at the end of the angiop1asty 
procedure. Primary angioplasty of the infarct-related vessel was successful in 136 
patients (97 %). A TIM! grade 3 flow was observed in 131 of these patients (96%) with 
a successful procedure. The relation between time from hospital admission to successful 
reperfusion is also given in Table 2. Patients who underwent immediate coronary 
angiography followed by emergency coronary artery bypass surgery were considered 
to have had restoration of adequate blood flow 120 minutes after admission (3 
additional patients). In 4 patients, the infarct-related vessel was opened successfully 
more than 120 minutes after admission. 
Enzymatic Infarct Size 
Values for peak creatine kinase and LDH estimated infarct size (LDH Q72) are given 
in Table 3. Peak CK values tended to be lower in the angioplasty treated patient group 
but this difference was not statistically significant. Cumulative enzyme release during 
the first 72 hours, with sufficient data from the sequential measurements and accurate 
timing of symptom onset, could be calculated in 92% of all patients, and the data are 
given in Table 3. For 10 patients in the angioplasty group and for 7 patients in the 
streptokinase group, data were insufficient for adequate analysis. Eight patients died 
within the first 48 hours, before serial enzyme release could be determined. Estimated 
infarct size using LDH Qn was lower in the angioplasty-assigned patients compared 
with patients assigned to receive streptokinase, representing a reduction of estimated 
infarct size of 23% (95% confidence interval [CI) 13% to 32%). The difference of the 
LDH Qn value between the two groups was greater in patients with anterior wall 
myocardial infarction than in patients with a nonanterior wall infarction. 
The relation between time from onset of symptoms to reperfusion therapy and LDH 
Qn is also shown in Table 3. In patients admitted to the hospital within 2 hours after the 
onset of symptoms, an even more pronounced difference was seen: LDH Q72 was 967 ± 
730 UlLin the angioplasty group versus 1403 ± 1157 UlLin the streptokinase group (P 
= .010), representing a reduction of estimated infarct size of 31 % (95% Cr,20% to 43 
%). 
Circulation Vol 90. No 2. August 1994. 
90 Chapter 4 
Left Ventricnlar Function 
Iu 149 patieuts iu the augiop1asty group (98 %) and 140 patients In the 
streptokinase group (94%) resting ejection fraction values were obtained. Three 
patients in the angioplasty-treated group and 9 patients in the streptokinase-treated 
group died before nuclear studies were performed. Global ejection fraction was 
measured in all 289 survivors. whereas regional wall motion could be obtained in 273 
patients (91 %). The interval between acute myocardial infarction and time of nuclear 
study was less in the angioplasty group than in the streptokinase group (14 ± 13 days 
and 17 ± 21 days respectively; P = .04). In all subgroups studied. resting global ejection 
fraction was significantly greater in patients assigned to primary angioplasty than in 
patients assigned to streptokinase therapy (Table 4). This difference was mostly due to 
better wall motion in the infarct-related region, although a relatively small but significant 
difference for non-infarct-related areas was also found between the two groups. There 
was a clear correlation between left ventricular ejection fraction and enzymatic infarct 
size in patients with a first myocardial infarction as shown in figure 1. Patients who had 
angioplasty for first nonanterior wall infarction had very well preserved left ventricular 
ejection fraction, and no regression line could be drawn. 
One hundred twenty-three patients in the angioplasty-treated group and 118 in the 
streptokinase-treated group could perform an exercise test with radionuclide 
ventriculography before discharge. In both groups, there was a remarkably flat response 
of left ventricular ejection fraction during exercise with small, but significant 
improvement after exercise when compared with baseline (Table 5). This "pattern" was 
observed in patients with anterior wall infarction as well as in those with nonanterior 
infarctions. However, patients assigned to receive primary angioplasty therapy had less 
frequently significant Sf-segment depression or angina during exercise than patients 
who received streptokinase (33 versus 49, P = .02). Finally, exercise tolerance of the 
patients assigned to angioplasty therapy was higher than of those assigned to 
streptokinase therapy, (98 ± 30 versus 90 ± 29 W,P = .03). 
Discussion 
The aim of the present study was to compare the effects of primary coronary 
angioplasty and thrombolysis as primary reperfusion strategy. Infarct size and left 
ventricular function improved after primary angioplasty. The sample size was not 
designed to examine mortality as an end point, although in-hospital mortality in this 
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study was significantly lower in the patients assigned to undergo primary coronary 
angioplasry than in those who received intravenous streptokinase (3 versus 11, P = 
,024) [10], In all subgroups, a good relation was observed between the degree of 
reduction of infarct size and preserved left ventricular function, 
Infarct Size 
Due to the very slow elimination of LDH from plasma, this enzyme allows 
calculation of cumulative release over 72 hours from only five to seven plasma samples, 
Although reperfusion causes earlier enzyme release, which is also observed for LDH 
[20], infarct size can be calculated accurately from LDH because a single measurement 
after 6 to 8 hours represents approximately the total release over that period, By that 
time, less than 10 % of total release has been eliminated from plasma, It has been 
demonstrated that relation between global ejection fraction and LDH infarct size is 
maintained, regardless of whether or not thrombolytic therapy is given [25], Similarly, in 
this study, regression lines relating infarct size and left ventricular function were the 
same in patients treated with primary coronary angioplasty or streptokinase (Fig 1). 
In patients assigned to angioplasry, infarct size (LDH Qn) was 23% (95% CI, 13% 
to 32%) lower than in those assigned to receive streptokinase (p = .012). Half of the 
patients in our study presented within 2 hours after onset of symptoms. In this 
subgroup, the lintitation of infarct size by primary angioplasty was even larger: 31 %. 
Beyond this "time window" of 2 hours, the reduction of infarct size by primary 
angioplasty was smaller and did not reach the level of statistical significance. This time-
related phenomenon had also been demonstrated in patients receiving thrombolysis 
compared with those treated with placebo [1,22,26]. 
Myocardial Salvage by Primary Coronary Angioplasty. 
Data from animal studies have demonstrated that myocardial salvage occurs 
primarily in the ftrst 3 to 4 hours after coronary artery occlusion [27-29] and therefore 
that very early reperfusion is important to limit infarct size. This will result in better left 
ventricular function and as a consequence may lead to better rate of survival [30]. Early 
complete perfusion (TIMI grade 3) of the infarct-related vessel is the key to myocardial 
salvage. Often, incomplete perfusion (TIMI grade 2) is also considered to represent 
successful therapy, but recent studies revealed that patients with grade 2 flow of the 
infarct-related artery have in fact indexes of myocardial infarction sintilarto those of 
patients with occluded coronary arteries (TIMI 0 and 1) [31-33]. Primary PTCAhas the 
potential to achieve more rapid and effective reperfusion, defined as TIMI grade 3 flow, 
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compared with thrombolytic therapy. In fact. TIMI grade 3 flow at 90 minutes or at 3 
hours was achieved in only 54% to 60% of patients who received the best available 
thrombolytic regimen in the GUSTO study and the TEAM-2 study [33,34]. Rapid 
complete reperfusion is, in our perception, the reason for the significant additional 
salvage by primary angioplasty. Our study shows that in patients who undergo primary 
coronary angioplasty, effective restoration of blood flow through the infarct-related 
artety can be accomplished in 51 % of patients by 60 minutes after admission, 81 % by 90 
minutes after admission, and in 92% by 120 minutes after admission. 
Left Ventricular Function 
Both global and regional left ventricular function were better preserved after 
primary angioplasty compared with after intravenous streptokinase in the present study 
(Table 3). Similarly, O'Neill and co-workers [35] reported a more effective preservation 
of ventricular function in patients who underwent primary coronary angioplasty 
compared with those who received intracoronary streptokinase, and Erbel et al [36] 
found improved left ventricular wall motion and patency after a combined medical and 
mechanical approach, a finding supported by data from a subgroup of the Dutch 
Interuniversity trial and a report by Belenkie and coworkers [37,38]. 
In one report, primary coronary angioplasty and tissue-type plasminogen activator 
therapy salvaged similar amounts of myocardium, as assessed by tomographic imaging 
with 99mTc-sestamibi, and additional left ventricular studies at discharge and after 6 
weeks failed to show a significant difference between the two patient groups. However, 
the time from onset of symptoms to start of therapy in this study was longer, and the 
percentage of anterior wall myocardial infarctions was lower (36%) than in our study 
population (49%) [9.39]. Furthermore, the Primary Angioplasty in Myocardial Infarction 
(PAMI) study [18] failed to demonstrate any differences in left ventricular function, as 
measured with a radionuclide technique, between two groups, randomized to receive 
coronary angioplasty or tissue plasminogen activator therapy. This contrast with our 
results may be caused by selection bias. These data were obtained in only 62% of 
patients whereas in our study these data could be obtained in 96% of patients. 
Although patients in our trial were allowed to enter the study between 12 and 24 hours 
(these patients were not included in the PAMI trial), the mean times from symptom onset 
to randomization (pAMI, 189 minutes) or admission (the present study, 185 minutes) 
were not strikingly different. Furthermore, about half of the patients in our study 
presented within 2 hours after symptom onset. This may have influenced the results. 
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Mechanisms 
In studies comparing thrombolytic therapy and placebo treatment, the differences in 
ejection fraction remained small although the greatest improvement was observed in the 
patients with an angiographically documented patent infarct-related artery [40,41]. 
Different mechanisms have to be considered to explain the remarkable differences 
between the two patient groups in the present study, 
First, patency of the infarct-related coronary artery is established in approximately 
70% to 80% of patients treated with thrombolytic therapy, whereas angioplasty results 
in patency rates of more than 90% [9,10,18,39,42], 
Second, by rapid restoration of TIMI grade 3 flow and reduction of the residual 
stenosis in the infarct-related vessel in 92% of the patients in our study, who underwent 
primary angioplasty, recovery from ischemia is initiated rapidly, probably resulting in 
improvement of wall motion and better healing of the infarct zone. A recent study 
showed a close nonlinear relation between the degree of residual stenosis of the infarct-
related artery and the degree of left ventricular dilation at both 6 months and 12 months 
after the ftrst myocardial infarction, which is also in accordance with our (in-hospital) 
findings [43]. The residual coronary artery obstruction may thus limitthe flow through 
the infarct-related artery after successful thrombolysis and result in continuing ischemia, 
delayed recovery, and even ongoing necrosis of the myocardial tissue involved [44,45J. 
Third, half of our patients presented early after symptom onset and were treated 
rapidly, with a mean time interval from admission to fust balloon inflation of 64 minutes 
in the angioplasty-assigned group. Several studies have shown that restoration of 
antegrade blood flow in the infarct-related vessel within 2 hours after symptom onset 
results in the highest probability of myocardial salvage [22,26]. 
Fourth, the preservation of left ventricular function after primary angioplasty 
compared with thrombolytic therapy may be different because of hemorrhagic 
extension to noninfarcted areas of myocardial tissue after thrombolytic therapy and 
subsequent delayed healing of myocardium. After primary angioplasty, an "anemic 
infarction" was seen in a small group of patients [17]. However, these phenomena are 
speculative and need further clinical information. 
Fifth, in patients with severe or diffuse three-vessel disease, enhancement of 
collateral flow to non-infarct-related areas of the myocardium may also contribute to 
improvement of left ventricular function, and the remodeling process may be reduced. 
The high incidence of sustained patency of the infarct-related coronary artery in the 
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angioplasty-treated patients may therefore be an important factor in this process [9]. 
Last, the avoidance of stimulation of platelet aggregation in patients without 
thrombolytic therapy could be responsible for the low incidence of reocclusion in 
patients undergoing primary angioplasty [46,47]. However, reocclusion remains a major 
problem after thrombolytic therapy as it resuits in increased mortality and impaired left 
ventricular function [38,48,49]. The reocclusion rate after initially successful 
thrombolytic therapy may be as high as 25% to 30% whereas reocclusion occurs only 
in 3% to 15% after primary coronary angioplasty [9,42,46,47,50,51]. 
Study Limitations 
This report is based on data from a single center with an experienced group of 
interventional cardiologists and optimal 24-hour coverage of interventional cardiology 
and cardiac surgical standby. Accordingly, the resuits cannot necessarily be transferred 
to the treatment of patients with acute myocardial infarction in general practice. 
It is unavoidable that measurement of infarct size and/or left ventricular function is 
missing for some of the patients. Still, it is unlikely that this has biassed our results 
because the data were very consistent and measurements were complete in at least 90% 
of the patients. Serial enzyme measurements were not available or were insufficient for 
adequate analysis for some patients (8%), but most of them also were "early" 
nonsurvivors, and these patients are likely to have had the largest infarcts. Because only 
3 patients died in the angioplasty group versus 11 patients in the streptokinase group, 
the observed difference in LDH Qn may have been underestimated. Missing data were 
distributed evenly over the two groups, and imputation for missing values would have 
strengthened rather than weakened the differences between the two treatment groups. 
Data derived from the nuclear technique used for measurement of regional wall 
motion may be suboptimal because limited information on certain segments of the left 
ventricular wall is available with the use of a single view. This radionuclide technique is 
based on measurements of volume and changes of volume, and it gives only an 
approximation of the actual regional wallmotion. Delineation of the apical and 
inferolateral segments is especially difficult, and overlap is likely to occur in patients 
with anterior wall myocardial infarction. This may be the explanation for the observed 
differences in non-infarction-related segments between the two groups. 
Eval uation of left ventricular function after myocardial infarction preferably should 
be done 2 to 3 weeks after the acute ischemic episode because "stunning" of the 
myocardium takes time to resolve [52,53]. Delayed recovery of left ventricular function, 
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however, may be observed much longer afterwards [54]. The sma!! difference in time (3 
days) between the two groups therefore is not likely to have influenced our study 
results. 
Finally, our observations on left ventricular function were made before or at 
hospital discharge. No statements about the persistence of the observed differences can 
be made. 
Conclusion 
Primary percutaneous transluminal coronary angioplasty in patients with acute 
myocardial infarction results in a reduction in enzymatic infarct size and in better 
preserved left ventricular myocardium, especially in the infarct-related zones, compared 
with patients initially treated with intravenous streptokinase. This resulted in markedly 
improved in-hospital survival. Rapid restoration of optimal blood-flow (TIMI grade 3). 
adequate reduction of the underlying stenosis in the infarct-related coronary vessel, and 
reduction of reocclusion probably are all related to the favorable results in patients with 
acute myocardial infarction treated with primary coronary angioplasty compared with 
therapy with intravenous streptokinase. 
Clinical Implications 
Because of the beneficial effects of primary coronary angioplasty on left ventricular 
myocardium, this procedure should be considered as the treatment of choice in a!! 
patients presenting with acute myocardial infarction and signs of involvement of a large 
amount of myocardial tissue. Primary coronary angioplasty will be particularly beneficial 
in patients with increased risk for intracranial bleeding or other severe bleeding during 
thrombolytic therapy [55]. Triage on admission should be able to identify which 
patients might benefit most from primary coronary angioplasty. A moderate time delay 
should not be a drawback to transportation of these patients to a hospital with 
experience and equipment for interventional cardiology, provided that transportation 
can be carried out safely. A study on the feasibility of such a policy will be of great 
importance for the optimal management of patients with acute myocardial infarction. 
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Figure 1 A: Plot showing correlation between global left ventricular ejection fraction 
in percent (x - axis) and LDH 072 (y - axis) in units per liter for patients with first acute 
anterior wall myocardial infarction (AMI) (both treatment arms). 
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Figure 1B 
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Figure 1 B: Plot showing correlation between global left ventricular ejection fraction 
in percent (x- axis) and LDH 072 (y - axis) in units per liter for patients with first acute 
nonanterior wall myocardial infarction (AMI) (both treatment arms). 
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Table 1 : Baseline Characteristics and Clinical Course. 
Angioplasty P Streptokinase 
n = 152 n = 149 
Age, years 59 ± 10 .06 61 ±9 
Male sex, n (%) 127 (84) .59 121 (81) 
Previous MI, n (%) 32 (21) .11 21 (14) 
Anterior MI, n (%) 79 (52) .27 68 (46) 
Killip class III or IV, n (%) 14 (9) .88 12 (8) 
Time onset -> admission, min. 195 (20 - 1440) .43 176 (25 - 975) 
Time admission -> therapy, min. 64±26 29 ± 16 
Multivessel disease, n (%) 95 (63) .63 88 (59) 
Mortality in hospital, n (%) 3 (2) .024 11 (7) 
Recurrent MI, n (%) 2 (1) <.001 15 (10) 
"Late" PTCA, n (%) 3 (2) <.001 24 (16) 
"Late" CABG, n (%) 7 (5) .16 14 (9) 
MI indicates Myocardial Infarction; PTCA, percutaneous transluminal coronary 
angioplasty; and CABG, coronary artery bypass grafting. 
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Table 2: Angiographic Data of the Patients assigned to Primary Coronary 
Angioplasty . 
Grade Baseline 60 min. 90 min. 120 min. 
Collaterals • 0 85 (60%) 
(n = 141) 1 45 (32%) 
2 11 (8%) 
3 0 
TIMlt 0 109 (72%) 56 (37%) 19 (13%) 7 (5%):1: 
(n=151) 1 15 (10%) 11 (7%) 3 (2%) (1%) 
2 17 (11%) 7 (5%) 7 (5%) 4 (3%) 
3 10 (7%) 77 (51%) 122 (81%) 139 (92%) 
• : Collateral classification: grade 0, no visible filling of any collateral channels; 
grade 1, filling by means of collateral channels of side branches of the vessel but 
without any dye reaching the epicardial segment of that vessel; grade 2, partial filling 
via collateral channels of the epicardial segment of the vessel; grade 3, complete 
filling of the vessel. 
t : Thrombolysis in Myocardial Infarction (TIMI) grade is flow grade through the 
infarct-related vessel according to the TIMI study flow classification (min indicates 
minutes after admission). 
:I: : In four patients, the infarct-related vessel was opened successfully more than 
120 minutes after admission. 
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Table 3: Enzyme Measurements and Estimated Infarct Size Expressed as LDH 072; 
Relation of Enzyme Measurements to Infarct Location and Interval From Onset of 
Symptoms to Admission. 
Angioplasty P 
(n=141) 
Peak CK U/L 1268 ± 1 088 .37 
LDH 072 All infarcts U/L 1003 ± 784 .012 
LDH 072 Anterior MI (U/L) 1158±918(n=71) .022 
LDH 072 Nonanterior MI (U/L) 853 ±580 (n = 70) .135 
Time from symptom onset to admission: 
< 2 hours: LDH 0 72 , U/L 
> 2 hours: LDH 072, U/L 
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967 ± 730 (n = 81) .01 
1052 ± 855 (n = 60) .36 
Streptokinase 
(n = 135) 
1404 ± 1276 
1310±1198 
1606 ± 1264 (n = 62) 
1060 ± 1085 (n = 73) 
1403 ± 1157 (n = 65) 
1224 ± 1237 (n = 70) 
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Table 4: Global Ejection Fraction and Regional Wall Motion (%) 
EF (all patients) 
IR wall motion (all patients) 
NIR wall motion (all patients) 
EF anterior MI 
EF nonanterior MI 
EF one-vessel disease 
EF multivessel disease 
Angioplasty 
50±9 (n= 149) 
42± 14 
55 ± 11 
46± 12 
53±9 
51 ±8 (n=57) 
48±12(n=92) 
Time from symptom onset to admission: 
< 2 hours:EF, % 
> 2 hours:EF, % 
51 ± 10 (n = 83) 
48± 12 (n = 66) 
P 
< .001 
< .001 
.005 
.002 
.02 
.002 
.002 
< .001 
.04 
Streptokinase 
45±11 (n=140) 
34± 13 
51 ± 12 
39 ± 12 
49±9 
46 ± 1 0 (n = 59) 
43±12(n=81) 
45 ± 11 (n = 70) 
44±12(n=70) 
EF indicates ejection fraction; IR, infarct-related; NIR, non-infarct-related; MI, 
Myocardial Infarction. 
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Table 5: Global Ejection Fraction at rest, during exercise and post-exercise in the two 
treatment groups. 
EF at rest, % EF exercise, % EF post-exercise, % P 
All patients 
Primary angioplasty 50 ± 10 50± 13 52± 12 
(n = 123) 
Streptokinase 45 ± 11 45± 14 47 ± 13 
(n= 118) 
Anterior Ml 
Primary angioplasty 46 ± 11 46± 14 48± 13 
(n = 64) 
Streptokinase 
(n = 53) 40 ± 11 39 ± 14 42± 14 
Nonanterior MI 
Primary angioplasty 54±8 55±9 57±7 
(n =59 ) 
Streptokinase 50 ± 10 49 ± 11 52± 10 
(n = 65) 
EF indicates ejection fraction and Ml myocardial infarction. 
* P value for comparison of EF at rest and EF after exercise. 
Circulation Vol 90, No 2, August 1994. 
< .001 
<.001 
.05 
.02 
<.001 
<.001 
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Page 108: Example of radionuclide ventriculography in combination with an 
exercise test, using the PAGE program. This technique uses the multiple gated 
equilibrium method following the labeling of red blood cells of the patient with 99mTc_ 
pertechnetate. This method was applied in Chapters 2 to 4. 
Before exercise the global left ventricular ejection fraction is 49% (A), whereas during 
exercise this value drops to 31 % (B). This can be attributed to ischemia and 
subsequent diminished systolic function of the posterolateral, inferolateral and 
inferoapical regions. After exercise these regions recover their previous function and 
the global ejection fraction is 47% (C). 
Circulation Vol 90. No 2. August 1994. 
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Abstract 
Background. 
The purpose of this study was to evaluate catheterization laboratory events and 
angiographic findings in patients randomly assigned to undergo primary coronary 
angioplasty or to receive intravenous streptokinase for acute myocardial infarction. 
Methods. 
We studied 301 patients with acute myocardial infarction randomly assigned to 
undergo primary coronary angioplasty without antecedent thrombolytic therapy or to 
receive intravenous streptokinase therapy. Follow-up coronary angiography was 
preferably performed after three months. All angiograms were analyzed with a 
quantitative coronary analysis system. 
Results. 
Of the 152 patients assigned to angioplasty treatment, 140 actually underwent this 
procedure with a success rate of 97%, a residual diameter stenosis of the infarct-related 
vessel (IRV) immediately after angioplasty of 27±15% and major events in the 
catheterization-laboratory in 14% of the patients. At follow-up angiography after a 
mean interval of 92 days in the angioplasty assigned patients, a diameter stenosis of 
35±22% was observed in this group. The restenosis rate was 28% and the reocclusion 
rate 5%. A Thrombolysis in Myocardial Infarction (TIM!) grade 2 flow innuediately after 
angioplasty was predictive for reocclusion at follow-up (P = 0.001). In the 
streptokinase assigned patients (149) the IRV was patent at follow-up angiography 
after a mean of 22 days in 66% of the patients with a mean residual diameter stenosis of 
77±20%. 
Conclusion. 
Primary coronary angioplasty is a highly effective and safe reperfusion modality for 
patients with acute myocardial infarction. Furthermore,TIMIgrade 2 flow through the 
IRV innuediately after angioplasty is a predictor of reocclusion. 
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Introduction 
Primary coronary angioplasty without antecedent administration of thrombolytic 
agents as a treatment modality for patients with acute myocardial infarction (AM!) has 
only recently been rediscovered [1-4J. Two studies have demonstrated a high primary 
success rate. a reduced rate of recurrent ischemia and reinfarction, and better in-hospital 
survival in patients with AM! treated with primary coronary angioplasty when 
compared with patients treated with thrombolytic therapy [1,2,4J. In a previous paper, 
we have reported that the left ventricular function as measured with a radionuclide 
technique in patients assigned to angioplasty treatment is better compared with those 
assigned to streptokinase treatment. This is probably related to early restoration of 
flow through the infarct-related vessel (IRV) in a high percentage of patients [1,4]. The 
incidence of restenosis and reocclusion after primary coronary angioplasty for AMI is 
unknown and may be higher than that reported for elective coronary artery 
angioplasty. It could be comparable to that in patients with unstable angina or 
recanalization of occluded coronary arteries but no pertinent data are available [5,6J . 
Several questions remain to be answered: 
First, how safe is the primary coronary angioplasty procedure; second, what is the 
incidence of reocclusion and does the better coronary anatomy, observed immediately 
after primary coronary angioplasty protect against reocc1usion, which is a major 
problem after initially successful thrombolysis,[7,8J and third, what is the incidence of 
restenosis after initially successful primary coronary angioplasty? 
Methods 
Our study group consisted of all patients admitted to the Zwolle trial between 
August 20,1990 and April 23,1993. The research protocol and initial results have been 
described previously [1,4J. In brief, all consenting patients <76 years of age with more 
than 30 minutes of symptoms characteristic of myocardial ischemia, diagnostic 
electrocardiographic ST segment elevation, presentation within six hours of symptom 
onset, and without contraindications to thrombolytic therapy were randomly assigned 
to coronary angioplasty or treatment with streptokinase, 1,5 million units given 
intravenously in 1 hour. If there was evidence of continuing ischemia between 6 and 
24 hours after symptom onset patients were included in the study. Randomization was 
performed by means of a closed-envelope system. All patients were treated with 
acetylsalicylic acid 300 mg intravenously and nitroglycerin intravenously in a dose 
designed to maintain a systolic blood pressure of 11 a mm Hg. Intravenous heparin was 
given in a bolus of 10000 U and thereafter in a continuous infusion in a dosage to keep 
the activated partial thromboplastin time between 2 and 3 times the normal value for at 
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least 2 days. The time from admission to the initiation of therapy was calculated as the 
time to the first balloon inflation or to the start of the streptokinase infusion. 
Coronary angiography and angioplasty. 
All patients in the angioplasty assigned group were transferred immediately to the 
catheterization laboratory and underwent angioplasty if their coronary anatomy was 
deemed suitable by coronary angiography. Only lesions of the IRVwere dilated as we 
feel that it is hazardous to dilate lesions of non-infarct related vessels in the primary 
coronary angioplasty procedure. The angioplasty was considered to be technically 
successful if there was a residual stenosis of less than 50% on visual estimation and a 
flow of TIM! grade 2 or 3. Left ventricular angiography in the acute phase of 
myocardial infarction was not performed in the majority of patients because of time-
delay, possible adverse reactions and the limited clinical value. 
In the angioplasty assigned patient group, all catheterization laboratory events 
were scored carefully during and immediately after the emergency procedure. Major 
and minor in-laboratory events were defined as new events not present before arrival in 
the catheterization room. Catheterization laboratory events with primary coronary 
angioplasty were assessed according to the classification as proposed by Kahn and 
colleagues [9]. 
Major catheterization laboratory events: 
* death. 
* 
* 
* 
cardiopulmonary resuscitation. 
ventricular fibrillation or tachycardia treated with electrical cardioversion. 
sustained hypotension defined as a systolic blood pressure $. 80 mm Hg requiring 
continuous intravenous vasopressor support, the insertion of an intra-aortic balloon 
pump or both. 
* urgent surgery. 
Minor catheterization laboratory events: 
* transient hypotension defined as a systolic blood pressure $. 80 mm Hg requiring 
intravenous therapy. 
* bradycardia or atrio-ventricular conduction abnormalities requiring bolus of 
intravenous therapy, a temporary pacemaker or both. 
Flow through the IRV was scored according to the Thrombolysis in Myocardial 
Infarction (TIM!) classification [10]. Reocclusion was defined as a reduction in TIM! 
perfusion grade 2 or 3 to TIM! grades 0 and I. To assess the restenosis rate and arterial 
patency in the angioplasty group, these patients preferably underwent repeat coronary 
angiography after 3 months [11,12]. Restenosis was defined as a more than 50% 
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diameter stenosis measured quantitatively, after an initially less than 50% stenosis after 
primary coronary angioplasty. Patients in the angioplasty assigned group, who 
underwent coronary artery bypass surgery, who had an unsuccessful angioplasty or no 
procedure at all, did not have a routine repeat angiography. Data of the coronary 
angiography and angioplasty procedures were collected and graded by two of the 
investigators. As blinding to angioplasty procedures was not possible, all angiograms 
were subsequently reviewed by an independent and highly experienced investigator 
(M.v.d.B.), not involved in other aspects of the ttial. Consensus on collateral flow, 
procedural success, TIMI flow before and after the angioplasty procedure, 
identification of the IRY, and extent of coronary artery disease was reached in all cases. 
TIMI flow before angioplasty was judged at first injection of contrast material. 
Collaterals to the infarct-related vessel were classified as proposed by Rentrop et al. 
[13]. Grade 0: no visible filling of any collateral channels, grade 1: filling by means of 
collateral channels of side branches of the vessel but without any dye reaching the 
epicardial segment of that vessel, grade 2: partial filling via collateral channels of the 
epicardial segment of the vessel, grade 3: complete filling of the vessel. 
Follow-up coronary angiography in the streptokinase assigned patient group was 
also preferably performed after 3 months. In both groups however, this procedure was 
allowed to be performed earlier or later at the discretion of the attending physicians. 
Qnantitative coronary angiography (QCA). 
All infarct-related vessels were analyzed objectively with a personal-computer-
based QCA system (CMS: Cardiovascular Measurement System, Software version 2.0, 
Medis Medical Imaging Systems, Nuenen, the Netherlands) [14]. The basic algorithms 
have been described elsewhere [14,15]. The system uses a high-quality cine-to-video 
converter that allowed a selected cine frame to be projected onto a digital video camera 
through an optical zoom lens. The video signal of the magnified region of interest was 
subsequently digitized. For calibration, the boundaries of a nontapering part of the 
catheter were determined automatically over a length of approximately 2 cm. To 
determine the contours of the vessel the user had only to indicate the beginning and 
end of the coronary segment to be analyzed, after which a path was computed 
connecting these two points [16]. The contour procedure was then performed 
iteratively by resampling the image along scan lines perpendicular to the path 
computed in the first iteration. Next, a mattix of cost coefficients was computed that 
represented for each point in the resampled mattix the edge strength based on the 
weighted sum of the TIrSt and second derivative functions. The initial contours were 
found by the minimal-cost contour-detection technique applied to the cost-coefficient 
mattix [17]. In the second iteration, the contours determined in the first iteration 
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functioned as models for the subsequent determination. The edge strengths were 
corrected for the limited resolution of the entire imaging chain, a procedure that is 
particularly important for the accurate measurement of small vessels. From the fmal 
contours a new center line was computed. A diameter was determined in absolute terms 
(in millimeters) by computing along the vessel center line the shortest distances 
between the left and right contours. Thereference diameter was defined as previously 
described [17]. An example of QCA analysis with the CMS system is given in Figure I. 
Statistical analysis. 
Differences between group means were tested by a two-tailed Student t test. A chi-
square method was used to test differences between proportions, and if appropriate 
calculation of odds ratios and their 95% confidence interval (CI). The Fisher exact test 
was used if there was an expected cell value < 5. Statistical significance was defined as 
a P value < .05. In the presentation of the data, continuous variables are given as mean 
value ± SD, whereas discrete variables are given as absolute values and percents. 
Resnlts 
Baseline clinical characteristics and clinical course are shown in Table I and were 
described in detail [4]. Baseline angiographic data are shown in Table 2. In the 
angioplasty assigned patient group immediate angiography was performed in lSI 
patients; one patient died before angiography could be performed. He had severe three 
vessel coronary artery disease at post-mortem examination. Four patients did not have 
significant coronary artery narrowing. Two of them, however, suffered a myocardial 
infarction, one of them showing residual thrombi in a large left circumflex artery. 
Coronary angioplasty was performed in 140 patients. Five patients with an open or 
small infarct-related artery were treated conservatively. Six patients with severe 
multivessel disease or left main stenosis had emergency coronary artery bypass grafting 
after insertion of an intra-aortic counterpulsation balloon. Primary angioplasty of the 
infarct-related vessel was successful in 136 patients (97%) resulting in a less than 50% 
residual stenosis and a TIMI grade 2 or 3 flow at the end of the procedure. In four 
patients the IRV could not be reopened. Three of these patients underwent immediate 
coronary artery bypass grafting; one was treated conservatively. All the in-laboratory 
events are summarized in Table 3. 
Of the 149 patients assigned to streptokinase therapy, one died before infusion 
could be started. Sixteen patients underwent a "rescue" coronary angioplasty because 
there was clinical evidence of failed reperfusion or hemodynamic collapse. In IS 
patients the procedure was successful, one underwent emergency coronary artery 
bypass grafting and was discharged alive after an otherwise uneventful in-hospital 
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stay. Further clinical and in-hospital events have been described elsewhere [4]. 
Technical characteristics of the actual primary angioplasty procedures are the 
following: one balloon was used in 97 patients, two balloons in 33 patients, three 
balloons in nine patients, and four balloons in one patient. The average number of 
balloons used per procedure thus was 1.41 whereas the mean number of balloons used 
in elective procedures in our institution is 1.28. The mean maximum balloon pressure 
was 9.9 atm. (range 3-16), the number of inflations 3.2 (range 1-10) with a mean total 
inflation time of 530 seconds (range 90 - 2400). After a successful procedure the 
attending interventional cardiologist described angiographic evidence of dissection in 
29 patients (21 %). 
Coronary angiography was performed after 22±38 days (range 0 - 304) in 139 of 
the 149 patients assigned to streptokinase therapy. Eight patients died before coronary 
angiography was performed, two patients refused angiography. The results of the 
quantitative coronary angiography (QCA) analysis are depicted in Table 4. The minimal 
lurninaldiameter (MLD) of the IRV increased from 0.25±0.62 mmbefore, to 2.22±0.62 
mm immediately after the primary angioplasty procedure. If all patients in the 
streptokinase group with an occlusion of the IRV were excluded, the mean diameter-
stenosis of the IRV was 64±13% and the mean minimal luminal diameter was L05± 
0.41 mm. 
Repeat angiography was performed after 92±67 days (range 1 - 389) in 130 of the 
136 patients in the angioplasty group who actually underwent a successful procedure. 
Reasons for not performing a repeat angiography were: death in two patients, early 
elective coronary artery bypass surgery because of concomitant left main coronary 
artery disease in two patients, malignancy detected after randomization in one patient 
and refusal in one patient. 
The IRV was patent in 66% of the patients (92 of 139) who received streptokinase 
and 95% of those assigned to angioplasty therapy (123 of 130), (P < 0.001; Odds Ratio 
[OR]: 8.9, 95% Confidence Interval [CI] 3.7 to 23). In the angioplasty group seven 
patients (5%) had an occluded IRV at follow-up angiography: the right coronary artery 
in 3 patients, the left anterior descending artery and left circumflex artery both in 2 
patients; of these seven patients three had a TIMI grade 2 flow immediately after the 
angioplasty procedure compared with two patients in the group with a patent IRVat 
follow-up angiography (P = 0.001). 
Among the patients assigned to angioplasty therapy only 7% had patent infarct-
related vessels (TIMI grade 3 flow) at baseline and 92% of the patients had patent 
vessels by 120 minutes after admission. As no early angiography was performed in the 
streptokinase assigned patient group, the data on TIMI grade 3 flow were compared 
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with the angiographic data from the GUSTO trial (Figure 2)[18]. QCA data of the 
infarct-related vessels in the angioplasty assigned patient group at repeat angiography 
are shown in Table 4. Restenosis, defined as stenosis of more than 50% in the dilated 
segment, was observed in 24 of 125 patients in the angioplasty group (20%). Although 
evidence has accumulated that the incidence of restenosis reaches a plateau at three 
months [11,12], the clinical implications of restenosis will become clear only after at least 
six months of follow-up. Excluding all angiography without evidence of restenosis 
perfonned within three months after angioplasty, the rate of restenosis was 28% (24 of 
87). 
Discussion 
Our results are consistent with the findings from other studies and demonstrate that 
primary coronary angioplasty for acute myocardial infarction can be perfonned safely 
and without major persistent sequelae as a result from the procedure itself [9]. Major in-
laboratory events were observed in 14% of the patients who actually had a primary 
coronary angioplasty and could be treated adequately in all patients. Although we 
found a significantly higher rate of minor complications in patients undergoing 
angioplasty of the right coronary artery these events could be anticipated and treated 
appropriately. The procedural success rate for angioplasty of the right coronary artery 
is high and sustained patency is as high as for angioplasty of other vessels. We could 
not confmn the findings by Gacioch and Topol who found a high major complication 
rate and in-hospital mortality for patients undergoing angioplasty of the right coronary 
artery [19]. Some kind of in-laboratory event (major plus minor) occurred in 32% of the 
patients. 
The coronary angiographic findings of trials of acute myocardial infarction have so 
far been mostly assessed by visual interpretation of the angiograms irrespective of 
whether stenosis grades or flow grades have been used [9,20-25]. Conventional visual 
interpretation of coronary angiograms has its limitations and more objective means 
should be developed to measure or assess the results of reperfusion therapies. In our 
study, quantitative coronary angiography (QCA) was used. Repeat angiography after 
successful coronary angioplasty should be perfonned after three months as this appears 
to be the optimal time interval to detect restenosis early [11,12]. 
The diameter stenosis of the IRV immediately after primary coronary angioplasty 
was 27±l5% and 35±22% at repeat angiography after a mean of 92 days; Only seven 
patients had an occlusion at follow-up angiography and the patients with an 
angiographic restenosis (17) all had a nonnal (TIM! grade 3) flow through the IRV. The 
rate of restenosis (28%) is comparable to the restenosis rate reported for elective 
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angioplasty [26]. 
The diameter stenosis in the streptokinase assigned patients was 77±20% 
(including 47 patients with an occlusion) although angiography in these patients was 
performed after a mean of 22 days. Angiography in the streptokinase assigned patients 
was obviously more often performed before this time interval of three months. The high 
incidence of occlusion or reocclusion (25% to 30%) after streptokinase therapy was 
confirmed by the APRICOT (Antithrombotics in the Prevention of Reocclnsion In 
Coronary Thrombolysis) study, where patency of the IRV was associated with a better 
left ventricular function [7]. 
Assessment of coronary flow and vessel patency should preferably be done by two 
investigators to avoid interobserver variability and we therefore asked a highly 
experienced investigator in the field of myocardial infarction studies to review the data 
[27]. Recent studies stressed the importance of flow through the IRV: Thrombolysis in 
Myocardial Infarction (TIM!) grade 2 flow, although until recently thought to represent 
effective recanalization, is associated with a greater risk for development of recurrent 
ischemia, congestive heart failure, diminished left ventricular function and a trend 
towards a higher mortality [18,28-31]. What remains unclear is whether TIM! grade 2 is 
a cause or a marker of adverse outcome, and diminished flow may in fact represent a 
relative no-reflow phenomenon [32]. In our stndy TIMI grade 3 was accomplished 
within 120 minutes after hospital admission in 92% of the angioplasty assigned patients 
and this is a likely explanation for the better left ventricular function as measured with 
radionuclide ventriculography in the angioplasty group [1,4]. 
TIMI grade 2 flow immediately after the primary coronary angioplasty procedure, 
with adequate reduction of the IRV stenosis, althongh observed in only 4% of the 
patients (5 of 136), seems to be a strong predictor of occlusion of the IRV at follow-up 
angiography (P = 0.001). The reduced flow may be caused by distal embolization or 
ischemic changes in the distal coronary vascular bed. 
Optimal balloon sizing in primary coronary angioplasty is probably a major 
determinant of early as well as late outcome. A small balloon will lead to underdilation 
and a more severe residual lesion whereas an oversized balloon will increase the 
endothelial disruption and damage, leading to more acute complications and possibly 
an increase of the incidence of restenosis [33]. In our study, the ratio of balloon-size 
and reference diameter of the IRV is almost one (2.93 versus 3.04 mm). 
The study by Leung and Lau showed a close non-linear relation between the 
degree of residual stenosis of the infarct-related artery after thrombolytic therapy and 
the degree of left ventricular dilation 6 months and 12 months after first (anterior) 
myocardial infarction [34]. Patients with a stenosis diameter of more than 1.5 mm had a 
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smaller left ventricular end-diastolic volume and there was no further left ventricular 
enlargement after I year. Reducing the degree of residual stenosis of the infarct-related 
artery by coronary angioplasty may thus be an effective therapy for preventing 
topographic changes to the left ventricle (left ventricular remodeling) [35]. 
Holmes and coworkers reported a reduction of luminal stenosis of the IRV from 
98% to 33% in a small series of patients who underwent primary angioplasty, without 
antecedent thrombolysis, for acute myocardial infarction [36].The residuallurninal 
stenosis of the IRV in the first randomized trial of primary angioplasty versus 
thrombolytic therapy by O'Neill et al. was reported to be 43% in the patients assigned 
to angioplasty, versus 83% in the patient group, treated with thrombolysis [37]. Clinical 
evidence indicates, that the residual stenosis after thrombolysis is perhaps the most 
important determinant of the frequency of reocclusion [38-40]. 
Restenosis after primary coronary angioplasty. 
The major biological obstacle of coronary angioplasty (often referred to as the 
··Achilles' heel") to be overcome remains the problem of restenosis after initially 
successful angioplasty procedures. After elective coronary angioplasty the incidence of 
restenosis is reported to be 20% to 40% whereas this incidence may be higher after 
angioplasty for unstable coronary syndromes [5,26]. In several studies the restenosis 
rate after primary coronary angioplasty was comparable to our findings namely 
between 27% and 37% and the reocclusion rate was 7.9% to 22%, but repeat 
angiography was performed only in approximately 70% of these patients [41-44]. 
Deposition and accumulation of platelets at the site of angioplasty is related to 
restenosis and reocclusion; adequate antiplatelet therapy may be an important tool in 
prevention of these phenomena [33,45]. No additional benefit of thrombolytic therapy 
may be expected in this setting and may even worsen the effects of angioplasty 
therapy [44]. 
Qnantitative Coronary Angiography in this study. 
Currently the QCA techniques have been developed to the point that the contour 
detection itself is quite robust and reproducible, thus requiring minimal editing of the 
contours by the user [15,17]. On the other hand, coronary arteriograms are only 
shadowgrams of the arterial tree, and therefore may be of limited value in the 
presentation of the actual morphology of the vessel, particularly in complex eccentric 
lesions as at post-coronary angioplasty. In this study several precautions were taken to 
rninimizethese limitations as much as possible. First of all, IRV was analyzed from at 
least two views (if possible orthogonal, but at least 60% apart). Each view was chosen 
such that the IRV was presented with minimal foreshortening, and parallel to the input 
screen of the image intensifier. Second, at follow-up angiography in the angioplasty 
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group, the views from the primary coronary angioplasty session were repeated as 
accurately as possible. Third, frame selection was done in a standardized manner: frames 
to be analyzed were selected in the end-diastolic phase. Under such a highly 
standardized aquisition procedure, it has been shown that the standard deviations for 
differences in repeat measurements for films I to 6 months apart is 0.24 mm for the 
minimal lumen diameter and 0.33 mm for the interpolated reference diameter [46]. The 
measured interpolated reference diameter between immediate post-angioplasty 
(3.04±0.62 rom) and at follow-up 92±67 days later (3.00±O.66 rom),as well as the fact 
that these values are at the average equal to the reference diameter values in the 
streptokinase group (3.00±O.56 rom) are supporting the theory that QCA is a reliable 
and objective method to assess coronary anatomy in studies on myocardial infarction. 
Limitations ofthis study. 
The results of this study should be seen in the light of the optimal conditions for 
performing primary coronary angioplasty in our hospital. This includes full 
cardiovascular surgical back-up and optimal support of the department of 
cardiovascular anesthesiology. Besides this, in our hospital coronary angioplasty is 
performed on a high volume basis (1400 procedures yearly) by 4 experienced 
interventional cardiologists (350 annual procedures per cardiologist) and a 
catheterization-laboratory team consisting of 10 well-trained persons. These results 
cannot be transferred to daily practice in community hospitals even if angiography 
facilities are available. 
Repeat angiography in the angioplasty assigned patient group was performed after 
a mean of 92 days. However, a considerable amount of patients had a repeat 
angiography within three months. The restenosis rate may be higher because of 
restenosis occurring during further follow-up in the subgroup of patients who had 
angiography within three months. Furthermore, we do not know if the observed 
"plateau of angiographic restenosis" that is reached at three months after elective 
angioplasty procedures will have the same behavior in time after primary angioplasty. 
The true rate of restenosis may thus be higher but patients do seldom present with 
occlusion of the IRV at follow-up angiography as was demonstrated in the present 
study. The discrepancy between time to follow-up angiography between the two 
treatment groups (despite the intention to perform angiography at three months) was 
induced by the fact that the protocol permitted early angiography at the discretion of 
the attending physicians. 
We did not routinely perform early angiography in the patients assigned to 
streptokinase therapy, but we do have the early angiographic data of patients treated 
with the same thrombolytic regimen in the GUSTO trial and there are no reasons to 
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assume that these data do not match the streptokinase-assigned patients in the present 
study [18]. As is shown in Figure 1, primary coronary angioplasty is far more effective 
in accomplishing early and optimal flow through the IRV than any regimen of 
thrombolytic therapy, available today. 
Finally, the observations reported in this study were made in a selected group of 
patients namely patients also eligible for thrombolytic therapy. As primary coronary 
angioplasty is also a treatment modality for patients with contraindications for 
thrombolysis the results in this group may be different. 
Conclusion. 
We conclude that primary coronary angioplasty in AMI can be performed safely 
and leads to a more rapid and complete reperfusion than does intravenous 
streptokinase. This is a likely explanation for the better left ventricular function in 
angioplasty patients compared with patients treated with intravenous streptokinase. 
The favorable in-hospital as well as late outcome in patients after primary coronary 
angioplasty is probably related to the better coronary anatomy after this procedure 
when compared with streptokinase therapy, as was demonstrated in the present study. 
We were able to show that this favorable anatomy is sustained in the majority of the 
angioplasty patients and that the reocclusion rate is low (5%). The observed restenosis 
rate of 28% is comparable to that after elective PTCA. Although occurring only in 
about 4% of the patients undergoing primary coronary angioplasty for AMI, TlMI 
grade 2 flow through the IRV immediately after the procedure is a strong predictor of 
reocclusion at follow-up angiography even if the infarct-related stenosis is reduced 
adequately. 
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Figure 1: Print-out from the personal-computer-based QCA system (CMS: 
Cardiovascular Measurement System, Software version 2.0) 
128 Chapter 5 
100 % 
75 
50 
25 
0+-----.-----.---1 1 -I 1 1 1 
o minutes 90 180 24 h 5-7 days 
Patency: TIM! 3 (%) iii Primary angioplasty Zwolle 
- - +- - GUSTO accelerated t-PA 
----e---- GUSTO t-PA + SK 
----Ji.---- GUSTO SK + IV heparin 
3 months 
Figure 2: Graphic display of Thrombolysis in Myocardial Infarction (TIMI) grade 3 
flow immediately after randomization: comparison of the angiographic results from 
the Zwolle and GUSTO trials_ The data on TIMI flow in the GUSTO trial were 
gathered from different patients, who were randomly assigned to angiography at 
different time intervals after start of therapy_ GUSTO indicates the Global Utilisation of 
Streptokinase and Tissue plasminogen activator for Occluded Coronary Arteries 
Study; tPA indicates tissue plasminogen activator; SK indicates Streptokinase_ 
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Table 1: Baseline and Clinical Characteristics, Clinical Course. 
Angioplasty P Streptokinase 
(N=152) (N=149) 
Age (years) 59 ± 10 0.06 61 ±9 
Male sex 127 (84%) 0.59 121 (81%) 
Anterior infarction 79 (52%) 0.27 68 (46%) 
Previous infarction 32 (21%) 0.11 21 (14%) 
Time onset -> admission (min)' 195 ±227 0.43 176 ± 172 
Time admission -> therapy (min) 64±26 29 ± 16 
Killip class III or IV on admission: 14 (9%) 0.73 12 (8%) 
Mortality in hospital 3 (2%) 0.024 11 (7%) 
Recurrent MI in-hospital 2 (1%) < 0.001 15 (10%) 
Hospital stay (first admission) 12.3 ±5.3 0.003 14.4 ± 6.8 
EF (%) 50±9 < 0.001 45± 11 
Recurrent ischemia first year 12 (8%) < 0.001 55 (37%) 
Mortality at one year 7 (5%) 0.15 13 (9%) 
• From onset of symptoms of myocardial infarction to hospital admission. Values 
presented are mean ± SD or number (%). EF = Ejection Fraction before discharge 
measured with radionuclide ventriculography. 
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Table 2: Baseline Angiographic Characteristics. 
Diseased vessels 
None 
One 
Two 
Three 
Left main 
Unknown 
Infarct-related vessel 
Left anterior descending artery 
Left circumflex artery 
Right coronary artery 
Left main coronary artery 
Saphenous vein graft 
Unknown 
Coliaterals 0 
(N=141) * 1 
2 
Angioplasty 
Group (N = 152) 
3 (2%) 
54 (36%) 
51 (34%) 
37 (24%) 
6 (4%) 
(1 %) 
60 (39%) 
25 (16%) 
58 (38%) 
2 (1%) 
3 (2%) 
4 (3%) 
85 (60%) 
45 (32%) 
11 (8%) 
Streptokinase 
Group (N = 149) 
1 (1%) 
59 (40%) 
37 (25%) 
41 (28%) 
1 (1%) 
10 (7%) 
57 (39%) 
21 (14%) 
58 (38%) 
(1%) 
4 (3%) 
10 (5%) 
* Only patients who had visualization of the non-infarct related artery before the 
attempted angioplasty procedure are included. 
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Table 3: Catheterization-Laboratory Events in the Primary Coronary Angioplasty 
Group (N = 140) 
N Percents 
Major in-laboratory events: 20 (14%) 
Involvement: 
Right coronary artery 8 (6%) 
Left anterior descending artery 8 (6%) 
Left circumflex artery 2 (1%) 
Graft 1 (1 %) 
Left main coronary artery 1 (1%) 
cardioversion 6 (4%) 
cardiopulmonary resuscitation 6 (4%) 
dopamine/adrenaline support 8 (6%) 
intra-aortic balloon pump support for hypotension 6 (4%) 
urgent surgery 3 (2%) 
Minor in-laboratory events: 29 (18%) 
Involvement: 
Right coronary artery 16 (11%) • 
Left anterior descending artery 6 (4%) 
Left circumflex artery 7 (5%) 
brief bolus atropin or pressor 23 (16%) 
temporary pacemaker 9 (6%) 
• Risk of minor in-laboratory events of right coronary artery angioplasty significantly 
higher ( P = 0.042) than for angioplasty of other vessels. 
Variable 
Projections 
analyzed (no.) 
Stenosis (%) 
Minimal luminal 
diameter (mm) 
Reference 
diameter (mm)t 
Largest balloon 
(mm) 
Table 4: Quantitative Angiographic Data' 
Angioplasty Group 
Before After Follow-Up 
at 92 ± 67 Days 
(N = 151) (N = 140) (N = 130) 
2.0 ± 0.5 2.2 ± 0.5 2.2 ± 0.5 
92 ± 19 27 ± 15 35±22 
0.25 ± 0.62 2.22 ± 0.62 1.99 ± 0.83 
2.93 ±0.39 
3.04±0.62 3.00±0.66 
(1.89-5.03) (1.45-4.99) 
P Value 
< 0.001 
< 0.001 
0.924 
• Plus-minus values are means ± SD. t By the interpolated method. 
Streptokinase Group 
at 22 ± 38 Days 
(N = 139) 
2.1 ±0.5 
77 ±20 
0.69 ±0.60 
3.00±0.56 
(1.72 - 4.82) 
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Abstract 
Backgrouud. 
Intravenons streptokinase and primary coronary angioplasty are both considered 
effective treatment strategies for patients with acute myocardial infarction. Primary 
coronary angioplasry is associated with a high patency rate and a well preserved left 
ventricular function but whether it results in a more favorable clinical outcome has not 
yet been verified in randomized studies. 
Mefuods. 
Clinical data were obtained after a mean follow-up of 18 months (range 6-36 
months) of 301 patients randomized to either primary coronary angioplasty (N=152) or 
intravenous streptokinase (N=149). The primary end-point includes cardiac death and 
non-fatal reinfarction. The secondary end-point is a weighted unsatisfactory outcome 
end-point which includes death, stroke, heart failure, shock, ejection fraction < 30%, 
reinfarction, reocclusion and bleeding complications. Furthermore, the need for 
revascularization procedures was recorded. 
Results. 
The relative risk of cardiac death and non-fatal reinfarction in the streptokinase 
group was 6.1 (95% confidence interval 2.9 - 12.7) as compared to the angioplasty 
group. There was a lower weighted unsatisfactory outcome score in patients 
randomized to angioplasty of 0.13 (median 0) compared to 0.34 (median 0.4) in 
patients randomized to streptokinase, (P < 0.001). Coronary angioplasry and/or 
coronary artery bypass grafting were more often performed in the streptokinase group, 
with a relative risk of 2.1 as compared to patients randomized to angioplasty, (95% 
confidence interval 1.5 - 3.2). 
Conclusion. 
Clinical outcome in patients with acute myocardial infarction after a mean follow-up 
of 18 months was more favorable in patients assigned to primary coronary angioplasry 
when compared with patients assigned to receive intravenous streptokinase. 
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Introduction 
Over the last decade the value of thrombolytic therapy andlor coronary angioplasty 
to restore patency of the infarct-related coronary vessel has been established [1-16]. 
Primary coronary angioplasty without antecedent thrombolytic therapy avoids the 
potentially adverse effects of systemic bleeding or myocardial and intra-plaque 
hemorrhage that can be observed after thrombolytic therapy [8,12,13,16]. We 
previously reported a randomized trial comparing primary angioplasty with intravenous 
streptokinase in patients with acute myocardial infarction. Ahigher patency rate of the 
infarct-related vessel, smaller infarct size, preserved left ventricular function, less 
recurrent ischemia and a reduction of hospital mortality were observed in patients 
assigned to angioplasty compared to those, treated with intravenous streptokinase [13-
15]. Another large multicenter trial confirmed these findings [16]. However, an 
important question still has to be answered before primary angiop lasty can be accepted 
as the most efficacious therapy for patients with an acute myocardial infarction: do the 
superior coronary anatomy and ventricular function result in a more favorable clinical 
outcome during long-term follow-up? 
Methods 
The research protocol was reviewed and approved by the institutional review 
board. Enrollment began on August 20, 1990 and ended on April 26, 1993. Inclusion 
criteria were: L symptoms of acute myocardial infarction persisting for more than 30 
minutes accompanied by an electrocardiogram with more than 1 rom (0,1 mY) $I 
segment elevation in two or mOre contiguous leads; 2. all patients presenting within 6 
hours after symptom onset, as well as those presenting between 6 and 24 hours, if they 
had evidence of continuing ischemia; 3. age less than 76 years; 4. no contraindication 
to thrombolytic intervention [13]. Before randomization the following variables were 
recorded: age, sex, KiUip class on admission [17], electrocardiographic site of infarction, 
history of prior infarction, time of symptom onset and time of hospital admission. 
Randomization and Treatment 
After informed consent was obtained, patients were randomly assigned to one of the 
two treatment modalities by means of a closed envelope system. All patients received 
aspirin and heparin [13]. Patients randomized to streptokinase received 1,5 million units 
intravenously in 1 hour. Patients randomized to coronary angioplasty were immediately 
transported to the catheterization laboratory and underwent coronary angiography. If 
the coronary anatomy was suitable for angioplasty this procedure was performed 
immediately using standard techniques. 
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End Points 
1. Pdmary end point: the primary end point includes cardiac death, and non-fatal 
recurrent myocardial infarction, defined as previously described [13]. 
2. Secondary end point: a weighted unsatisfactory outcome end point, as proposed by 
Braunwald et al. [18] (see Table I). Each patient is assigned a score that represents 
the single most serious outcome. 
3. Revascularization procedures: coronary artery bypass grafting andlor coronary 
angioplasty (excluding the index infarct angioplasty). 
Follow-np 
Follow-up information was obtained in September 1993. All out-patient reports 
were reviewed, general practitioners as well as patients were contacted by telephone. 
For patients who died during follow-up hospital records and autopsy data were 
reviewed. No patieut was lost to follow-up. 
Statistical Analysis 
All end points were analyzed according to the principle of intention to treat. 
Differences between group means were tested by the two tailed Student-t test. A chi-
square method or the Fisher exact test was used to test differences between 
proportions. Differences in the unsatisfactory clinical outcome score were tested by the 
Mann-Whitney (or Wilcoxon's) rank sum test. Statistical significance was defined as a 
P-value of less than 0.05. Survival functions were calculated, using the Kaplan-Meier 
product limit method [19]. The Mantel-Cox (or log-rank) test was applied to evaluate 
the differences between survival functions. Multivariate analysis was performed by 
fitting Cox' proportional hazards model [20]. Odds ratios, that may be interpreted as 
relative risks with 95% confidence intervalS, were calculated. In the multivariate 
analysis, adjustments were made for differences in age (continuous variable), gender, 
infarct location (anterior versus non-anterior), Killip class on admission, time from onset 
of symptoms to admission and previous myocardial infarction. 
Results 
During the enrollment period 301 patients were randomized, 152 to coronary 
angioplasty and 149 to streptokinase therapy. Baseline characteristics are shown in 
Table I. None of these characteristics differed significantly between the two treatment 
groups. All patients assigned to angioplasty underwent immediate coronary 
angiography except one patient with cardiogeruc shock who died immediately. Five 
patients had an open infarct-related artery and were treated conservatively. Six 
patients with extensive coronary artery disease considered not suitable for angioplasty 
underwent primary coronary artery bypass grafting. Angioplasty was performed in 140 
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patients, and the procedure was successful in 136 (97%). An intra-aortic balloon pump 
was inserted in 19 patients for hemodynamic support. Seven underwent elective 
coronary artery bypass grafting for left main coronary artery or extensive 3-vessel 
coronary artery disease. The mean time from admission to the first balloon inflation was 
64 minutes. In 4 patients angioplasty failed to reopen the infarct-related artery, 3 of 
them underwent emergency coronary artery bypass grafting. 
All patients assigned to therapy with intravenous streptokinase were treated 
accordingly, with one exception: I patient with cardiogenic shock died immediately 
following randomization. The mean time from admission to start of the streptokinase 
infusion was 29 minutes. Sixteen patients with hemodynamic compromise and signs of 
ongoing ischemia within 24 hours after admission underwent rescue angioplasty with 
procedural success in 15 patients, emergency coronary artery bypass grafting was 
performed in one patient. In 12 patients an intra-aortic balloon pump for hemodynamic 
support or as a bridge to cardiac surgery was inserted. Sixteen additional patients 
underwent emergency coronary angioplasty before hospital discharge because of signs 
of recurrent ischemia, with procedural success in 15 patients, and emergency coronary 
artery bypass grafting in one patient. Nine patients underwent elective angioplasty and 
13 patients underwent elective coronary artery bypass grafting before hospital 
discharge for symptoms and signs of exercise induced myocardial ischemia. The 
remaining patients (94) did not undergo a revascularization procedure before hospital 
discharge. Follow-up coronary angiography was performed in 141 of the 149 patients 
assigned to receive streptokinase (95%). 
The mean follow-up timewas 18 months, with a maximurnof 36 months. Follow-up 
time did not differ between the two treatment groups. During follOW-Up a total of 26 
patients (8.6%) died, of whom in 24 patients the cause of death was cardiovascular. 
Two patients died due to malignant disease, which was demonstrated by autopsy. 
Causes of death are shown in Table 3. Recurrent myocardial infarction occurred in 34 
patients (11.3%), during the fOllow-up period. Differences between the two treatment 
groups during the follow-up period are shown in Table 4. The patients who were 
treated with thrombolytic therapy had in particular a higher incidence of recurrent 
myocardial infarction. The combined incidence of cardiac death and non-fatal recurrent 
infarction is shown in Figure L The incidence of revascularization procedures during 
the follow-up, (coronary angioplasty and/or bypass surgery) was 88/149 = 59% in 
patients randomized to streptokinase compared to 44/152 = 29% (P < 0.001) in patients 
randomized to primary angioplasty, resulting in a relative risk of patients randomized to 
streptokinase for revascularization procedures of 2.1 (95% confidence interval 1.5 -
3.2). Event-free survival, that is survival without recurrent infarction, stroke or a 
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revascularization procedure is shown in Figure 2. Some clinical variables were strongly 
related to events during follow-up. Killip class on admission of ~ 2 was associated with 
a relative risk of cardiac death of 2.2 (95% CI 104 - 3.5). Patients with multi-vessel 
disease had a relative risk of 1.7 (95% CI 1.2 - 204) to develop any of the end-points 
during the follow-up period. 
Multivariate analysis showed that after adjusting for differences in age. gender, 
localization of infarction, Killip class, multi-vessel disease, time from onset of symptoms 
to admission and previous myocardial infarction, the patients who were randomized to 
thrombolytic therapy had a higher risk of cardiac death, recurrent myocardial infarction 
and the combination of cardiac death and recurrent infarction, compared to patients 
randomized to primary angioplasty. Results of the univariate and multivariate analysis 
are summarized in Table 5. 
There was a marked difference in the combined primary clinical end point of cardiac 
death and non-fatal recurrent myocardial infarction of 6% versus 29% in angioplasty 
and streptokinase patients respectively (P < 0.001) (see Figure I). 
There was a lower weighted unsatisfactory outcome score, in patients randomized to 
primary angioplasty therapy, of 0.13 (median 0) compared with 0.34 (median 004) in 
patients randomized to receive streptokinase (P < 0.001) (see Table 2). 
Revascularization procedures were more often necessary in patients randomized to 
streptokinase, with a relative risk of 2.1 (95% confidence interval 1.5 - 3.2) compared 
with patients randomized to coronary angioplasty. 
Discussiou 
This study shows that primary coronary angioplasty in patients with an acute 
myocardial infarction is associated with a lower incidence of cardiac death and 
recurrent infarction in comparison with "standard" streptokinase therapy. Furthermore, 
there was a lower weighted unsatisfactory outcome score, and the incidence of 
revascularization procedures during follOW-Up was lower in patients randomized to 
angioplasty, as compared with streptokinase therapy. Over the last decade, great efforts 
have been made to assess the optimal treatment for patients with an acute myocardial 
infarction with attention focusing on large scale trials using mortality as the primary 
end po·int. However,the funds and patient numbers to support multiple"megatrials" to 
compare all theoretically attractive treatment strategies, are simply not available 
[18,21,22]. Left ventricular ejection fraction has been proposed [22] as well as rejected 
[21] as end point in trials in acute myocardial infarction. In a previous paper [14] we 
showed that primary angioplasty results in better preserved left ventricular ejection 
fraction when compared with intravenous streptokinase. Long term survival after 
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reperfusion therapy is related to left ventricular ejection fraction [6]. Recently, a 
composite clinical end point has been introduced [21,18] and this unsatisfactory 
outcome end point may serve as an approach to evaluate new therapeutic strategies in 
patients with an acute myocardial infarction. Therefore we haven chosen the 
unsatisfactory outcome score to assess whether the better preserved left ventricular 
function and the higher patency rate that result from primary angioplasty are indeed 
"translated" into clinical benefit during fOllow-up. 
The primary target of all reperfusion therapies is the rapid and complete reopening 
of acutely occluded coronary arteries. Acute patency rates achieved with primary 
angioplasty are currently not obtainable with thrombolytic agents [7,13,14]. The results 
of the GUSTO trial (Global Utilization of Streptokinase and Tissue plasminogen 
activator for Occluded coronary arteries) strongly supports the hypothesis that earlier 
reperfusion leads to improved survivaL This observation, which bears on the 
mechanism by which reperfusion therapies confer clinical benefit, may be the most 
important message of the GUSTO trial [23-25]. Coronary patency, defined as the 
restoration of normal blood flow through the infarct-related vessel, results in myocardial 
salvage and improved survivaL Our data certainly fit within this hypothesis: a higher 
patency rate (of angioplasty patients compared to streptokinase patients) results in a 
more preserved left ventricular ejection fraction [13,14] and improved survival (see 
Figure I and Tables 4 and 5). A slight improvement of short-term clinical outcome was 
observed in the GUSTO trial after a regimen of accelerated tissue-type plasminogen 
activator with intravenous heparin compared with streptokinase and intravenous 
heparin, as was used in our study. However, long-term outcome seems not to be related 
to selection of thrombolytic agent but rather to infarct-related artery patency and left 
ventricular function [26]. A second mechanism by which primary angioplasty results in 
a better long-term clinical outcome is the low incidence of reocclusion three months 
after successful angioplasty of 5% [13], compared to a reocclusion rate of about 30%, 
three months after successful reperfusion by thrombolytic agents [27]. 
Conclusion 
Primary coronary angioplasty for acute myocardial infarction results in a more 
favorable clinical course, a reduction of recurrent infarction and a reduction of 
revascularization procedures during a longer follow-up period, when compared with 
intravenous streptokinase therapy. Long-term infarct-related vessel patency and a 
better preserved left ventricular function are a plausible explanation for this 
observation. Further research to determine the role of primary angioplasty in the 
treatment of patients with acute myocardial infarction, especially to investigate which 
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patients benefit most from this approach, are urgently needed. 
Appendix 
An interim survey of the most important endpoints death, recurrent infarction and the 
combination of death and recurrent infarction, in May 1994 gave the following results 
(univariate analysis) with relative risks and 95% confidence interval (CI) of patients 
assigned to streptokinase therapy compared with angiopJasty treatment. 
8. 
Death 10 
Recurrent infarc1ion 5 
Death and recurrent infarc1ion: 10 
s.. 
16 
31 
42 
P value Relative Risk 95% CI 
0.28 
< 0.001 
< 0.001 
1.7 
7.7 
5.6 
0.8-3.9 
2.9-20.5 
2.7-11.6 
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Figure 1: Survival without non-fatal recurrent myocardial infarction in 301 patients 
with acute myocardial infarction, randomized to treatment with thrombolysis (- - - -) or 
primary angioplasty ( __ ) (P < 0,001), 
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Figure 2: Survival without clinical events in 301 patients with acute myocardial 
infarction, randomized to treatment with thrombolysis ( - - - -) or primary angioplasty 
( __ ) (P < 0.001). An event was defined as cardiac death, recurrent myocardial 
infarction, stroke, coronary angioplasty or bypass grafting. 
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Table 1: Baseline Characteristics 
Age (years) 
Male sex 
Anterior infarction 
Previous infarction 
Time onset-admission (min) 
Killip class on admission: I. 
II. 
III. 
IV. 
Multivessel disease 
Angioplasty 
(N=152) 
59 ± 10 
127 (84%) 
79 (52%) 
32 (21%) 
195 ±227 
116 (76%) 
22 (14%) 
6 (4%) 
8 (5%) 
95 (63%) 
P 
0.06 
0.59 
0.27 
0.11 
0.43 
0.22 
0.26 
0.41 
0.14 
0.63 
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Streptokinase 
(N=149) 
61 ±9 
121 (81%) 
68 (46%) 
21 (14%) 
176 ± 172 
122 (82%) 
15 (10%) 
9 (6%) 
3 (2%) 
88 (59%) 
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Table 2: Weighted Unsatisfactory-Outcome End Point, 18 months 
(range: 6-36 months) after randomization: 
Event Score P S 
(N=152) (N=149) 
1. Death 1.0 10 16 
2. Intracranial hemorrhage with severe 
permanent neurological deficit 1.0 0 0 
3. Development of severe, sustained CHF or 
cardiogenic shock 0.8 0 2 
4. Ejection fraction < 30% • 0.6 11 15 
5. Reinfarction 0.5 2 22 
6. Occlusion or reocclusion of IRV at F-U 
angiography 0.4 3 29 
7. Major hemorrhage requiring blood 
transfusion or intracranial hemorrhage 
without severe or permanent neurological 
deficit 0.3 4 4 
8. None of the above 0.0 122 61 
P = primary angioplasty, S = streptokinase, CHF = Congestive Heart Failure, IRV = 
Infarct Related Vessel, F-U = Follow-Up, • determined by radionuclide technique 
before hospital discharge [12]. 
The mean score of Primary angioplasty patients was 0.13 
(median = 0; 25 percentile = 0; 75 percentile = 0) 
The mean score of Streptokinase patients was 0.34 
(median = 0.4; 25 percentile = 0; 75 percentile = 0.5), P < 0.001. 
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Table 3: Causes of death in 152 patients assigned to angioplasty and 
149 patients assigned to streptokinase 
Angioplasty p Streptokinase 
Heart failure 4 (3%) 0.15 9 (6%) 
Cardiac rupture 0 0.24 2 (1%) 
Sudden death 2 (1%) 0.45 4 (3%) 
Cardiac Death 6 (4%) 0.04 15 (10%) 
Stroke 2 (1%) 1.0 1 (1%) 
Malignancy 2 (1%) 0.50 0(1%) 
10 (7%) 0.28 16 (11%) 
Table 4: Comparison of outcome during a mean follow-up of 18 months between 
152 patients assigned to primary angioplasty and 149 patients assigned to 
streptokinase therapy for acute myocardial infarction (univariate analysis) 
A S RR 95%CI 
Number of patients 152 149 
Cardiac death 6 15 2.5 1.1 - 6.5 
Recurrent myocardial 
infarction 4 30 8.3 2.9 - 23.5 
Cardiac death or recurrent 
infarction 9 42 5.1 2.5 - 10.6 
A = Angioplasty, S = Streptokinase, RR = Unadjusted Relative Risk of outcome, 
streptokinase compared with angioplasty, CI = Confidence Interval. 
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Table 5: Relative risks of outcomes during a mean follow-up period of 18 months in 
152 patients assigned to primary angioplasty, compared to 149 patients assigned to 
streptokinase therapy' 
Outcome 
Cardiac death 
Recu rrent myocardial 
infarction 
Cardiac death or non-fatal 
reinfarction 
Relative Risk 
3.5 
8.9 
6.1 
95% Confidence interval 
1.3 - 9.3 
3.1 - 25.6 
2.9 - 12.7 
• adjusted for differences in age, gender, localization of infarction, Killip class, 
multivessel disease, time from onset of symptoms to admission, previous infarction. 
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Introduction 
Iu the Zwolle trial patients with acute myocardial infarction were randomly assigned 
to undergo primary coronary angioplasty or to receive intravenous streptokinase. A 
higher patency rate of the infarct-related vessel, smaller infarct size, preserved left 
ventricular function, less recurrent ischemia and a reduction of hospital mortality were 
observed in patients assigned to angioplasty compared to those, treated with 
intravenons streptokinase. [1,2,3]. Another multicentertrialconImned these findings [4]. 
However, facilities for primary coronary angioplasty are restricted or not widely 
available, and the costs of the initial procedure are considerably higher than for 
thrombolytic therapy. Still the higher initial costs may be acceptable when these would 
be balanced against the additional benefits and when account is taken of the potential 
savings. In the short run, primary coronary angioplasty ( i.e. angioplasty without 
concomitant thrombolytic therapy) leads to a decreased risk of bleeding and 
hemorrhagic stroke, implying lower costs. In the long run, additional savings migbt 
occur due to lower rates of recurrent ischemia and reinfarction [1,2,4]. The present study 
addresses the balance between costs and effects during the first year after initial 
treatment. The calculation of costs is based on total medical costs, including all hospital 
admissions, additional procedures and other medical events. Effects are defined as event 
free survival, including recurrent infarction, stroke and death as events. No patients 
were lost for follow-up. 
Methods 
Patient selection and treatment 
Included were 301 patients with signs of acute myocardial infarction, with an age 
less than 76 years, without contra-indications for thrombolysis, and who presented 
within 6 hours after onset of symptoms. If there were signs of ongoing ischemia, patients 
could also be included up to 24 hours. After informed consent was obtained, 152 
patients were randomly assigned to undergo primary angioplasty and 149 patients were 
assigned to treatment with streptokinase, 1.5 million units intravenously in I hour. 
Patients assigned to coronary angioplasty were immediately transported to the 
catheterization laboratory and underwent coronary angiography. If the coronary 
anatomy was deemed suitable for angioplasty, this procedure was performed 
immediately, using standard techniques. 
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Cost-Effectiveness Analysis 
The question of efficiency was addressed by way of a cost-effectiveness (CIE) ratio, 
the difference in costs in the denominator, the difference in effects in the numerator. The 
estimates of costs concern the direct medical costs. They were estimated by multiplying 
volumes with estimates of unit costs. The volumes concern hospital days (distinguishing 
between normal care, coronary care and postoperative intensive care), procedures and 
medication (including the thrombolytic drugs given). All volumes were registered during 
the initial admission, during readmissions and during visits to the outpatient clinic. By 
general survey of patients (mostly by telephone interview) and of the referring 
physicians, readmissions to other hospitals could be traced and these data were added 
to the database. All patients were scheduled for follow-up angiography after three 
months and the costs of this procedure were included in the calculations. Data were 
collected for 12 to 14 months of follow-up after the index myocardial infarction. 
Effects were measured in terms of event free survival after one year. Events in 
survivors include recurrent myocardial infarction and stroke. Coronary angioplasty or 
bypass grafting during follow-up were not included. However, they do effect the CIE 
ratio due to their effect on the costs. Information about mortality, morbidity and 
functional status (expressed in terms of the functional classification of the New York 
Heart Association, NYHA) was gathered during visits to our outpatient clinic and by 
telephone interview with referring physicians. 
Unit costs for procedures and hospital days were calculated on the basis of hospital 
administration data of 1992. They included the professional charges and were corrected 
for the costs of procedures during the night or the weekend (One Dutch Guilder is 
approximately 0,53 U.S. Dollar). Costs applied for a diagnostic catheterization were Dfl. 
1,500, for angioplasty Ofl. 8,000, for bypass surgery Ofl. 18,000, for 1 day in the 
coronary care unit Ofl. 1,550, for 1 day in the postoperative intensive care unit Dfl. 
2,250, and for one day on a general ward Ofl.500. Costs for streptokinase and tPA were 
Ofl. 400 and Ofl. 2,000 respectively. The costs for the radionuclide studies were not 
included in the analysis, since these studies were used in all patients for the 
determination of end-point data rather than for patient care. All costs were recorded and 
analysed according to the intention to treat principle. 
Medication was classified using the main groups of cardiovascular drugs, and was 
obtained at discharge and after one year of follow-up. The costs of medical treatment 
was based on the average treatment costs of the different drugs according to their prices 
in 1992. This amount was calculated per month and includes costs for prescription and 
administration. The costs for oral anticoagulant therapy including hematological 
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monitoring were estimated on Dfl.400 per year as was calculated for the Anticoagulants 
in the secondary prevention of events in coronary thrombosis (ASPECT) research group 
[5]. The groups of drugs and their costs were (per month): nitrates: Dfl. 20, aspirin Dfl.. 
10, coumadin Dfl. 33, ~-blockers Dfl. 60, calcium-blockers Dfl. 70, diuretics Dfl. 30, 
Angiotensin Converting Enzyme -inhibitors Dfl. 105, antiarrhythmic agents Dfl,35 and 
cholesterol lowering drugs Dfl. 135. Also the number of patients receiving thrombolytic 
therapy at readmission were registered. 
Statistical analysis, 
Differences between groups were tested by the Student t-test or the Mann-Whituey 
rank-sum test when appropriate. For comparison of rates of discrete outcome variables a 
conventional chi-square test was used. Relative risks with 95% confidence intervals 
were calculated, The Fisher exact test was used if there was an expected cell value of 
less than 5. Achi-squared test for trend was used for differences in functional status and 
medication. All P values are two-sided; a P-value of less than 0.05 was considered to 
indicate statistical Significance. In our presentation of the data, continuous base-line and 
outcome variables are given as means ±I SD, whereas discrete variables are given as 
absolute values and percentages. The uncertainty surrounding the CIE ratios was 
assessed using the methodology outlined by van Hout et aI [6]. The basis for this 
methodology is that average costs and average effects approach a bivariate normal 
distribution. This allows for the calculation of a 95% confidence ellipse, i.e. a 
simultaneous confidence region for both costs and effects. Furthermore, P values can be 
calculated to indicate the probability that one treatment is more cost-effective than the 
other. 
Results 
Clinical course 
Baseline characteristics and clinical course have been described elsewhere [2], In-
hospital mortality and reinfarction rate were lower, left ventricular ejection fraction was 
better and infarct size was smaller in the angioplasty-assigned patients compared with 
those, treated with intravenous streptokinase [2,3]. Seven patients (5%) in the 
angioplasty assigned group and 13 patients (9%) in the group assigned to receive 
streptokinas~ had died at one year (P = 0.15). The incidence of revascularization 
procedures (except procedures as treatment for the index infarction) in the first year was 
significantly reduced in the angioplasty assigned patients (49/152 versus 84/149, P = 
0.04), Recurrent infarction, death or stroke at one year occurred in 11 patients in the 
angioplasty assigned group versus 39 patients in the streptokinase assigued group (P < 
0.001). 
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In,hospital costs and costs during follow,up 
Follow,up data could be collected in all patients. After 1 year, the functional status 
defined as NYHA class, was better in the angioplasty patients and 79% of these patients 
were in NYHA class 1 versus 62% of the patients in the streptokinase group (P value for 
trend 0.026; Table 1, Figure 1). This was also evident from costs for pharmacological 
therapy during the first year. The mean total costs of pharmacological therapy per 
patient after one year were Ofl. 1047 for the angioplasty assigned patients and Ofl. 1356 
for the streptokinase patients (P = 0.01). 
In,hospital costs, and costs during follow,up are presented in Table 2 together with 
the procedures performed. The calculated total costs of in,hospital treatment in both 
groups after I year of follow,up of all patients were Ofl. 26,355 per patient in the 
angioplasty assigned group and Ofl.25,027 (P = 0.12) in the streptokinase assigned 
group. One patient in the angioplasty assigned group, a 75 year old woman who 
underwent coronary artery bypass surgery three months after the qualifying infarction, 
was responsible for 16% of all costs in this group during follow,up. She died after 50 
days in the intensive,care unit. Excluding this patient, the average costs in the frrstyear 
in the angioplasty group would amount to Ofl. 25,297. In Figure 2, the cumulative costs 
(in,hospital costs and costs of medication) during the first year are depicted. After one 
year the total costs per patient in both treatment groups are almost the same (Ofl. 27,354 
for the angioplasty and OfL 26,264 for the streptokinase group, P = 0.22). The 
efficiency of both treatment modalities can be addressed by putting forward the average 
costs per event free survivor, where revascularization procedures were not considered 
to be events. The CIE ratios were Ofl.29,280 for the patients assigned to angioplasty 
treatment and Of!. 34,941 for those assigned to streptokinase therapy. The marginal CIE 
ratio (defined as additional costs per additional event free survivor: difference in costs of 
the two treatment groups divided by the difference in effects) were estimated at DfL 
5,968. The reliability of this estimate is indicated in Figure 3 where change in costs (t.C) 
and change in effects (t.E) are depicted as a bivariate normal distribution. From this we 
may estimate the probability that treatment with primary angioplasty is more cost, 
effective than treatment with streptokinase to be 0.975 (thus representing a P value of 
0.025). The results would be similar when coronary angioplasty and bypass grafting 
during follow,up were included in the measurement of effects (P < 0.00l). Furthermore, 
changing all unit cost estimates with 20% did not effect the base line conclusion that 
treatment with angioplasty is more cost,effective than treatment with streptokinase. 
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Discussion 
The present study indicates that primary coronary angioplasty is effective with 
regard to mortality, morbidity and functional status in the surviving patients. The 
concern that this new approach is far more expensive than "conservative" 
thrombolytic therapy was not confirmed. 
Previously it was demonstrated that the combination of thrombolytic therapy and 
immediate angioplasty has no additional clinical benefit above "stand alone" 
thrombolytic therapy [7,8]. The rate of complications with this combined approach is 
considerable and the costs of emergency angiography and angioplasty are high, 
resulting in more costs during admission for the qualifying infarction without apparent 
benefit. Until recently however, it was unclear if, under optimal interventional 
cardiology covering, coronary angioplasty would be effective as a "stand alone" 
procedure. Furthermore the cost-effectiveness of this therapy was only subject of 
debate in one report, concluding that angioplasty was not more expensive than 
thrombolytic therapy [9]. 
In the present study, we examined resource consumption, the actual costs and 
functional status in 30 I patients admitted for acute myocardial infarction, randomly 
assigned to treatment with primary coronary angioplasty or intravenous streptokinase, 
during the first year. Knowledge of the coronary anatomy as was obtained early in the 
angioplasty assigned patient group, will certainly influence the amount of 
revascularization procedures during the in-hospital stay. On the other hand, ifrecurrent 
ischemia is encountered more frequently in the thrombolysis treated patients this will 
increase the incidence of readmissions and revascularization procedures in this group 
during follow-up. 
The better functional status of the angioplasty assigned patients in the present study, 
together with lower consumption of pharmacological and other sources compensated 
the higher costs on first admission associated with primary angioplasty. In view of the 
better clinical status at I year, the better left ventricular function and better coronary 
anatomy, compared with patients treated with intravenous streptokinase, it may be 
expected that primary angioplasty will have a more pronounced beneficial effect on 
health care costs in the following years, in favor of the angioplasty treated patients 
(Figure I). 
The present study was carried out in a hospital with the preexisting infrastructure for 
interventional cardiology (inclUding a 24 hour cardiosurgical covering) and with a high 
case-load of 1400 angioplasty procedures per year. The data are not necessarily 
transferable to community hospitals without these facilities. Furthermore, it is unrealistic 
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to assume that all patients presenting with myocardial infarction can be treated with 
primary angioplasty because of limited availability and the enormous logistic burden for 
hospitals, doctors and ancillary personnel. 
Conclusion 
The present study demonstrates superior clinical outcome in patients after primary 
coronary angioplasty when compared with streptokinase therapy, at approximately the 
same costs per patient in the fIrst year. When assessed in relation to survival without 
recurrent infarction or stroke, it was apparent that treatment of acute myocardial 
infarction with angioplasty is more effIcient than streptokinase therapy. Additional 
savings of angioplasty treatment may be expected during longer follOW-Up. 
The results of this study may help to encourage introduction of primary angioplasty 
as a treatment modality for patients with acute myocardial infarction in hospitals with 
existing interventional cardiology programs. Ongoing and future studies will further 
defIne which patients will benefIt most from primary coronary angioplasty for acute 
myocardial infarction. Health care organizations and politicians, who feel that quality of 
care is as important as saving costs, should be aware of this new indication for coronary 
angioplasty . 
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Table 1: FollOW-Up data at 1 year. 
Angioplasty P Streptokinase 
(N=152) (N=149) 
NYHA 
1 120 (79%) 93 (62%) 
2 23 (15%) 34 (23%) 
3+4 2 (1%) 9 (6%) 
Deceased 7 (5%) 0.15 13 (9%) 
Trend analysis 0.0026 • 
Days alive (all patients) 353 0.51 335 
Anterior 339 0.61 321 
Non-anterior 365 0.50 345 
Medication at 1 year N= 145 N= 136 
Aspirin 121(81%) OA7 109 (80%) 
Coumadin 16 (11%) 0.15 23 (17%) 
Nitrates 12 (8%) 0.012 • 25 (18%) 
~ - blocker 34 (23%) OA7 37 (27%) 
Ca - blocker 42 (28%) 0.30 32 (24%) 
Diuretics 13 (9%) 0.067 22 (16%) 
ACE inhibitor 32 (21%) 0.09 42 (31%) 
Antiarrhythmic drugs 9 (6%) OAO 12 (9%) 
Cholesterol -lowering drugs4 (3%) 0.74 5 (4%) 
Medication (aspirin excluded) 
0 52 (36%) 32 (24%) 
61 (42%) 49 (36%) 
;;,,2 32 (22%) 55 (40%) 
Trend analysis 0.001' 
NYHA = New York Heart Association classification; ACE = Angiotensin Converting 
Enzyme; • P value significant. 
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Table 2: Total costs during the first year 
Days CCU first admission 
Days ICU first admission 
Days general ward 
Procedures first admission 
Angiography 
Angioplasty 
Bypass surgery 
Thrombolysis 
Costs first admission 
Days CCU follow-up period 
Days ICU follow-up period 
Days general ward follow-up period 
Procedures follow-up period 
Angiography 
Angioplasty 
Bypass surgery 
Additional costs first year 
Costs pharmacological treatment 
during the first year. 
All costs per patient 
(intention to treat): 
Angioplasty 
N = 152 
485 (3.23±0.13) 
64 (4.00 ± 4.37) 
1352 (9.07 ± 4.97) 
49 
142 
16 
Dfl.3,014,800 
10 
73 
587 
90 
21 
10 
Dfl. 956,250 
Dfl. 151,811 
Dfl. 27,354 
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Streptokinase 
N = 149 
590 (4.01 ± 2.52) 
41 (2.93 ± 1.98) 
1483 (10.90±5.10) 
79 
51 
15 
148 
Dft. 2,570,450 
66 
40 
673 
56 
23 
20 
011. 1,156,800 
Dft.184,490 
Dfl.26,264 
CCU = Coronary Care Unit (days); ICU = Intensive Care Unit (Postoperative) (days); CA = 
Coronary Angiography (no); P = Percutaneous Transluminal Coronary angioplasty (no); B = 
Bypass surgery (no). 
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Figure 1: Graphic display of proportion of patients in each functional class during the 
first year in the two treatment arms. Class I - IV indicates functional class according to 
the New York Heart Association (NYHA) classification. 
162 Chapter? 
30000 Dfl. 
25000 
20000 
15000..l-,.---.----,-..,--.-,.---.-----r-..,--.-,.---r-----r-
First admission 2 3 4 56? 8 9 10 11 12 Month 
---0-- AngiopJasty 
........ ¢-....... Streptokinase 
Figure 2: Total cumulative costs during the first year per patient, including in-hospital 
costs and costs of pharmacological treatment (in surviving patients) in both treatment 
arms. Dfl. = Dutch Guilders. 
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Figure 3: Bivariate normal distribution of cost and effects comparing primary 
coronary angioplasty and streptokinase treatment for acute myocardial infarction. 
A 99 % confidence ellipse, i.e. a simultaneous confidence region for both costs and 
effects is calculated. Differences in effects (x- axis) and costs (y- axis) are presented. 
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Introduction 
Reperfusion therapy of acute myocardial infarction has revolutionized management 
of this illness. Mortality reduction has been demonstrated for both intracoronary [1,2] 
and intravenous thrombolytic therapy [3,4].Recently the GUSTO (Global Utilisation of 
Streptokinase and Tissue plasminogen activator) trial [5] and the GUSTO angiographic 
sub-study [6] have confirmed the importance of early coronary patency after 
thrombolytic therapy. Both mortality reduction and preservation of systolic ventricular 
function depend on early, effective coronary artery recanalization. 
The need for rapid arterial reperfusion has fuelled renewed interest in 
nonpharmacologic reperfusion therapy. Institutions with skilled operators and staff can 
achieve very high rates of arterial reperfusion with angioplasty therapy [7,8]. 
Pretreatment with intravenous thrombolytic therapy is unnecessary and may even have 
deleterious effects [9,10]. The potential advantages of angioplasty, including high rates 
of reperfusion, lesser residual stenosis and lower risk of stroke, might be negated by the 
potential time delay to treatment and potentially greater hospital costs incurred, 
compared to thrombolytic therapy. Three prospective clinical trials have been recently 
completed to attempt to resolve these issues [11,12,13]. 
However, none of these studies was large enough to answer the crucial question 
whether differences in mortality occurred after these greatly different treatment 
strategies. Furthermore, the individual studies did not allow definition of patientgroups 
with greatest benefit of primary angioplasty. Therefore the three groups have 
collaborated to combine the data, and to report the pooled outcome from these studies. 
Since access to primary data was allowed, detailed analysis of comparability to patient 
groups, subgroup analysis and multivariable regression analysis could be performed. In 
perfortning this pooled analysis, the role of angioplasty as an alternative reperfusion 
modality could be better clarified. 
Methods 
Protocol Design 
The Primary Angioplasty in Myocardial Infarction (PAMI) study was conducted in 
12 centers in the U.S.A. and France between June 1990 and July 1992. Patients 
presenting within 12 hours of symptom onset were randomized to angioplasty versus 
thrombolytic therapy. Thrombolytic therapy with tissue plasminogen activator (rt-PA, 
activase) at a dose of 100 mgover 3 hours (or 1,25 mg per kilogram of body weight for 
patients weighing less than 65 kilograms). The primary endpoint was freedom from 
either death or nonfatal reinfarction. 
The Netherlands (Zwolle) study was a single-institution study in which 301 patients 
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presenting between August 1990 and April 1993 were recruited. Patients presenting 
with symptoms less than 6 hours duration or those presenting 6 to 24 hours after 
symptom onset with ongoing ischemia were randomized to angioplasty or thrombolytic 
therapy with intravenous streptokinase: 1.5 mega units over one hour. The primary 
endpoint of this study also was freedom from death or nonfatal reinfarction. 
Finally, the Mayo Clinic study was a single-center study conducted between April 
1989 and June 1991. Patients presenting within 12 hours of symptom onset were 
randomized to angioplasty or thrombolytic therapy. The thrombolytic agent was 
double-chain tissue plasminogen activator (duteplase). A total dose of 0.6 mega units 
per kilogram of body weight was administered over 4 hours. In the three studies in-
hospital outcomes were reported. 
Results 
Comparability of Studies 
Each of these three randomized clinical trials tested the strategy of inunediate 
catheterization and angioplasty compared to intravenous thrombolytic therapy with 
"watchful waiting". For this reason, the major findings comparing the efficacy of these 
strategies can be pooled. Although the studies used three different thrombolytic agents, 
the use of heparin and aspirin was the same. Most importantly, the thrombolytic groups 
were treated without routine immediate catheterization so the principle of mechanical 
versus pharmacologic reperfusion was tested in each study. Baseline demographics 
were compared to sex and severity of illness of these patients in each study. Patients in 
the Zwolle study more often presented with anterior myocardial infarction compared to 
the PAMIor Mayo Clinic study. Also patients from the Zwolle study were more often 
male. Patients in the Mayo Clinic study less frequently had a history of previous MI 
and also less frequently underwent in-hospital bypass surgery. Patients presented 
earlier in the Zwolle study than in the PAMI trial and later in the Mayo Clinic study. In 
spite of these minor differences in baseline variables, there were no major differences in 
clinical outcome; overall mortality was similar as were the rates of reinfarction and rates 
of stroke. Recurrent ischemia was defined the same as in the PAMI and Zwolle study, 
and the outcome was similar for both studies. These data justify the pooling of 
outcomes for comparison. 
In each study, careful analysis has been performed to assure that randomization was 
successful in segregating comparable treatment groups. When the data were pooled, 
severity of illness was identical for thrombolytic and angioplasty groups. In both 
groups, patients tended to have greater proportion of previous MI than other 
contempory thrombolytic trials [3,5]. 
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While severity of illness was similar, the clinical outcome was dramatically different 
between the two groups. A mortality rate of 6.4% (26/405) was observed in the 
thrombolytic group, compared to a 2.6% mortality (10/394) for the angioplasty group, P 
= 0.008. Thisrepresents a ratio for risk reduction of2.5 (95% Confidence Interval (CI) 
1.21 to 5.55). Similarly, a 3.9 risk ratio reduction for reinfarction (2% versus 7.9%, P < 
0.001, CI 1.8 to 8.4) for angioplasty treated patients was observed. Combining the two 
major adverse outcomes of death andlor reinfarction, angioplasty reduced the risk by a 
factor 3.0 (4.3% versus 13.1%, P < 0.00001, CI 1.8 to 5.1). Finally, angioplasty therapy 
resulted in a 9.7 risk ratio reduction (0.3% versus 2.5%, P = 0.007, CI 1.3 to 75.6) in the 
incidence of stroke. Freedom from any of these events was observed in 95% of patients 
treated with angioplasty compared to 85% of patients treated with thrombolytic 
therapy. 
Subgroup analysis was performed to identify patients with greatest potential benefit 
from angioplasty therapy. Previously, the Thrombolysis in Myocardial Infarction (TlMI) 
study [14] had stratified patients in two groups: low risk versus those not at low risk, 
based on age, infarct location and admission heart rate. Mortality was equally low for 
thrombolytic therapy and angioplasty treated patients in the low risk group. The main 
mortality advantage occurred in the angioplasty treated patients at high risk. Risk of 
reinfarction or combined endpoint of death or reinfarction favored angioplasty whether 
the patients were at high risk or low risk. Risk of stroke was greater in the high risk 
patients treated with thrombolysis since by definition all elderly patients were 
considered high risk. In order to further determine which separate clinical variable 
incurred increased risk, an analysis was done of the impact of therapy on groups 
subdivided by age, infarct location or admission heart rate. Maximum benefit appears to 
accrue for patients with anterior infarction who are treated with angioplasty therapy. 
Finally, all baseline variables and treatment variables were analyzed to determine 
which variables were associated with improved survival probability. Those variables 
with significant differences were then subject to multi variable linear regression analysis 
to determine variables independently associated with improved survival probability. 
The most potent independent predictor of improved survival was treatment with 
primary angioplasty. In addition, heart rate, less than 100 beats per minute and age less 
than 70 years were independently associated with improved survival. Of note: 
although women had a higher mortality than men (8.1 % versus 3.4%, P = 0.008), 
gender was not associated with altered survival probability. Similarly, infarct location 
did not, of itself, independently predict survival probability in the multivariable analysis. 
These findings suggest that therapy with primary angioplasty has removed gender and 
infarct location as important baseline severity of illness discriminators. 
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Discussion 
It is unrealistic to assume that mechanical reperfusion therapy is a viable worldwide 
treatment strategy for myocardial infarction. Logistics, the need for well-trained and 
dedicated personnel and catheterization laboratory makes this therapy impractical in 
remote areas and underdeveloped countries. In the developed Western and Pacific rim 
countries however, this therapy might be available on a larger scale. Even in institutions 
with facilities and personnel readily available this therapy is so specialized and 
personnel intensive, that compelling data must exist before many institutions will 
embark on this method of reperfusion therapy. 
The three randomized trials have each shown encouraging trends towards benefit 
for angioplasty therapy. The PAMI trial and the Zwolle study showed a reduction in 
the combined endpoint of death or nonfatal reinfarction for angioplasty treated 
patients. Although the Mayo Clinic study showed no reduction in infarction size, the 
trend towards lower 6 month cost of therapy was present for angioplasty patients. 
None of these studies had sufficient sample size to show a mortality benefit with 
adequate power. Combining these three trials now does provide a compelling argument 
for mortality benefit from angioplasty therapy. In addition a striking reduction in the 
risk of stroke was observed for primary angioplasty therapy. 
In an attempt to strengthen the confidence of this pooled analysis, we were 
provided full access to the prospectively collected databases. Thus, a more detailed 
analysis of the comparability of these studies could be performed. Although some 
differences in baseline variables occurred between the three studies, initial 
randomization successfully segregated comparable groups. Overall, therefore, the 
thrombolytic groups and the angioplasty groups had comparable severity of illness. 
Two other studies were not included in the present analysis because of major 
differences in protocol design. The first thrombolytic versus angioplasty trial employed 
emergency catheterization on all patients [15]. It furthermore employed intracoronary 
streptokinase and did not routinely employ aspirin for angioplasty treated patients. The 
study of Ribeiro et al, [16] did not routinely employ aspirin therapy. More importantly, 
8 patients in the angioplasty group were deemed not technically suitable for 
angioplasty, yet the procedure was still performed. Death occurred in 4/8 of these 
patients. Even with these deficiencies, if all of these studies were summarized, mortality 
occurred in 17 (3.5%) angioplasty treated patients and 29 (6.1%) thrombolytic treated 
patients (\.7 risk reduction ratio, CI 0.9 to 3.2). 
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Conclusion 
These preliminary results from a pooled analysis of the three major trials comparing 
primary coronary angioplasty and thrombolytic therapy for acute myocardial infarction 
are the first to indicate that primary angioplasty is clinically the most effective 
reperfusion modality. The major drawbacks are availability and high initial costs. 
Furthermore, these are the combined results of very experienced interventional 
cardiology centers. The different thrombolytic regimens, used in the present studies had 
comparable effects on clinical outcome. However, the most effective non-mechanical 
reperfusion mOdality known today is a thrombolytic regimen with tPAin an accelerated 
dosing schedule [5,6]. Yet, the rate of early effective reperfusion with this regimen is 
much lower than that accomplished with primary angioplasty [ll,I2,13]. 
Patients who will benefit most from primary angioplasty are those considered to be 
at high risk (previous infarction, signs of anterior wall infarction, elderly patients, 
patients in Killip class ;0: 2) and those at increased risk of stroke. In these patients 
primary coronary angioplasty is the treatment of choice, provided that all the 
prerequisites for optimal interventional cardiology are available. 
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General Discnssion and Conclnsions 
The life saving effect of reperfusion therapy for myocardial infarction has been well 
established. In most patients thrombolytic agents are administered to achieve 
reperfusion of the occluded infarct-related vessel. Still. the major limitations of such 
thrombolytic therapy are failure to achieve initial reperfusion of the infarct-related 
vessel in 20% to 30% of all patients, combined early and late reocclusion of the infarct-
related vessel despite aggressive regimens of heparin and aspirin in 10% to 30% of 
patients, intracranial bleeding in I % of patients, and contraindications to this therapy in 
a considerable part of the patients (particularly related to the increased bleeding risk). 
Primary coronary angioplasty without adjunctive use of thrombolytic agents offers the 
possibility to overcome most of these problems. Major drawbacks of this treatment 
modality are limited availability and high initial costs. Several questions about primary 
angioplasty, that remained to be answered are raised in Table I of Chapter 1 and have 
been addressed in Chapters 2 to 8. The main conclusions, that can be drawn from these 
data, together comprising the most important results from the "Zwolle study", are 
summarized in this final chapter and remaining problems related to primary angioplasty 
are addressed. 
I. Early and full perfusion i.e. Thrombolysis in Myocardial Infarction (TIMI) grade 3 
flow, which is necessary to achieve maximal benefit of therapy, occurs in approximately 
half of all patients treated with fibrinolytic therapy and early reocclusion occurs in at 
least 6% to 15% of patients who initially achieve patency (Chapter 1)[1,2]. In the 
present study, TIMI grade 3 flow was accomplished in more than 90% of the patients 
treated with primary angioplasty, within 120 minutes after hospital admission. The 
ability of angioplasty to reduce residual coronary artery stenoses and to break up most 
thrombi seems to be the most important mechanism. There is no thrombolytic regimen 
that can match these results (Chapter 1, 2, 4 and 5). 
Although in the early stage of myocardial infarction in more than 80% of the 
patients a total occlusion of the infarct-related vessel is found, the procedural success 
rate of angioplasty is very high (more than 90%). This is in contrast with the results 
obtained after angioplasty of chronically occluded vessels where success rates of less 
than 70% have been reported, depending on the "age" of the occlusion [3]. The 
material comprising the occlusion in patients with myocardial infarction is usually softer, 
miling guide wire and balloon crossing easier than in chronic total occlusions. 
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2. The coronary anatomy as analyzed with quantitative coronary angiography is 
better, with sustained patency in 92% and a restenosis rate of 28% in the patients 
assigned to angioplasty (Chapter 5). TIMI grade 2 flow immediately after the 
angioplasty procedure, despite an adequate reduction of the stenotic lesion, is highly 
predictive for reocclusion. The ability to document the early result of reperfusion 
therapy is a major advantage of primary angioplasty above intravenous thrombolytic 
therapy. Finally, the application of a balloon to vessel reference diameter ratio of 
approximately one seems to be an adequate approach for dilation of the target lesion 
(Chapter 5). 
3. Primary coronary angioplasty results in a reduction of infarct size (measured with 
serial enzyme release) and better left ventricular function (measured with radionuclide 
ventriculography), when compared with intravenous streptokinase therapy (Chapter 3 
and 4). The most pronounced beneficial effects of primary coronary angioplasty are 
observed in patients with anterior wall infarction and patients who present within two 
hours after onset of symptoms. The relation between left ventricular ejection fraction 
and enzymatic infarct size in all patients, together with the very high early TIM! 3 flow 
rates for patients treated with primary angioplasty suggest that these effects are 
accomplished by rapid and effective restoration of blood flow through the infarct-
related vessel (Chapter 4). 
4. Primary coronary angioplasty in patients with acute myocardial infarction results in 
less recurrent ischemia, reinfarction, and a lower in-hospital mortality when compared 
with patients treated with intravenous streptokinase (Chapter 2,3 and 8). This is 
probably related to the better coronary anatomy and better left ventricular function 
after primary angioplasty (Chapter 3,4 and 5). The need for additional revascularization 
procedures during initial admission was reduced significantly in the angioplasty-
assigned patients compared with patients assigned to streptokinase therapy. 
5. The beneficial effects of primary coronary angioplasty are sustained throughout a 
follow-up period ranging from 6 to 36 months (Chapter 6). 
6. The costs of primary angioplasty compared with the costs of intravenous 
streptokinase therapy at one year are approximately the same. The functional class is 
better and the need for pharmacological therapy at one year is less in the angioplasty 
treated patients. This makes primary coronary angioplasty a cost-effective therapy in 
hospitals with facilities for interventional cardiology and cardiac surgery (Chapter 7). 
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The results of Chapter 7 and the more favorable clinical outcome after primary 
angioplasty when compared with thrombolytic therapy, may help to encourage 
introduction of primary angioplasty as a treatment modality for patients with acute 
myocardial infarction in hospitals with existing interventional cardiology programs, 
Health-care organizations should be aware of this new indication for coronary 
angioplasty without fear of increasing costs, 
Together with the initial results of our investigations [4], two other studies were 
published, both with results compatible with ours (the Primary Angioplasty in 
Myocardial Infarction (PAMI) study and the Mayo Clinic Study [5,6], Another study 
did not show any benefit from primary angioplasty above streptokinase therapy but 
the design of this study was essentially different from the PAMI trial and the Zwolle 
study [7], This study from the Sao Paulo Group, did not routinely employ aspirin 
therapy, More importantly, in patients in the angioplasty group, with a coronary 
anatomy deemed not suitable for angioplasty, the procedure was still performed, 
However, all these studies indicate that success rate of primary coronary angioplasty 
is very high. The most important conclusion of the GUSTO (Global Utilisation of 
Streptokinase and Tissue plasminogen activator for Occluded coronary arteries) study 
is that survival is determined by rapid restoration (90 minutes) of normal flow through 
the infarct-related vessel [1,8] and this stresses the potential benefits of primary 
coronary angioplasty (Chapter 4). An analysis of pooled data from the Zwolle, the 
PAMI, and the Mayo Clinic trials performed in May 1994, demonstrate a favorable 
outcome after primary coronary angioplasty compared with thrombolytic therapy and 
preliminary data from this analysis are presented in Chapter 8. Primary angioplasty for 
myocardial infarction has the ability to accomplish a reduction of mortality in patients 
considered to be at high risk and with an anterior wall infarction, a reduction of 
reinfarction, and a reduction of stroke. These data may have considerable impact on the 
treatment of patients with myocardial infarction in the future. 
Questions that have to be addressed include: 
1. Who should be offered coronary angioplasty for AMI? 
Although data from this thesis and the PAMI study indicate that coronary angioplasty 
is a highly effective treatment, a large group of patients with AMI will fare well with 
thrombolytic therapy. Patients with large anterior wall infarctions, patients in 
cardiogenic shock and probably all patients in Killip class 2 or more, are candidates for 
primary coronary angioplasty (Chapter 3,4 and 8) [9]. Easily obtainable parameters 
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for early decision making have to be identified and the ECG can be a of help. Two-
dimensional doppler-echocardiography on admission is a technique that can provide 
useful information on extent of jeopardized myocardium. regional and global systolic 
wall motion and valvular function. without further discomfort for the patient. but skilful 
interpretation is required. 
Simoons and Arnold have proposed a benefit/risk model for tailoring thrombolytic 
therapy [l0] and new reperfusion modalities should also encompass primary coronary 
angioplasty. This new concept of "tailored reperfusion therapy" has to be tested in 
clinical models. 
2. Is there an age-limit for patients that should be offered primary coronary 
angioplasty? 
In our recent experience with primary angioplasty in very old patients (not included in 
this study) we e~countered many problems ranging from difficult vascular access, 
massive bleeding at vascular puncture site and other vascular complications, to 
difficulties in decision making when severe coronary artery disease, not suitable for 
angioplasty, was found. The absolute gain in life years is lower and the burden for 
hospital organization and house-staff is high. However the elderly seem to benefit even 
more from primary angioplasty compared with thrombolytic therapy as was 
demonstrated by the results from the pooled analysis described in Chapter 8 and by the 
PAMI investigators [11]. In the very old but otherwise very fit patients, primary 
coronary angioplasty should not be denied if they present with large myocardial 
infarctions. 
3. Where, when and who should perform primary coronary angioplasty? 
We all need to examine our local logistic infrastructure to decide how primary 
angioplasty can be incorporated as a treatment option for patients with myocardial 
infarction. Although this is arguably the most important question, no definite answer 
may be expected from any study on primary angioplasty because extrapolation of 
study results to other operators in other settings is not justified. Primary coronary 
angioplasty, like elective angioplasty, is associated with an operator-dependent 
morbidity and mortality that varies with the skills and experience of the interventional 
cardiologist. Therefore, no general recommendations for application of primary 
angioplasty can be given. However, data from this thesis support the idea that primary 
angioplasty for myocardial infarction should strongly be considered in patients 
presenting early and when an experienced angioplasty team is available. Furthermore, 
emergency coronary artery bypass surgery is more often needed after primary coronary 
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angioplasty compared with elective angioplasty (Chapter 3). This was confirmed by 
data from the Primary Angioplasty Registry (PAR) [1 2]. In the Zwolle study, six (4%) of 
the angioplasty assigned patients underwent bypass surgery within the first few hours 
after admission for myocardial infarction and all these patients survived. On-site 
cardiosurgical standby is therefore in our view a prerequisite for safe performance of 
primary coronary angioplasty and data from the primary angioplasty studies cannot be 
extrapolated to hospitals without these facilities. 
4. Is there a place for new devices in the treatment of myocardial infarction? 
Recent reports gave promising results from DCA ( Directional Coronary Atherectomy) 
and TEC (Transluminal extraction atherectomy) applied in smalls group of patients 
[13,14] but the skills and costs required for these techniques, the loss of time to achieve 
adequate flow through the infarct-related vessel due to technical preparations and the 
risk not to reach the culprit lesion, are major drawbacks. The excellent results of balloon 
angioplasty are difficult to beat. Stent placement at the culprit lesion site seems very 
unattractive because of the high thrombogenicity of both the device and the vascular 
trauma. Laser thrombolysis is a new and relatively unknown treatment modality but 
preliminary data are disappointing although it may have a role in the future [15]. A 
diverse array of drills, shavers, burrs and other exotic interventional devices have been 
proposed but not yet investigated in the setting of myocardial infarction. The use of an 
intra-aortic baUoonpump (IABP) as an adjunct to reperfusion therapy has been 
evaluated in the TAMI trials and the benefits of this assist device were demonstrated in 
high-risk patients [16]. An increase in peak coronary blood flow velocity may prevent 
reocclusion and recurrent thrombus formation [17]. However further investigations are 
needed to define the role of IABP during and after primary coronary angioplasty for 
myocardial infarction. 
5. Is primary angioplasty for AMI really safe? 
Safety of the angioplasty procedures was addressed in this thesis and in several other 
studies. Patients may survive after a hemorrhagic stroke following thrombolytic therapy 
but major neurological deficits may be such a threat to the quality of life that the 
advantage of an open IRV is questionable. Little is known about the occurrence of 
adverse events in patients treated with primary coronary angioplasty although the 
results of the studies from experienced centers, together with data from Chapter 5 
suggest that primary coronary angioplasty can be carried out safely. 
However, we do not know if patients might even be harmed by primary angioplasty, 
but if this subgroup exists, it will probably be smaIl. Finally, the pooled data from the 
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major trials on primary angioplasty (Chapter 8) give strong support to the theory that 
the incidence of stroke is greatly reduced with this approach [4,5,6]. 
6. How do we monitor patients after successful primary angioplasty? 
Although data from Chapter 5 indicate that reocclusion is a relatively rare phenomenon 
after primary angioplasty, reocclusion is a serious threat for every patient after 
successful reperfusion therapy for myocardial infarction. The angioplasty-assigned 
patients in the present study comprises a selected group because they were also 
candidates for thrombolytic therapy and there was an age-limit for smdy inclusion. The 
small number of patients in Killip class 3 and 4 are probably more susceptible for 
reocclusion but no definite data are available. Assessment of initial reperfusion after 
intravenous thrombolytic therapy has its limitations [18], but primary angioplasty gives 
the unique opportunity to document patency angiographically, still regarded as the 
"gold standard". Noninvasive monitoring of markers that can indicate reocclusion 
after successful reperfusion include clinical signs (chest pain, hemodynamic 
deterioration), recurrence of ST elevation on the electrocardiogram, and monitoring of 
specific cardiac proteins in plasma [19]. Apractical and a very promising approach for 
non-invasive monitoring is the Myocardial Infarction Diagnosis and Analysis (MIDA 
1000 Ortivus Medical AB, Tiiby, Sweden) system, that is routinely used in our coronary 
care unit since 1992. [20]. This is a computerized system for on-line dynamic analysis of 
the QRS complex and ST segment changes using eight electrodes placed according to 
the Frank method. Three orthogonal leads X,Y and Z are continuously monitored and 
analyzed. Electrocardiac signals from the above mentioned electrodes compare the 
averaged complex to the initial complex and displays this information in trend graphs, 
that are continuously updated. The two most important parameters are the ST vector 
magnitude (ST-VM) which reflects the extent of ischemic tissue at risk and the QRS 
vector difference (QRS-VD) reflecting changes in the shape of the QRS complex. All 
these data can be stored on a computer internal hard-disk for further analysis; decision 
making by the physician in charge can be guided by the graphic display. An example 
of a MIDA scan during and after primary coronary angioplasty is depicted in Figure I. 
However, more information is needed to define the sensitivity and selectivity of this 
monitoring teChnique in the prediction of reocclusion. 
7. How do we measure the efficacy of new reperfusion strategies? 
The diversity of patients when we broaden our indications and eligibility for 
angioplasty treatment, the possible role of new agents as an adjunct to primary 
angioplasty (all in a time of restricted economical resources, cost containment and 
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logistical problems for centers that can offer an adequate cardiac interventional 
approach), and the simple fact that reduction of mortality is more difficult to measure 
against an already low mortality baseline, will force us to leave the concept of 
megatrials as the only way to evaluate new treatment strategies. Therefore the use of a 
composite unsatisfactory endpoint which measures failure of therapy together with 
adverse events ("'net clinical benefit") [2], as was used in Chapter 6, seems to be a 
promising alternative. Infarct size as measured from enzyme release can also be used as 
a "marker of efficacy" as was demonstrated in Chapter 4. Thorough assessment of 
different combinations of reperfusion modalities will translate into treatment 
recommendations for myocardial infarction. A pragmatic strategy of "tailored 
angioplasty" as was proposed in the final paragraph of Chapter 3 with primary 
angioplasty for patients with large infarctions and/or signs of hemodynamic problems 
and thrombolytic therapy for other patients, is an example of a new approach that can 
be assessed with a composite unsatisfactory endpoint. 
8. How do we convince health care organizations and politicians to give us the 
opportunity to treat our patients better? 
In the future, continuous cost-efficacy and costs-utility assessment of the different 
treatment modalities will be part of our work and an attempt in this direction was made 
in Chapter 7. Recurrent ischemic events occur far less frequently and are even rare after 
angioplasty compared with thrombolytic therapy [21], as was demonstrated in this 
thesis and early discharge seems to be a reasonable approach (Chapter 2, 3 and 6). 
Early discharge of patients after infarcts treated with primary angioplasty was reported 
from two other studies [22,23] and readmissions for recurrent ischemia were reduced 
significantly (this thesis) resulting in substantial cost savings without additional risks. 
9. What is the best treatment after myocardial infarction, regardless of the initial 
therapy? 
Late angioplasty of occluded infarct-vessels after failed thrombolysis may have benefits 
with regard to left ventricular function and survival but early or "rescue PTCA" has a 
disappointing outcome [24,25,26]. However, coronary angiography and subsequent 
"tailored" therapy should be considered in all patients with severe problems after any 
kind of reperfusion approach. We do not know the optimal moment to perfonn 
angioplasty of an occluded infarct vessel late after failed reperfusion therapy and 
maybe it is appropriate to introduce a period of "cooling down" in asymptomatic 
patients, when angioplasty is considered. However, the reocclusion rate may be 
considerably higher than with primary coronary angioplasty [26]. 
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Coronary artery restenosis in response to arterial injury is the Achilles' heel of 
angioplasty and prevention remains a clinical challenge after primary angioplasty 
especially because thrombus is thought to induce neointimal proliferation [27]. New 
pharmacological interventions may reduce the incidence of restenosis. Despite this 
limitation, in our experience, patients rarely present with an occluded vessel at follow-
up angiography (Chapter 5) and repeat coronary angioplasty can be carried out safe if 
restenosis occurs. 
It is highly desirable that patients, enrolled in the Zwolle, the PAMI and the Mayo 
Clinic trials, will not be lost for follow-up and that the endpoints death, recurrent 
infarction and need for revascularization are carefully recorded for the next ten years. 
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Figure 1: Continuous monitoring of six hours duration of ST vector magnitude (ST-
VM) changes in a 59 year old patient with an acute infero-posterior infarction 
undergoing primary angioplasty of an occluded right coronary artery. The vector ECG 
leads X, Y and Z more or less resemble V5, II and V2. On arrival in the catheterization 
laboratory the sum of ST-segment deviation is 0.7 mV (A). The arrow indicates the 
first deflation of a 3.5 mm balloon and an immediate decrease of ST-segment 
deviation with subsequent relieve of chest pain and angiographic TIMI 3 flow (8). C 
and E indicate some of the multiple repeat balloon inflations and recovery of the ST-
segments thereafter (D and F). During transportation of the patient to the coronary 
care unit (CCU) the registration was temporarily interrupted. On the CCU the ST level 
stabilizes and ischemic episodes remained absent. Accordingly, the QRS-vector 
difference (not presented here) did not indicate additional myocardial necrosis after 
successful reperfusion. 
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Angioplasty or the art of infarct vessel maintenance 
"Obstruction of a coronary artery or any of its large branches has long been regarded 
as a serions accident" 
J.B. Herrick. 1912. 
Primary coronary angioplasty is a highly effective intervention in patients with 
acute myocardial infarction. However, as a primary reperfusion strategy for all patients 
only centers with a large experience in performing coronary angioplasty will be able to 
match the results described in this thesis. The role of the staff of the catheterization 
laboratory, the coronary care and intensive care unit, the cardiovascular surgeons, and 
the cardiovascular anesthesiologists cannot be overemphasized. All recently published 
results should be seen in this light. Often the most difficult part of the emergency 
procedure is to identify the infarct-related vessel and serious complications can be 
induced by performing angioplasty of non-infarct-related vessels. If there is doubt 
about the "culprit" lesion, immediate consultation of other interventional cardiologists 
and cardiac surgeons is warranted. Maybe this is one of the most important reasons to 
perform primary angioplasty only in centers with a large experience in interventional 
cardiology and cardiovascular surgery. 
Patients presenting with large infarcts, patients in cardiogenic shock and patients 
with contraindications to thrombolysis are probably best treated with primary coronary 
angioplasty. Referral of these patients from community hospitals to centers with 
experience in performing primary angioplasty should always be considered. 
This thesis is not a guide or "cook-book" for cardiologists who are not familiar with 
the techniques used or described in different parts of this study. Every cardiologist 
facing a patient with an acute myocardial infarction should offer the best treatment 
available. Primary coronary angioplasty should be considered in all patients but 
thrombolysis is an effective and efficient treatment modality if not combined with 
coronary angioplasty. The American Heart Association/American College of 
Cardiology Task Force on assessment of diagnostic and therapeutic cardiovascular 
procedures (committee on percutaneous transluminal coronary angioplasty) changed 
their appreciation of primary coronary angioplasty as a treatment option for acute 
myocardial infarction [I]. The degree of consensus of the committee members was 
graded as Class 1: "Conditions for which there is general agreement that coronary 
angioplasty is justified". It is worth while to cite the first paragraph on primary 
coronary angioplasty for evolving acute myocardial infarction: 
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Class I: This category applies the dilation of a significant lesion in the infarct-related 
artery only in patients who can be managed in the appropriate laboratory setting and 
who 
1. are within 0 to 6 hours of the onset of a myocardial infarction (the procedure is used 
as an alternative to thrombolytic therapy), 
2. are within 6 to 12 hours of the onset of a myocardial infarction but who have 
continued symptoms of ongoing myocardial ischemia, or 
3. are in cardiogenic shock with or without previous thrombolytic therapy and within 
12 hours of the onset of symptoms". 
Maybe the most important conclusion of this thesis is that primary coronary 
angioplasty as treatment for patients with acute myocardial infarction is here to stay. In 
our institution, primary coronary angioplasty is a practical and safe intervention for 
myocardial infarction, with improved patient outcome and without an increase in costs, 
when compared with conventional treatment. This was confirmed by other groups with 
the same attitude to interventional cardiology and reperfusion therapy for myocardial 
infarction. "The sigh of relief' uttered after rejection of angioplasty as additional 
approach after or during thrombolytic therapy [2] has to be changed to a "jump for 
joy" to welcome primary coronary angioplasty as a generally accepted treatment 
modality. 
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Summary 
This thesis addresses the value of primary coronary angioplasty, i.e. angioplasty 
without adjunctive thrombolytic therapy, as treatment for patients with acute 
myocardial infarction. In recent years, thrombolysis has been established as the 
treatment of choice for patients with evolving myocardial infarction. Reperfusion of 
ischemic myocardium through reopening of the occluded infarct-related vessel results 
in limitation of infarct size and reduction of morbidity and mortality. Coronary 
angioplasty or PICA (Percutaneous Transluminal Coronary Angioplasty) was believed 
to be dangerous, expensive and ineffective and was only considered as an alternative 
when contraindications for thrombolytic treatment were present. However, several 
reports from a few large centers with extensive experience in performing coronary 
angioplasty, demonstrated the potential benefit of this approach. Until 1993 only data 
from one small randomized trial comparing thrombolysis and primary angioplasty were 
available. In that year the results of three major trials were published in one issue of the 
New England Journal of Medicine. One of these studies is described in detail in this 
thesis. 
One problem of evaluating reperfusion therapy following AMI is the choice and 
definition of endpoints. Mortality is often considered to be the only relevant endpoint 
but mortality studies require enormous numbers of patients. Other endpOints have 
therefore been proposed to evaluate the efficacy of new treatment strategies for AMI: 
1. Angiographic data, especially coronary artery patency and residual stenosis of the 
IRY, as was used in Chapter 2 and 5 of this thesis. 
2. Infarct size, measured from enzyme release as was applied in Chapter 4. 
3. Left ventricular function, as was used in Chapters 2,3 and 4 of this thesis. 
4. Acomposite clinical endpoint combining mortality, stroke, reinfarction and other 
adverse outcome events. This approach was used in Chapter 6 of this thesis. 
In addition in Chapter 7 an attempt was made to evaluate the cost-effectiveness of 
primary coronary angioplasty on the basis of data from all 30 1 patients included in this 
study. In Chapter 8 preliminary results from a pooled analysis of the three major studies 
on primary coronary angioplasty are presented. 
Chapfer 1: Introduction 
An overview of thrombolytic therapy for myocardial infarction is given with 
emphasis on the risk-benefit-ratio of this therapy. The role of coronary angioplasty as 
an adjuvant to, or instead of thrombolytic therapy is discussed in detail and the 
inconsistent results of the different trials that evaluated coronary angioplasty in the 
setting of myocardial infarction are presented. It is concluded that more information is 
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required especially with regard to coronary angioplasty as a stand-alone procedure. 
Until 1993 only one small randomized trial addressed the possible role ofthis approach. 
Chapter 2 
In this chapter the results of the fIrst 142 patients randomized in the Zwolle trial are 
presented, as published in 1993. This trial was designed to evaluate the role of primary 
coronary angioplasty (i.e. without previous or adjuvant thrombolytic therapy) as a 
treatment modality for patients with signs of acute myocardial infarction (AMI). This 
initial report presented the results in 70 patients with AMI randomly assigned to 
coronary angioplasty and 72 patients assigned to streptokinase therapy. Even in this 
relatively small group of patients remarkable differences between the two treatment 
arms were demonstrated. Primary coronary angioplasty after AMI was associated with 
a higher rate of patency of the infarct-related vessel, a less severe residual stenotic 
lesion, better left ventricular function and less recurrent myocardial iSChemia and 
reinfarction compared with intravenous streptokinase. 
Chapter 3 
Primary coronary angioplasty was compared with intravenous streptokinase therapy 
with regard to hospital mortality, reinfarction and left ventricular function in a larger 
series of 301 patients admitted to the Zwolle trial. The in-hospital mortality rate in the 
angioplasty group was signifIcantly lower than in the streptokinase group (2% versus 
7% respectively, P = 0.024). Recurrent myocardial infarction occurred less frequently 
and left ventricular ejection fraction was better (50 versus 44%) in angioplasty patients 
compared with patients assigned to streptokinase therapy. From these data it is 
concluded that primary angioplasty results in a lower risk of death, recurrent 
myocardial infarction and a better left ventricular function. 
Chapter 4 
Primary coronary angioplasty and intravenous streptokinase treatment were 
compared with regard to infarct size measured with serial enzyme release and left 
ventricular ejection fraction measured with a radionuclide teChnique in more than 90% 
of the 301 patients enrolled in the Zwolle trial. Early effective blood flow through the 
infarct-related coronary vessel could be accomplished within 2 hours after hospital 
admission in 92% of all patients assigned to angioplasty which is a plausible 
explanation for the observed benefit of this therapy. Estimated infarct size was 23% 
smaller in patients assigned to primary coronary angioplasty. Global left ventricular 
function was better preserved, particularly in the angioplasty assigned patients 
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presenting within 2 hours after symptom onset or with anterior wall infarction. It is 
concluded that primary coronary angioplasty is the treatment of choice in these 
subgroups of patients, provided that this procedure can be carried out by an 
experienced interventional cardiology team. 
ChapterS 
This chapter provides additional angiographic data and catheterization laboratory 
events during primary angioplasty procedures in the Zwolle trial. Patency of the 
infarct-related vessel in the streptokinase assigned patients was 66% and the residual 
stenosis was 77% ± 20% at follow-up angiography after a mean of 22 days. In 
contrast, the stenosis of the infarct-related vessel was reduced from 92% ± 19% to 27 ± 
15% immediately after the angioplasty procedure. At follow-up angiography after a 
mean of 92 days the residual stenosis was 35% ± 22%, the incidence of restenosis was 
28%, and the incidence of reocclusion was 5% in the angioplasty assigned patients. 
TIMI grade 2 flow immediately after the angioplasty procedure was a strong predictor 
for reocclusion at follow-up angiography and additional therapeutic measures are 
recommended in these patients. Major complications during primary angioplasty were 
observed in 14% of the patients. 
Chapter 6 
Follow-up data were obtained after 18 months (range 6-36 months) of all 301 
patients in the Zwolle study. The relative risk of cardiac death and non-fatal 
reinfarctionin the streptokinase group was 6.1 (95% confidence interval 2.9 - 12.7) as 
compared with the angioplasty group. Additional revascularization procedures during 
follow-up were more often performed in the streptokinase group, with a relative risk of 
2.1 as compared to patients randomized to angioplasty, (95% confidence interval 1.5 -
3.2). It is concluded that primary coronary angioplasty for acute myocardial infarction 
results in a more favorable clinical course, a reduction of recurrent infarction and a 
reduction of revascularization procedures during a longer follow-up period, when 
compared with intravenous streptokinase therapy. Long-term infarct-related vessel 
patency and a better preserved left ventricular function are a likely explanation for this 
observation. 
Chapter 7 
In-hospital costs after the qualifying myocardial infarction, costs of all readmissions 
and additional procedures, and costs of pharmacological treatment during the fIrst year 
were recorded. The accumulated costs for angioplasty treatment after one year were 
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not significantly higher compared with streptokinase treatment. 
The functional status following the New York Heart Association classification was 
better in the angioplasty group and the average consumption of pharmacological 
therapy was less in the angioplasty-assigned group. After one year seven patients died 
in the angioplasty-assigned group and thirteen in the group assigned to streptokinase 
therapy (P = 0.15). The marginal cost-effectiveness ratio, defined as additional costs per 
additional event free survivor were estimated at Of!. 5,968. From this it is concluded 
that treatment with primary angioplasty is more cost-effective than treatment with 
streptokinase. 
ChapterS 
A pooled analysis of the three major studies on primary angioplasty for acute 
myocardial infarction, the Zwolle study, the Primary Angioplasty in Myocardial 
Infarction study, and the Mayo Clinic study was performed with full access to the 
prospectively collected databases. In spite of the differences in thrombolytic regimens 
and minor differences in clinical characteristics, overall rates of mortality, reinfarction 
and stroke were the same for the three studies. This justifies the pooling of outcomes 
for comparison. A mortality rate of 6.4% (26/405) was observed for the thrombolytic 
group, compared to a 2.6% mortality (10/394) for the angioplasty group, (P = 0.008). 
This represents a ratio for risk reduction of 2.5. Combining the two major adverse 
outcomes of death andlor reinfarction angioplasty reduced the risk by a factor 3.0 
(4.3% versus 13.1%, P < 0.00001). The incidence of stroke was reduced in angioplasty 
treated patients: 9.7 risk ratio reduction (0.3% versus 2.5%, P = 0.007). Greatest benefit 
of angioplasty treatment was observed in patients at high risk (age> 70 years, heart 
rate on admission> leo per minute) and those with anterior wall infarctions. It is 
concluded that in patients who are considered to be at high risk (previous infarction, 
signs of anterior wall infarction, elderly patients, patients in KilIip class ~ 2) and those at 
increased risk of stroke, primary angioplasty is the treatment of choice, provided that all 
the prerequisites for optimal interventional cardiology are available. 
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InIeiding, hoofdstuk 1 
De inzichten omtrent de behandeling van het acute hartinfarct zijn in het laatste 
decennium sterk gewijzigd. In 1980 toonden DeWood en medewerkers aan dat het 
acute hartinfarct doorgaans gepaard gaat met een trombotische afsluiting van een 
kransslagader. meestal gesuperponeerd op een atherosclerotische afwijking. Deze 
bevinding heeft ertoe geleid dat in de acute fase trombolyse (het oplossen van het 
trombotische materiaal door middel van thrombolytica) en ballondilatatie van de 
kransslagader (percutane transluminale coronaria-angioplastiek; PTCA) werden 
toegepast. De grate gerandomiseerde onderzoeken van de jaren tachtig tonen een 
belangrijke reductie van de sterfte aan het acute hartinfarct. narnelijk van 13-15% in het 
pre-trombolyse-tijdperk tot ongeveer 7%-10% thans. Het is inmiddels onomstotelijk 
aangetoond dat dit gunstige effect terug te voeren is op het weer opengaan van de 
afgesloten kransslagader door het oplossen van het aanwezige stolsel. De grootte van 
het myocardinfarct is afhankelijk van het tijdstip van effectieve reperfusie. Van 
wezenlijk belang is het duurzaarn open blijven van het met het infarct sarnenhangende 
vat (het open-arterie-concept). Hiervoor is aanvullende behandeling met 
acetylsalicylzuur (aspirine) en in de initiele fase met heparine van nut gebleken. 
Het beJang van reperfusie 
In de eerste uren na het hartinfarct is de ischemische schade het grootst en sterven 
de meeste myocardcellen af; in het algemeen wordt aangenomen dat bij de meeste 
patienten irreversibele beschadiging van de linker hartkarner binnen 4-6 uur tot stand 
gekomen is. 'koege en succesvolle trombolysetherapie beperkt de grootte van het 
infarct. Het is dan ook opmerkelijk dat steeds meer onderzoeken aantonen dat 
doorgankelijkheid van de met het infarct samenhangende kransslagader een 
voorwaarde is voor een gunstig beloop na een doorgemaakt hartinfarct en dat dit 
beloop zelfs voor een deel onafhankelijk is van de functie van de linker hartkarner en 
het tijdstip van reperfusie. Inmiddels zijn daarvoor verklaringen aangedragen. waarvan 
de belangrijkste hier kort worden genoemd. 
Bevorderen van genezing. Het genezingsproces in het necrotische en ischemische 
myocardweefsel kan worden bevorderd door een adequate bloedvoorziening en 
daarvoor is een open kransslagader van belang. Dit zou kunnen betekenen dat de 
incidentie van myocardruptuur (met harttarnponade), murale trombusvorming. acute 
mitralisklepinsufficientie. karnerseptumruptuur en aneurysma cordis kan worden 
teruggedrongen. 
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Beperken van ritmestoornissen. Rondom het gelnfarceerde hartspierweefsel 
bevindt zich een ischemische randzone waarin de electrische instabiliteit bij afsluiting 
van de betreffende kransslagader groter is dan bij een open kransslagader; dit zou 
voorallevensbedreigende ritmestoomissen tot gevolg kunnen hebben. 
Collaterale circulatie. Een open kransslagader kan in de acute fase van het 
myocardinfarct, maar ook later. dienen als altematieve bloedvoorziening bij meertaks-
coronaria:aandoeningen (collaterale circulatie) en vormt op deze wijze een ingebouwd 
veiligheidsmechanisme, dat vooral op langere termijn van belang is. 
Coronaria-angioplastiek met en zonder tromholyse 
Een belangrijk nadeel van trombolyse behandeling is de kans op bloeding en 
beroerte: in de literatuur wordt de kans op een emstige bloeding geschat op 1-2% en 
de kans op een beroerte 0,5-2%. Deze kans neemt toe naarmate de patient ouder is; 
ook is de kans groter als de patient andere aandoeningen in de anarnnese heeft, waarbij 
speciaal gedach~ moet worden aan gastro-intestinale aandoeningen, een beroerte, een 
recente chirurgische ingreep of een trauma. Tevens moet bij jonge vrouwen menstruatie 
of op korte termijn te verwachten menstruatie als een contra-indicatie worden 
beschouwd. Een ander nadeel is dat 20-30% van de kransslagaders niet open gaat na 
trombolytische therapie. 
Indien ballondilatatie zonder trombolyse wordt toegepast, kunnen deze nadelen 
worden voorkomen; deze behandeling wordt wei directe of primaire coronaria-
angioplastiek genoemd. Aanvankelijk werd deze benadering incidenteel gebruikt bij 
patienten die niet in aanmerking kwamen voor trombolytische behandeling. 
Dit proefschrift tracht de rol van primaire coronaria-angioplastiek als eerste 
behandeling van het acute myocardinfarct te definieren aan de hand van de 
bevindingen in 30 I patienten. De resultaten, beschreven in genoemde hoofdstukken, 
worden tegenwoordig in de Angelsaksische literatuur vaak aangeduid als "the Zwolle 
trial". Tijdens de voltooiing van dit proefschrift is een Amerikaanse studie (de PAMI: 
Primary Angioplasty in Myocardial Infarction study) gepubliceerd die de resultaten van 
dit onderzoek ondersteunt. 
In hoofdstuk 2 worden de resultaten van de eerste 142 patienten beschreven. De 
patienten met een hartinfarct werden aselect verdeeld voor behandeling met primaire 
coronaria-angioplastiek of iritraveneus toegediende streptokinase. Er werd een hoog 
succespercentage van coronaria-angioplastiek (98%) en een reductie van het optreden 
van hemieuwde ischemie gevonden. Tevens was de waarde voor de ejectiefractie van 
de linker hartkamer, gemeten met radionuclide-ventriculografie, belangrijk hoger in de 
patientengroep behandeld met angioplastiek. Uit het onderzoek blijkt verder dat de 
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rest-stenose van de met het infarct samenhangende kransslagader minder ernstig was 
na primaire coronaria-angioplastiek, hetgeen de resultaten op lange termijn kan 
be"invloeden ten gunste van de met angioplastiek behandelde groep. 
In hoofdstll.k 3 worden de resultaten van aile 301 garandomiseerde patienten 
beschreven. De in hoofdstuk 2 beschreven verschillen ten gunste van de met primaire 
coronaria-angioplastiek behandelde patienten werden ook gevonden in deze studie, 
die een uitbreiding is van het oorsproukelijke onderzoek. De mortaIiteit in de eerste 
ziekenhuisfase in de met angioplastiek behandelde patienten was 2%, tegenover 7% in 
de met streptokinase behandelde patienten. In de streptokinase groep trad een recidief 
infarct op bij 10% van de patienten terwijl dit slechts optrad bij 1 % in de angioplastiek 
groep. De functie van de liuker hartkamer, gemeten met radionuclide-ventriculografie, 
was belangrijk beter in patienten die een primaire coronaria-angioplastiek hadden 
ondergaan (50% versus 44%). 
In hoofdstuk 4 wordt getracht, naar aanleiding van de resultaten van enzymatische 
infarct-grootte bepaling, de linkerkamer functie gemeten met radionuclide-
ventriculografie en de coronair-angiografische gegevens een verklaring te vinden voor 
de opvallend betere resultaten, behaald na behandeling met primaire coronaria-
angioplastiek. Dit hoofdstuk is de kern van het gehele onderzoek aangezien het een 
paradigma ondersteunt dat zeer waarschijnlijk de verklaring is voor de gerapporteerde 
resultaten. Het wordt aannemelijk gemaakt dat het bewerkstelligen van een snellere en 
meer effectieve reperfusie door toepassing van primaire coronaria-angioplastiek de 
verklaring is voor de goede resultaten. Vfoege en effectieve doorstroming van het met 
het infarct samenhangende vat kon worden bereikt binnen twee uur na 
ziekenhuisopname, in 92% van de patienten die werden gerandomiseerd voor primaire 
angioplastiek. De infarctgrootte, geschat door middel van enzymbepalingen, was 
gemiddeld 23% kleiner in de voor angioplastiek gerandomiseerde patienten. Ook was 
de liukerkamer ejectiefractie, gemeten met radionuclide-ventriculografie significant 
beter, namelijk 50% versus 45%. Deze gunstige effecten van primaire angioplastiek 
werden met name gezien bij patienten die zich vroeg (binnen 2 uur) na het begin van 
de klachten in het ziekenhuis melden en bij patienten met een voorwand infarct. 
In hoofdstuk 5 worden de angiografische bevindingen en complicaties tijdens het 
verblijfin de hartcatheterisatie-kamer beschreven. De ernst van de stenose van het met 
het infarct samenhangende vat, gemeten met een quantitatieve angiografiscbe methode 
werd door de primaire coronaria-angioplastiek procedure teruggebracht van gemiddeld 
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92% tot 27%. Belangrijke, maar goed te behandelen complicaties tijdens verblijf in de 
hartcatheterisatie-kamer werden gevonden bij 14% van de met angioplastiek 
behandelde patienten. 
Bij angiografisch na-onderzoek na gemiddeld 92 dagen bleek een groot deel van 
het initiele effect behouden te zijn en de rest-stenose was dan gemiddeld 35%. In 28% 
van deze patienten wordt een stenose van meer dan 50% gevonden (re-stenose) en 
reocclusie van het met het infarct samenhangende vat werd bij slechts 5% van de met 
angioplastiek behandelde patienten gevonden. Van deze 7 patienten hadden drie een 
verminderde doorstroming door het vat, onmiddellijk na de procedure en dit bleek een 
goede voorspeller te zijn voor late reocclusie. Doorgankelijkheid van het met het 
infarct samenhangende vat werd bij na-onderzoek na gemiddeld 22 dagen gevonden 
bij slechts 66% van de met streptokinase behandelde patienten, terwijl de quantitatief 
angiografische rest-stenose gemiddeld 77% was. Indien aileen de open vaten werden 
geanalyseerd bleek de rest-stenose 64% te zijn. 
Hoofdstuk 6 beschrijft de data bij vervolg-onderzoek na gemiddeld 18 maanden 
van de patienten in de Zwolle studie. Van aile patienten konden vervolg-data worden 
verkregen. Het relatieve risico voor overlijden en een niet fataal recidief infarct was in 
de streptokinase groep 6,1 (95% betrouwbaarheidsintervallen 2,9 tot 12,7) indien 
vergeleken met patienten behandeld met primaire coronaria-angioplastiek. 
Revascnlarisatieprocednres gedurende de vervolg-periode moesten vaker uitgevoerd 
worden na streptokinasebehandeling, met een relatief risico van 2.1 vergeleken met 
patienten die aselect werden gekozen voor behandeling met angioplastiek (95% 
betrouwbaarheidsintervallen 1,5 tot 3,2). 
Hoofdstuk 7 betreft een analyse van de kosten van de twee behandelingsmethoden 
gedurende het eerste jaar. De ziekenhuiskosten, gemaakt in de eerste fase, de kosten 
van aile daaropvolgende nieuwe opnames en additionele procedures, en de kosten van 
medicijngebruik tijdens het eerste jaar werden geregistreerd. De totale kosten van 
behandeling met coronaria-angioplastiek waren nauwelijks hoger dan die van 
behandeling met streptokinase. 
De functionele klasse van de patienten volgens de indeling van de New York Heart 
Association was beter en de gemiddelde consumptie van medische middelen was lager 
in de voor primaire coronaria-angioplastiek aangewezen patientengroep. 
De raming van de additionele kosten per "gewonnen" patient, die het eerste jaar na 
het infarct overleeft zonder een hemieuwd infarct (de marginale kosten-eflectiviteits-
ratio) wordt geschat op fl. 5968,-. Op grond van deze gegevens kan worden 
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geconcludeerd dat behandeling van het acute hartinfarct met primaire coronaria-
angioplastiek zeer kosten-effectief is, indien vergeleken met behandeling met 
streptokinase. 
Hoofdstnk 8 is een voorlopige analyse van de drie belangrijkste onderzoeken naar 
de rol van primaire coronaria-angioplastiek bij het acute myocardinfarct: de Zwolle 
studie, de PAMI studie, en de studie van de Mayo Clinic. De analyse werd verricht met 
volledige toegang tot de gegevens. Ondanks verschillen in studieopzet en kleine 
verschillen in eigenschappen tussen de patientengroepen was de incidentie van totale 
sterfte, het hernieuwd optreden van een infarct, en het optreden van een beroerte gelijk 
voor de drie studies. Dit rechtvaardigt een overkoepelende analyse. 
De sterfte in de trombolyse groep was 6,4% (26/405), vergeleken met 2,6% (10/394) 
in de met angioplastiek behandelde groep (P = 0.008). Dit betekent een reductie van 
het sterfterisico met een factor 2,5. Indien de twee belangrijkste eindpunten, overlijden 
en het optreden van een hernieuwd infarct, samen werden geanalyseerd was de 
risicoreductie een factor 3 (13,1% versus 4,3%) in het voordeel van de angioplastiek 
groep. Het risico voor een beroerte was aanzienlijk lager in de met angioplastiek 
behandelde patienten namelijk een reductie van het risico met een factor 9,7 (2,5% 
versus 0,3%,P = 0.007). Patienten met een hoog risicoprofiel (met een inhet verleden 
doorgemaakt hartinfarct, met een voorwandinfarct, ouder dan 70 jaar, of met tekenen 
van pompfalen) hadden het meeste baat bij behandeling met angioplastiek. 
Geconcludeerd wordt, dat deze groep bij voorkeur behandeld dient te worden met 
primaire coronaria-angioplastiek, vooropgesteld dat aan aIle voorwaarden voor 
optimale interventiecardiologie kan worden voldaan. 
Figuur op pagina 199: Schematisch overzicht van randomisatie en 
daaropvolgende procedures in de Zwolle studie. Aileen de gebeurtenissen in de 
eerste lase na randomisatie (tot 30 dagen) zijn weergegeven. PTCA = percutane 
transluminale coronaria-angioplastiek, CABG = coronaire bypass chirurgie, SK = 
streptokinase, t = overleden. 
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Het onderzoek, beschreven in dit proefschrift, is niet uit de lucht komen vallen en 
heeft een voorgeschiedenis. In Januari 1988 werden in het Ziekenhuis de 
Weezenlanden in Zwolle hartchirurgie en PTCA (percutane transluminale coronaria-
angioplastiek) geYntroduceerd na jarenlange voorbereiding. Tevens werd, na een goed 
veriopende aanloopfase, waarover al snel gerapporteerd werd [1,2,3], onderzoek 
geiniueerd naar de mogelijkheden om diagnostische en therapeutische toepassingen 
van hartcatheterisatie te combineren in een procedure [4], naar de waarde van een 
aggressieve therapeutische benadering van patienten met cardiogene shock als gevolg 
van een acuut hartinfarct [5], en de indicatiestelling voor coronaria-angioplastiek [6]. In 
1989 en 1990 werd in het kader van The European Cooperative Study Group 
geparticipeerd in twee onderzoeken betreffende trombolyse en PTCA bij het acute 
myocardinfarct [7,8]. In het voorjaar van 1990 bestond er een "onderzoeksvacuum" 
waarin Felix Zijlstra,Jan Hoomtje en ik, naast reeds lopend eigen onderzoek, naarstig 
op zoek gingen naar aaniuiting bij andere studies. Het daaropvolgend mnlticenter-
onderzoek (the effects of a glycoprotein IIblIIIa platelet receptor blocker on PTCA in 
unstable angina pilot study [8]) kon pas begin 1991 worden gestart. Jan Hoomtje en ik 
behandelden patienten met een hartinfarct al incidenteel met primaire angioplastiek 
(tegen de toen algemeen gerespecteerde opvattingen in) en hadden daar goede 
ervaringen mee. Felix Zijlstra, die ons in 1988 kwam versterken verbaasde zich in hoge 
mate over de voortreffelijke resultaten van deze behandeling. Immers, uit het grote, 
vanuit het Thoraxcentrum Rotterdam geiniueerde onderzoek naar PTCA verricht 
tijdens of omniddellijk na trombolyse [9] was gebleken dat deze behandeling niet 
wenselijk of zelfs gevaarlijk was. De idee voor de Zwolle studie was toen geboren. 
Eind 1991 konden wij ons gelukkig prijzenmet de komst van Harry Suryapranata. De 
unieke infrastructuur van het ziekenhuis de Weezenlanden, de goede intercollegiale 
verhoudingen en het grote aanbod van patienten heeft het mogelijk gemaakt een 
onderzoek te initieren dat imniddels ook bniten Zwolle de aandacht heeft getrokken. 
Met Professor Dr M.L.Simoons reizend naar Wenen (om precies te zijn op 8 mei 
1992) werd de idee voor dit proefschrift geboren. 
I. de Boer MJ, Hoomtje JCA, Zijlstra E Starting a PTCA center: the Zwolle experience. Neth 
J Card 1990;3:54-57. 
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verricht aansluitend aan diagnostische hartcatheterisatie. Ned Tijdschr Card 1990;4:250-54. 
3. de Boer MJ, ZijlstraE Acuuthartinfarct? Open het betrokken vat. Kliuische les. Ned Tijdschr 
Geneesk 1993;137:1433-37. 
202 Nawoord 
4. Ottervanger JP, Steendijk CB. Zijlstra F, de Boer MJ. Hoorntje JCA. Complications of 
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Erkenning, dank of erkentelijkheid 
Deze letterlijke vertaling van "acknowledg(e)ment" geeft drie betekenissen weer 
van het oorspronkelijke woord. Aan iedereen die hier vervolgens genoemd wordt laat 
ik de interpretatie van ·'acknowledgment". 
Professor Dr M.L. Simoons, Maarten, je was "the fifth Beatle" of wei de George 
Martin van ons onderzoek. Een groter compliment kan ik je niet maken. 
Dr Felix Zijlstra, animator, initiator en paranymf; door de combinatie van je scherpe 
analytische geest en je relativerende humor is er tussen ~ns een soort "chemistry" 
ontstaan die rechtstreeks, en in een v~~r mijn gevoel recordtempo, tot dit proefschrift 
geleid heeft. Felix, misschien wordt het nog wei eens wat. 
Dr Jan Hoomtje en Dr Harry Suryapranata. Jullie bijdrage, opbouwende kritiek en 
steun waren en blijven van onschatbare waarde. 
Daarnaast wi! ik de rol van mijn vriend en collega Peter Remkes voor de 
ontwikkeling van de cardiologie in de Weezenlanden nog eens benadrukken. Zonder 
anderen te kort te willen doen kan ik stellen dat hij een belangrijke gangmaker voor het 
hele gebeuren is geweest. 
Mijn collegae Willem Beukema, Rob Bloemers, Dr Rob Enthoven, Dr Hans 
Holtkamp, Willem-Jan Louridtz, Angela Maas, Henk Oude Luttikhuis, Ton van Nus en 
Dr Anand Ramdat Misier wi! ik danken voor hun medewerking, solidariteit en begrip. 
Mijn opleiders Dr Jan ten Bokkel Huinink, Professor Dr Albert Bruschke en 
daamaast mijn basisopleiders Broeder van Berlo en Zuster Huls, destijds werkzaam op 
de afdeling A 6 van het Ziekenhuis de Weezenlanden, hebben mijn klinische educatie 
extra aandacht gegeven. 
Verder wil ik bedanken: 
De personeelsleden van het hartcatheterisatieteam van het Ziekenhuis de 
Weezenlanden, maar in het bijzonder Dirk Dijkstra en Henk Eenhuizen. Zij hebben bij 
nacht en ontij lief,leed en hectische toestanden met ons gedeeld. In de periode van 
1981 tot 1985 hebben wij patienten met een hartinfarct behandeld met intracoronaire 
streptokinase en de basis voor de huidige infrastructuur werd daarmee gelegd. 
Rene Bakhuizen, Max Haalebos, Frans Leicher en Hau Sie, mijn cardiochirurgische 
collega's. Dr Johan Damen, Ben Mooi, Wouter Siemons, Dr Peter van der Starre, J ohan 
Wever en hun afdeling thoraxanesthesiologie. Het voJtallige personeel van de 
hartbewaking en de verpleegafdelingen cardiologie. Dr Kor Miedema en Professor Dr 
Ton Casparie, die mij ooit hebben verleid tot een eerste stap naar wetenschappelijke 
publicatie, Evelien van Voorst tot Voorst en de afdeling klinische chemie. Dr Stoffer 
Reiffers (co-auteur van diverse artikelen en co-Groninger), Wim Huumink en de 
afdeling nucleaire geneeskunde voor hun inbreng en inzet bij de ·"kemproeven". 
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Ay Lee Liem, Gijs van den Brandhof en Jan Paul Ottervanger voor hun hulp bij het 
vergaren van data en hun bijdrage aan delen van het manuscript. 
Dr Ir. Hans Reiber, Dr Wim Hermens en Dr Ben van Hout v~~r hun drempelloze 
bereidheid om een niet acadernisch geinitieerd onderzoek te steunen. 
Dr Tbijs Plokker, Dr Sjef Ernst en het cardiologieteam van rnijn opleidingskliniek het 
St. Antonius Ziekenhuis, destijds nog gevestigd te Utrecht. Zij hebben mij de 
gelegenheid gegeven om te ondervinden dat interventiecardiologie meer is dan een 
ballon opblazen. 
Professor Dr Patrick Serruys, Professor Dr Frans Rutten en Dr Marcel van den Brand 
voor hun steun en interesse voor het gehele onderzoek. Professor Dr Jan Weening, Dr 
Evert van Ballegooie en paranyrnf Paul Versteegh, v~~r hun continue pogingen om mij 
te motiveren voor een promotieonderzoek. 
Rein van der Wal, v~~r zijn foto-plak en diawerk, niet alleen v~~r dit proefschrift 
maar ook v~~r de vele voordrachten die gehouden moesten worden. Vera Derks v~~r 
het vele secretariele werk en haar opmerkingen over mijn typkunst. Peter Paul Kint 
voor de bewerking van de illustratie op pag. 184. De dames van de bibliotheek: M w 
H.A.M. Venselaar-Bakx en Mw T.R. Lucassen-Huitema die bijna 1000 literatuur 
referenties v~~r rnij uit de archieven hebben opgevist. En verder alle medewerkers van 
het Ziekenhuis "de Weezenlanden" die rnisschien hier niet met name genoemd worden 
maar die in een ingewikkelde keten van multidisciplinair werk hun medewerking 
verlenen aan wetenschappelijk onderzoek in een perifere kliniek. 
Furthermore, I would like to thank Dr William O'Neill for his interest, support, and 
enthusiasm for this study that has confirmed ideas he already propagated since 1985. 
Misschien weI de belangrijkste dank ben ik verschuldigd aan de patienten die aan 
dit onderzoek hebben meegewerkt. Het is de gezamelijke taak van de patient en de 
dokter om nieuwe behandelingsmethoden te evalueren en te valideren. Het in ons 
gestelde vertrouwen was groot en ik hoop en denk dat deze wederzijdse 
vertrouwensband de sleutel tot succes van dit onderzoek geweest is. 
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